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A PHARMACOKINETIC INVESTIGATION OF CHLOROQUINE ANALOGUES IN 
CANCER AUTOPHAGY MODULATION 
 
 
 Hydroxychloroquine (HCQ) is currently being investigated for safety and efficacy 
as an autophagy inhibitor in Phase I/II cancer clinical trials.  It is the only clinically-
approved autophagy inhibitor for use in cancer clinical trials in the United States.  HCQ 
is used in combination with other chemotherapeutics to augment their efficacy and has 
shown moderate success in treating patients with late stage cancers.  While HCQ has a 
good safety index and shows promise as an addition to standard of care treatment 
regimens, it suffers from several critical pharmacologic shortcomings which we take 
steps to address herein.  The primary issues with usage of HCQ addressed in this work 
are the metrics used to predict patient tumor concentration of the drug following various 
dosing regimens.   
HCQ pharmacokinetics (PK) are highly variable in patients, with no correlation 
between traditional plasma:tumor concentrations.  The first step taken to address this 
problem is to characterize likely sources of interindividual variability in HCQ PK.  To do 
this a physiologically-based pharmacokinetic (PBPK) model was developed to 
investigate absorption, distribution, metabolism, and toxicity (ADMET) factors relating to 
HCQ in a mathematical system representative of the human body.  This model was 
developed based on physiological and biochemical parameters relevant to HCQ 
iii 
 
ADMET in mice and scaled to represent humans.  The model was capable of simulating 
single and multiple dosing regimens in humans, that would be characteristic of a cancer 
clinical trial.   
PBPK modeling addressed variability that would be associated with the 
macrophysiologic scale, but intrinsic and extrinsic factors on the cellular scale needed to 
be further defined to strengthen the understand of HCQ PK.  To investigate factors that 
affect cellular uptake and sub-compartment localization of HCQ, a base PK model of 
lysosomotropic agents like HCQ was applied.  Model specific parameters were 
identified for a panel of four human breast cancer cell lines, and a majority of 
differences in cellular uptake of the drug could be attributed to differences in the relative 
lysosomal volume fraction of each cell line.  The model was able to characterize HCQ 
PK under different extracellular pH conditions, and identified a positive-feedback loop, 
related to transcription factor EB (TFEB) activation.  This feedback loop caused the cell 
to increase its lysosomal volume over time of exposure to HCQ, resulting in a 
continuous increase of HCQ concentration within the cell.  
Through sensitivity analysis of the model, acidic extracellular pH was identified 
as a critical limiting factor of HCQ uptake into cells – which is particularly important as 
the tumor microenvironment is physiologically acidic.  HCQ concentrations in cells 
cultured in an acidic microenvironment are decreased up to 10-fold, which cannot be 
overcome without the aid of agents that neutralize this pH.  Dimeric analogues of HCQ, 
Lys05 and DC661, have been reported to maintain potency in acidic conditions and so 
were investigated in a comparative context to HCQ.  Lys05 and DC661 were found to 
behave similarly to HCQ pharmacokinetically – i.e. highly dependent on the lysosomal 
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profile of the cell.  These drugs exhibited similar kinetic uptake curves as HCQ, and also 
induced the lysosomal biogenesis PK feedback loop.  Unlike HCQ, Lys05 and DC661 
uptake was not completely inhibited by acidic extracellular pH, and they were able to 
maintain activity under these conditions.  PK of these drugs was characterized in a 
murine model to investigate their potential as in vivo agents, suggesting they could 
maintain high concentrations for a longer duration than HCQ.   Lys05 and DC661 share 
many pharmacologic similarities to HCQ, while not sharing significant shortcomings 
such as inactivity under acidic extracellular conditions suggesting they should be 
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Autophagy and Cancer 
Overview 
 Autophagy is a naturally occurring catabolic process that involves recycling of a 
cell’s own proteins, organelles, and other cellular debris.  Serving as a key regulator of 
cellular homeostasis, autophagy constantly operates at a basal level and shifts activity 
in response to cellular stress, which can include nutrient-deprivation, hypoxia, 
pharmacologically-induced stress, and rise of reactive oxygen species (ROS) to name a 
few.  Autophagy exists in three main forms – macroautophagy, microautophagy, and 
chaperone-mediated autophagy (CMA).  Macroautophagy is the primary autophagic 
pathway and serves as a recycling mechanism for damaged proteins and organelles.  It 
involves a double-membraned vesicle (phagophore) engulfing the substrate of interest 
to form an autophagosome.  Autophagosomes are shuttled through the cytoplasm to the 
lysosome, a highly acidic organelle responsible for many cellular degradation 
processes, fusing together to form an autolysosome wherein autophagosome contents 
are degraded by acid hydrolases.  Microautophagy involves contents of the cytosol 
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directly taken up into the lysosome through invaginations in the membrane.  CMA is a 
more complex process involving substrate tagging, transport to, and entry into the 
lysosome by a protein called heat shock cognate 70 (hsc70).  Each process is involved 
in maintaining cellular homeostasis, but most of this dissertation will focus on 
macroautophagy, which will simply be referred to as “autophagy” for the remainder of 
this work.  
Mechanism 
 The molecular mechanism of autophagy is primarily governed by a family of 
autophagy-related genes (ATG) and consists of three main steps – autophagy initiation 
and autophagosome nucleation, autophagosome maturation, and lysosomal fusion and 
degradation.   
Autophagy initiation (step 1) begins with the mTORC1 complex, located on the 
lysosomal membrane and often regarded as the primary regulator of autophagy.  Under 
nutrient-rich conditions mTORC1 maintains phosphorylation of the ULK1 (ATG1) 
complex which suppresses autophagy (active at a basal level).  Class I PI3K activates 
mTORC1 through Rag and Rheb GTPases, whose signaling is driven by amino acids, 
glucose, O2, ATP, growth factors (including cytokines), and hormones (including insulin) 
(Dibble and Cantley, 2015).  Abundant levels of these signaling factors maintain 
mTORC1 activation, which inhibits autophagy (step 1a).  mTORC1 can be 
pharmacologically inhibited by drugs like rapamycin or temsirolimus to induce 
autophagy (Chude and Amaravadi, 2017).  The activated ULK1 complex targets Vps34 
on the downstream class III PI3K complex (step 1b).  Vps34 is attached to the tumor 
suppressor Beclin 1 (BECN1) (Liang et al., 1999), and activates another attached 
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protein, BECN1-regulated autophagy protein (AMBRA1), to drive autophagosome 
biogenesis and maturation (Wu et al., 2010; Dowdle et al., 2014).  Autophagosome 
formation can be pharmacologically inhibited by Vps34 inhibition using SAR405, or by 
inhibition of the PI3K class III complex as a whole using 3-methyladenine (3-MA), 
wortmannin, and LY294002 (Chude and Amaravadi, 2017).   
Autophagosome maturation (step 2) involves conjugation of ATG16L1 with the 
ATG5-ATG12 complex, driven by ATG7 and ATG10, causing membrane expansion 
(step 2a).  Additionally, microtubule-associated protein light chain 3 (LC3) is 
incorporated into the autophagosome membrane to promote vesicle growth (step 2b).  
This process involves LC3-II formation that occurs when LC3-I is lipidated with 
phosphatidylethanolamine (PE) by ATG4B and ATG7, after which LC3-II is incorporated 
into the autophagosome membrane (Levy et al., 2017).  Buildup of LC3-II, also referred 
to as MAP1LC3B, is one of the common markers of autophagic flux (Klionsky et al., 
2016).  LC3-II buildup can be prevented by inhibiting ATG4B, which blocks catalyzation 
of LC3-I lipid conjugation (Chude and Amaravadi, 2017).   
The final step of autophagy (step 3) involves fusion of the autophagosome with 
the lysosome, forming an autolysosome, and subsequent degradation of the 
intravesicular products by lysosomal acid hydrolases.  Degradation products are 
recycled and used to power other cellular metabolic processes (Levy et al., 2017).  
Adaptor protein sequestosome 1 (p62, SQSTM1), a substrate-to-autophagosome 
targeting protein, is degraded during lysosomal fusion along with LC3-II (Levy et al., 
2017).  Both p62 and LC3-II protein levels are commonly used as markers of 
autophagic flux (Klionsky et al., 2016).  Lysosome-autophagosome fusion and 
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degradation is a function of multiple factors including lysosomal Ca2+ content, lysosomal 
membrane permeability, and lysosomal pH, just to name a few (Lu et al., 2017).  
Inhibition of this step is the primary target of pharmacologic autophagy inhibition in the 
clinic, and can be achieved with the clinically-approved autophagy inhibitors chloroquine 
(CQ) and hydroxychloroquine (HCQ), and other non-approved drugs such as 
bafilomycin A1 (BafA1), Lys05, quinacrine, mefloquine, and others (Chude and 
Amaravadi, 2017).  A detailed description of this process, and steps which can be 
inhibited, are outlined in Figure 1.1.  
Recovery of lysosomes from autophagy involve the formation of new lysosomes 
that bud off autolysosomes that have completed autophagic degradation.  These proto-
lysosomes mature in the Golgi where they acquire acid hydrolases and vacuolar 
ATPase (V-ATPase), which are lysosomal membrane-bound proton pumps that 
maintain acidic luminal pH (Rubinsztein et al., 2012; Yin et al., 2016).  Additionally, 
lysosomal biogenesis can be directly initiated by the coordinated lysosomal expression 
and regulation (CLEAR) network through master lysosomal transcription factor EB 
(TFEB), which is bound to mTORC1 on the lysosomal membrane.  This mechanism as 
it relates to autophagy and lysosomal dynamics will be discussed in detail in Chapter 2.   
Role of Autophagy in Cancer 
 Autophagy in cancer has often been referred to as a “double-edged sword”.  As 
more recent research has suggested, it serves a suppressing or promoting role 
depending on the stage of tumor progression.  In early stages of cancer progression 
autophagy serves as a suppressing mechanism, increasing rapidly to counteract the 




Figure 1.1.  Mechanism of autophagy and inhibitors of each step.  Step 1 (left):  
Autophagy initiation occurs when the mTORC1 complex is inhibited.  This can happen 
through inhibition of Class I PI3K, nutrient deprivation, or pharmacologic inhibition 
through rapamycin analogs.  Inhibited mTORC1 releases its hold on the ULK1 complex, 
which then activates Class III PI3K to begin autophagosome nucleation.  Components 
of Class III PI3K can be inhibited through spautin-1 or SAR405, or directly by 3-MA, 
wortmannin, or LY294002.  Step 2 (center):  The phagophore begins to sequester its 
cargo, including p62-tagged substrates, and transitions into an autophagosome.  This 
can be inhibited by verteporfin.  The autophagosome matures as LC3-1 is lipidated with 
PE by ATG7 and ATG4B to form LC3-II.  LC3-II is then incorporated into the membrane 
of the mature autophagosome.  Step 3 (right): Lysosome/autophagosome fusion begins, 
forming an autolysosome.  Fusion can be inhibited by deacidifying the lysosome using 
clinically-approved autophagy inhibitors chloroquine and hydroxychloroquine, or by 
Lys05, quinacrine, and VATG-027.  Fusion can also be inhibited by blocking the proton 
pump on the lysosomal surface, V-ATPase, by bafilomycin A1 or proton pump inhibitors.  
When fusion occurs successfully the contents of the autophagosome are degraded by 
acid hydrolases.  Waste is excreted extracellularly, and nutrients are recycled for use 




2011).  As the premalignancy transitions to the primary tumor stage, autophagy is 
suppressed allowing for rapid tumor growth and maintenance.  The tumor will continue 
to progress to later stages, which are associated with harsh microenvironmental 
conditions such as nutrient deprivation and hypoxia, causing a subsequent rise in 
autophagy to promote survival in this environment (Lazova et al., 2012).  Roles of 
autophagy in the survival of these late stage tumor cells include providing nutrients 
through catabolism and recycling organelles and proteins damaged by attempted 
cancer treatments, promoting resistance to drug therapies (Amaravadi and Thompson, 
2007). 
Preclinical Studies 
 The role of autophagy in late stage cancer has been investigated in many 
preclinical studies using clinically-approved autophagy inhibitors CQ and HCQ, and 
others that are not approved for clinical studies, like BafA1 and Lys05.  The tumor 
suppressing role of autophagy was first demonstrated in mice with allelic loss of 
BECN1/ATG6, which was associated with development of hepatocellular carcinomas in 
aged mice and eventually led to BECN1 classification as a tumor suppressor (Qu et al., 
2003).  The role of autophagy in tumorigenesis has also been investigated in vitro in the 
context of p62 accumulation.  Autophagy suppresses rise of ROS through sources like 
old/damaged mitochondria and defective proteins.  Buildup of p62 is associated with 
activation of NRF2, which is normally activated during inflammation and injury to 
express antioxidant proteins (White, 2013).  When these scenarios occur and 
autophagy is significantly suppressed, NRF2-promoted antioxidant effects are not 
sufficient to quell the rise of ROS, describing why inflammation and tumorigenesis are 
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linked when autophagy is inhibited, and observed by p62 accumulation (Degenhardt et 
al., 2006; Mathew et al., 2009).  On the other hand, lower incidence of cancer has been 
linked to autophagy induction in cases of caloric restriction and exercise (Blagosklonny, 
2010).  Amaravadi et. al. (Amaravadi, 2011) examines this tumor suppression role 
further to show that autophagy is important in suppressing early stages of 
tumorigenesis, but the role reverses at later stages to serve as a survival mechanism.  
 Later stages of cancer increase autophagy as a survival mechanism in response 
to the harsh tumor microenvironment, which includes conditions such as hypoxia, 
nutrient and growth factor deprivation, extracellular acidity, and cancer treatment-
induced stress (Hanahan and Weinberg, 2011; White, 2013). Basal autophagy also 
shifts in late stage cancers, specifically being much higher than normal cells, even 
under nutrient-rich conditions (Mizushima et al., 2004; Mizushima, 2009).  This 
observation has fueled attempts to classify types of cancer as autophagy-dependent or 
independent, either in terms of molecular signaling mutation/expression or histologically.  
As outlined by Levy et. al. (Levy et al., 2017), autophagy-dependence is currently being 
investigated in activation/mutation of four main signaling pathways – RAS, PI3K, JAK-
STAT, and p53.  RAS is a known oncogene, and when activated causes a significant 
increase in autophagy (Guo et al., 2011; Lock et al., 2011).  Specifically, sensitivity to 
autophagy inhibition has been linked to pancreatic cells exhibiting KRAS mutation (Guo 
et al., 2011; Yang et al., 2011; Perera et al., 2015), BRAF V600E mutant melanoma and 
lung cancer (Levy et al., 2014), and JNK1 expression in the presence of hypoxia (Jin et 
al., 2016).  PI3K signaling, especially in the context of EGFR mutation/amplification, 
influences autophagy through downstream pathways like PI3K-AKT-mTOR (Jutten and 
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Rouschop, 2014).  The relationship of JAK-STAT signaling in autophagy was shown in 
breast cancer cells that were autophagy-dependent by way of signal transducer and 
activator of transcription 3 (STAT3) and IL-6 secretion (Maycotte et al., 2015).  Finally, 
tumor promoter 53 (TP53, p53) activation has been linked with autophagy dependence, 
though the role is unclear in that p53 located in the nucleus is associated with the 
autophagy dependence, whereas if located in the cytoplasm is associated with 
autophagy inhibition (Levine and Abrams, 2008; Tang et al., 2015).  Overall, 
classifications of autophagy-dependent vs. independent tumor types are still being 
investigated.   
 Currently, the only clinically approved autophagy-inhibitors in cancer therapy are 
chloroquine (CQ) and hydroxychloroquine (HCQ).  Preclinical treatment efforts using 
these two inhibitors in combination with a multitude of other treatment methods have 
shown moderate to high success in a significant amount of studies.  To name a few, in 
the case of renal cell carcinoma (RCC) HCQ has been shown to promote cell death as 
a single agent (Lee et al., 2015), and synergistically in combination with the mTOR 
inhibitor temsirolimus (Bray et al., 2012).  Results from this combination have been 
recapitulated in melanoma spheroids and xenografts (Xie et al., 2013).  In breast cancer 
HCQ increased sensitivity to gefitinib (Dragowska et al., 2013) and estrogen receptor 
positive breast cancer cells to tamoxifen (Cook et al., 2014).  Gemcitabine toxicity in 
LM7 osteosarcoma cells was amplified with HCQ treatment as well (Farrill et al., 2017).  
HCQ has been shown to amplify chemotherapy regimens in myeloid leukemia 
(Helgason et al., 2013), myeloma, lymphoma, and hepatocellular carcinoma cells (Pan 
et al., 2011; Li et al., 2013a).  In contrast to these findings, some treatments with CQ 
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and HCQ have shown antagonistic effects in combination with other drugs.  One study 
of note was cisplatin/CQ combination in relation to tumor progression.  This study 
showed neoadjuvant CQ treatment in metastatically induced cells delayed metastatic 
development, but adjuvant treatment did not.  On the contrary, trehalose, an autophagy 
inducer, caused metastatic development to occur much more quickly (Barnard et al., 
2016).  Clinical observations in the usage of HCQ for other diseases, like rheumatoid 
arthritis and lupus, suggest it accumulates readily in inflamed tissues, acting as an anti-
inflammatory agent, and also inhibits immune system activity through reduction of T-cell 
cytokine production and toll-like receptor signaling (Schrezenmeier and Dorner, 2020).  
These mechanisms are likely to have an impact in cancer treatment as well.  
Clinical Studies 
 The first round of phase I clinical trials using HCQ to augment primary cancer 
treatment, published in 2014, showed the potential benefit of autophagy inhibition as a 
supplement to treatment.  Clinical trials looked at increasing doses of HCQ up to the 
FDA-allowed maximum of 600mg twice per day.  The results were very positive for four 
of the six trials.  The trial using temozolomide in combination with HCQ in patients with 
solid tumors recorded no dose-limiting toxicity (Rangwala et al., 2014b).  Temsirolimus 
and HCQ was a combination that showed synergistic activity in preclinical models, and 
reported a 74% stable disease rate in patients (0% in temsirolimus alone) with 
autophagy inhibition shown in PBMCs at 1200mg/day (although this biomarker was later 
shown not to be indicative of autophagy inhibition in the tumor) (Rangwala et al., 
2014a).  A trial in myeloma used the proteasome inhibitor bortezomib with HCQ and 
reported 45% stable disease rate with some cases of grade 2 GI toxicity and cytopenia, 
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but a maximum tolerated dose (MTD) of HCQ was not achieved (Vogl et al., 2014).  A 
trial in canine lymphoma patients using doxorubicin (DOX) in combination with HCQ 
allowed for dose de-escalation of the primary treatment (DOX), while observing 100% 
clinical benefit (Barnard et al., 2014).  On the contrary the two other trials did report an 
MTD for HCQ.  Vorinostat (HDAC inhibitor) and HCQ combination treatment reported 
fatigue and GI toxicity at 600mg/day of HCQ, but noted these were known side-effects 
of vorinostat (Mahalingam et al., 2014).  A second temozolomide trial in patients with 
glioma reached HCQ MTD at 800mg/day and observed no significant improvement with 
the combination in patients (Rosenfeld et al., 2014).  The overall conclusion from the six 
trials was that inhibiting autophagy was not automatically too toxic in patients, opening 
the door to the 75+ cancer clinical trials that have or are using HCQ either alone or in 
combination with another chemotherapeutic regiment (ClinicalTrials.gov, May 10th, 
2018).   
 Results from the next round of clinical data with HCQ are starting to be reported.  
To name a few – in a patient with BRAF V600E mutant brain cancer, CQ treatment has 
been shown to overcome acquired resistance to vemurafenib (Levy et al., 2014).  HCQ 
is currently being used in combination with BRAF autophagy and MEK inhibition in 
metastatic melanoma expressing BRAF V600E and BRAF V600K [NCT02257424].  On 
the negative side of things, a trial using HCQ alone in patients with pancreatic cancer 
showed negative results, indicating that HCQ should be used in combination (Wolpin et 
al., 2014).  However, another phase I/II clinical trial using HCQ and gemcitabine in 
patients with pancreatic adenocarcinoma showed partial response and no dose limiting 
toxicity at 1200mg/day HCQ (Boone et al., 2015).  An additional phase I/II trial 
11 
 
investigated everolimus, an mTOR inhibitor and thus autophagy-inducer, in combination 
with HCQ in patients with late-stage renal cell carcinoma. The study was able to 
achieve dosing of 600mg HCQ BID (1200mg/day), which is the highest achievable dose 
in phase I cancer clinical trials.  This study reported stable disease and partial response 
in 67% of patients tested and a progression-free survival of greater than 6-months in 
45% of patients (Haas et al., 2019).   
 The major route of toxicity causing patients to discontinue long term treatment 
with CQ and HCQ is retinopathy.  In the past, retinopathy has been relatively rare in 
patients taking the drug for extended periods of time, 5-10 years, but is irreversible 
(Pandya et al., 2015).  Between the cancer treatment strategies requiring high doses 
and the development more sensitive detection techniques, retinopathy in cancer trials 
has been observed in as many as 7.5% of patients (Melles and Marmor, 2014).  Current 
HCQ dosing regiments have resulted in retinal toxicity reported within 11 months of 
starting treatment during clinical trials of HCQ and erlotinib for non-small cell lung 
cancer (Leung et al., 2015).  Actual concentrations associated with retinopathy are 
unknown, but patients classified as high risk are categorized as those receiving >6.5 
mg/kg per day for >5 years (Pandya et al., 2015).  
 Pharmacodynamic (PD) evaluation of autophagy in the clinic is another source of 
problems for treatment.  Barnard et. al. (Barnard et al., 2014) showed LC3-II increase 
and accumulation of p62 in HCQ-treated tumor samples vs. control, but this required 
tumor resection, which is not always an option.  Peripheral blood mononuclear cells 
(PBMCs) were another biomarker used in early clinical trials, analyzed via TEM for 
autophagosome buildup, but this method was unreliable as it was not correlated with 
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autophagy inhibition in tumor samples (Mahalingam et al., 2014).  Current clinical trials 
and preclinical studies are heavily focused on establishing better biomarkers.  
Multiple works have attempted to develop population-based pharmacokinetic 
models for HCQ, albeit with differing results among studies.  An older study investigated 
a population pharmacokinetics (popPK) model of HCQ in rheumatoid arthritis patients 
and was supported by a one-compartment model with estimated bioavailability of 0.75 
(Carmichael et al., 2003).  Another study looked at HCQ popPK in Japanese patients 
with cutaneous or systemic lupus erythematosus and reported a one-compartment 
model. The model was characterized by first-order absorption and absorption lag time 
and the major covariate was body-weight, although this was hypothetically likely to be 
significant as they dosed HCQ based at 200-400mg daily rather than dosing on a mg/kg 
basis (Morita et al., 2016).  Furthermore, a recent Phase I/II trial with HCQ and 
everolimus (Haas et al., 2019) also developed a popPK model for HCQ in blood.  They 
reported a 2-compartment model with first-order absorption and no lag time, and also 
did not identify any covariates that improved model fit.  The population data emphasized 
large interpatient variability in HCQ pharmacokinetics.  Even though previous studies 
suggested body weight should have a significant effect on HCQ disposition, these were 
not observed in this cancer popPK model.  There has been one recent attempt to 
characterize HCQ PK in the context of SARS-CoV-2 treatment through development of 
a physiologically-based pharmacokinetic (PBPK) model using SimCyp commercial 
software. but did not report model covariates, sensitivity of parameters, or 
characterization of residual or interindividual variability (Yao et al., 2020). 
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 Inconsistent PK/PD relationships with CQ and HCQ in tumor tissue is another 
issue the clinic is facing at the moment (Barnard et al., 2014).  First, autophagy 
dependence of tumor cells vs. peripheral cells are likely different, and so inhibition of 
autophagy may require more or less drug exposure in the tumor.  Differences may also 
be due to pharmacokinetic relationships of HCQ.  PK studies with HCQ have shown up 
to 10-fold higher concentrations in tissue vs. blood (Collins et al., 2018), and up to 100-
fold higher in tumor vs. plasma (Barnard et al., 2014).  HCQ and CQ uptake and activity 
is also highly dependent on tumor pH, the driver of HCQ and CQ volume of distribution, 
has been shown to be markedly variable in tumor cells (Barnard et al., 2014; Koltai, 
2016).   Overall, better in vivo biomarkers are needed to evaluate autophagy inhibition, 
as well as a stronger understanding of the PK/PD relationship of currently used 
autophagy inhibitors.   
Pharmacology of Autophagy Inhibitors 
 Mechanistically, CQ derivatives are weakly basic compounds that alkalinize the 
highly acidic lysosome, preventing the autophagosome-lysosome fusion step of 
autophagy (de Duve, 1983; Lu et al., 2017). This mechanism drives their 
pharmacokinetics (PK), primarily through an ion-trap accumulation observed in 
lysosome and other acidic compartments, which can be seen in Figure 1.2.   
HCQ PK has been well characterized in multiple species, and the PK profile 
appears to scale linearly with dose escalation, though exhibits a significant amount of 
intersubject variability (McChesney, 1983; Tett et al., 1988; Furst, 1996; Lim et al., 
2009; Fan et al., 2015). Sources of variability are likely due to these studies having 




Figure 1.2.  Intracellular mechanism of HCQ PK with pH dependence.  HCQ 
crosses membranes readily, but accumulates in acidic compartments due to being non-
permeable in its +2 state. 
 
in absorption, distribution, metabolism, and elimination (ADME) factors related to the 
physicochemical properties that drive HCQ PK.  Of note HCQ and CQ have similar 
potency and PK properties, but HCQ has been shown to be less toxic in long term 
dosing than CQ (Shi et al., 2017).   
HCQ is typically administered as an oral tablet, in doses ranging from 100 to 
1200 mg daily, by which it is readily absorbed within 2–4 hours (Browning, 2014). The 
fraction absorbed is estimated to be 74% (Tett et al., 1989; Browning, 2014). HCQ 
blood concentration peaks shortly after the absorption phase and falls relatively quickly 
due to rapid partitioning into organs. Accumulation in lysosomes appears to drive the 
large volume of distribution in plasma, whereas binding to melanin contributes to the 
long terminal half-life (t1/2) (Tett et al., 1990). It is approximately 50% bound to plasma 
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protein in the blood (Furst, 1996). Metabolism appears to be the primary driver of HCQ 
clearance. It occurs in the liver through CYP3A4- and CYP2C3-driven dealkylation to 
form desethylhydroxychloroquine, desethylchloroquine, and bisdesethylchloroquine, the 
former that exhibits therapeutic activity and PK thought to be comparable to HCQ 
(McChesney et al., 1965; Kim et al., 2003; Browning, 2014; Qu et al., 2015). Rate of 
metabolism varies tremendously across species, leading to significant cross-species 
differences in t1/2 that ranges from hours in mice to days in humans (Tett et al., 1988). 
Excretion takes place primarily in the kidneys, accounting for about 22% of HCQ total 
blood clearance, with liver clearance assumed to account for the rest (Tett et al., 1988). 
Mean renal clearance from plasma is reported as three to four times greater than 
glomerular filtration rate (GFR) corrected for protein binding, suggesting the drug is 
secreted in addition to filtration (Tett et al., 1988). 
Regarding actual ability to inhibit autophagy CQ derivatives work well, but fall 
short of the mark in terms of potency.  To achieve an LC3-II/I increase, 1µM CQ must 
be reached and climbs linearly to maximize at 100µM.  Cell death with HCQ alone 
begins at 50µM and scales linearly to 100µM, and cell death with HCQ and another 
stressor begins at 10µM and scales linearly to 100µM.  Putting this into perspective, 
clinically achievable concentrations of HCQ peak at about 10µM in the blood with 
roughly five to six weeks of dosing required due to the extremely long half-life.  It is of 
note that HCQ has been reported as much as 100-fold higher in the tumor vs. blood, but 
there is not yet a reliable biomarker to consistently determine this (Barnard et al., 2014).   
Next generation autophagy inhibitors are currently being investigated as future 
alternatives to CQ and HCQ.  One of the more well-known is Lys05, which is a dimeric 
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version of CQ shown to be up to 10x more potent at inhibiting autophagy both in vitro 
and in human xenografts in vivo (Amaravadi and Winkler, 2012).  Additionally, Lys05 
was reported to have a much more pronounced cytotoxic effect in cell lines known to be 
resistant to HCQ alone, showing that it has significant anti-tumor capabilities on its own 
(Amaravadi and Winkler, 2012).  This carried over to in vivo studies where 10mg/kg 
Lys05 dosed intraperitoneally (i.p.) caused significant antitumor activity alone, whereas 
HCQ autophagy inhibition is rather inconsistent and single agent antitumor activity is 
much less pronounced (McAfee et al., 2012).  Lys05 was also shown to be a more 
potent lysosomal deacidifier, as 50µM could completely deacidify the lysosome whereas 
doses as high as 100µM HCQ could not (McAfee et al., 2012).  The only reported side 
effect of Lys05 in in vivo studies was GI toxicity due to Paneth cell destruction in mice 
observed at only the highest dose of 80mg/kg (McAfee et al., 2012).  Some other next 
generation autophagy inhibitors being investigated for potential future use include the 
Vps34 inhibitors SAR405 (Pasquier, 2015) and spautin-1 (Shao et al., 2014); the 
inhibitor of autophagosome formation verteporfin (Donohue et al., 2011); and 
antimalarials mefloquine (Sharma et al., 2012), quinacrine, and VATG-027 (Goodall et 
al., 2014).  On the unconventional side structurally, ferroquine (FQ) is an organometallic 
chloroquine structural derivative with increased potency both as a single agent or in 
combination with other chemotherapeutics in vivo (Kondratskyi et al., 2017). 
Further investigation into dimeric quinoline-based compounds like Lys05, has 
been investigated by the Amaravadi and Winkler group and ultimately elucidated 
mechanistic targets of these drugs.  Recent reports suggest that dimerization of multiple 
quinoline compounds, including quinacrine, mefloquine, and primaquine, all led to an 
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increase in potency relative to the monomeric versions (Nicastri et al., 2018; Rebecca et 
al., 2019).  The study by the Amaravadi group identified a highly potent version, dimeric 
quinacrine 661 (DQ661), and investigated its molecular target as PPT1 (Rebecca et al., 
2017).  Inhibition of PPT1 mechanistically works to both inhibit mTORC1 while 
simultaneously inhibiting autophagy to block autophagosome-lysosome fusion. 
Presence of a methyl group on the carbon-chain linker (indicated by a 1 for a methyl 
group or 0 for no methyl group) indicated whether the dimeric quinacrine had affinity for 
PPT1 on the lysosomal membrane, or accumulated in the nucleus of the cell.  Further 
investigation of the role of PPT1 in cancer suggests that it is correlated with reduced 
patient survival, and its genetic inhibition is significant in reducing tumor progression 
(Rebecca et al., 2019).   Investigation of structure activity relationship (SAR) of dimeric 
quinolines ultimately found dimeric chloroquine 661 (DC661) to be the most efficacious 
version of these compounds in vitro.  DC661 was reported to have much higher potency 
than Lys05 and HCQ, with strong growth inhibition and autophagy blocking potential 
between 0.1-1uM, where the formers are 0.5-5uM and 5-30uM based on in-house data.  
Additionally, DC661 was shown to be capable of overcoming a major shortcoming of 
HCQ, which is efficacy under acidic extracellular conditions (Rebecca et al., 2019).   
Overall autophagy has been shown as a double-edged sword in tumor 
development, in that it serves as a tumor suppressor in early stages and a tumor 
promoter at later stages.  Preclinical treatment methods have shown that autophagy 
inhibition can be highly beneficial as an adjuvant to primary chemotherapy, although 
classifications of autophagy-dependence are still becoming clear.  These studies have 
led to 75+ clinical trials involving autophagy inhibition using CQ or HCQ, which have 
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shown mostly positive results when used in combination with the primary treatment.  
Autophagy inhibition remains a promising strategy to improve cancer patient outcomes, 
which will surely evolve with discovery of better clinical biomarkers of autophagy-
dependence and development of more potent autophagy inhibitors.   
 
Lysosomal Dynamics and Cancer 
Overview 
Lysosomes, the primary organelle involved in autophagy, were first discovered 
by Christian de Duve in 1955.  They are described as vesicles of roughly 100-500nm in 
diameter (Xu and Ren, 2015) with characteristic acidic pH between 4.6-5.0, and a 
variety of different acid hydrolases optimized to function in these conditions (Mellman et 
al., 1986).  Lysosomes are often regarded as the garbage disposal of the cell due to 
their role as the autophagy mediator, as well as their involvement in endocytic and 
phagocytic degradation, cytosolic protein proteolysis (Lawrence and Brown, 1992), and 
cholesterol homeostasis (Guillaumot et al., 2010).  They serve many other functions, 
including regulation of calcium homeostasis by serving as the calcium store of the cell 
(Feng and Yang, 2016).  The key role of interest in the context of autophagy is 
lysosomal adaptation during nutrient starvation conditions.  Specifically, lysosomes fuse 
with each other resulting in many less (~100/cell to <50) but larger lysosomes (up to 
1500nm diameter) that redistribute from their uniform cellular distribution to a 
perinuclear concentration wherein autophagosome-lysosomal fusion takes place (Xu 
and Ren, 2015).  
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Lysosome formation, functional maintenance, and trafficking through the cell are 
dynamic, complicated processes that are critical to their cellular role.  Briefly, lysosomes 
formation occurs within the Golgi network, wherein newly formed vesicles are fused with 
endosomes (Cooper, 2000). Acidic lysosomal pH is maintained by proton pumps 
located on the membrane, referred to as vacuolar-type H+ ATPase (V-ATPase), in 
combination with a lysosomal membrane potential of -20 to -40 mV (Ohkuma et al., 
1983; Steinberg et al., 2010).  This results in a proton homeostatic concentration of 
roughly 100-1000 times higher than that of the cytosol.  Lysosomal trafficking, the 
processes involved in lysosomal fusion and fission, throughout the cell is highly 
regulated and involves lysosomal degradation of autophagy substrates, supply of 
hydrolases, export of catabolites, and lysosomal recycling and biogenesis.  Trafficking is 
regulated by the H+ homeostasis / membrane potential interplay, but primarily by Ca2+ 
storage and efflux (Luzio et al., 2007; Li et al., 2013b).  Impairment of lysosomal 
trafficking, along with other lysosomal processes, can lead to a number of issues 
including cell impairment and disease.   
There is a large group of relatively uncommon genetic diseases that are caused 
by lysosomal dysfunction, known as lysosomal storage diseases (LSDs).  They tend to 
come about most often due to a deficiency in one or more lysosomal enzymes, resulting 
in a buildup of the enzyme-targeted substances in the lysosome.  LSDs are further 
classified by alteration of the following: signaling pathways, intracellular calcium 
homeostasis, lipid biosynthesis, and endosomal/lysosomal trafficking (Ballabio and 
Gieselmann, 2009).  Autophagy is almost always involved in LSDs, as it relies on the 
lysosome.  Blocking or inducing autophagy due to the specific feature of the LSD results 
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in autophagosome accumulation, which is a result of issues with lysosome-
autophagosome fusion (Ballabio and Gieselmann, 2009).  The proposed mechanism for 
cell death in LSDs is similar to the proposed mechanism by which lysosomotropic 
autophagy inhibitors, like HCQ, cause tumor cell death.  Specifically, defective 
autophagosome-lysosome fusion observed in these diseases prevents autophagosome 
degradation.  Consequently, substrates of the autophagosome, like ROS, defective 
proteins, and aberrant mitochondria, accumulate within the cell.  Cell death ultimately 
occurs through subsequent damage and inflammation (Ballabio and Gieselmann, 2009).    
Lysosomal involvement in cancer has been recently investigated, and while still 
not clearly defined, it is known to play a dual role in both cancer treatment and 
progression.  Extending from the cancer-treatment role in autophagy-inhibition and 
death related to overwhelming autophagosome accumulation, lysosomes can serve as 
a target for tumor cell death due to lysosomal membrane destabilization (LMD) 
associated with cathepsin release and subsequent caspase activation (Foghsgaard et 
al., 2001), or oppositely a source of multi-drug resistance (MDR) due to their protective 
effects against hydrophobic weak bases.  Lysosomes dual role in tumor progression is a 
bit more complicated, specifically in regard to location of cathepsin release.  Cathepsins 
released into the extracellular space are associated with tumorigenesis (Ilan et al., 
2006; Mohamed and Sloane, 2006; Palermo and Joyce, 2008), but if released into the 
cytosol promote apoptotic cell death (Foghsgaard et al., 2001; Kirkegaard and Jaattela, 
2009).  This can by visualized directly through lysosome migration and dispersion within 
the cell.  Peripheral concentration of lysosomes is correlated with tumor progression, as 
compared to the normally observed perinuclear concentration (Koblinski et al., 2000).  
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Regarding tumorigenesis – higher expression levels of cathepsins B, D, and L in the 
extracellular space have been linked to tumor progression (Kos and Lah, 1998), while 
pharmacologic inhibition of cathepsins is associated with delayed tumor progression in 
mouse models and increased cell sensitivity to additional chemotherapeutic agents in 
vitro (Shree et al., 2011).  The proposed mechanism involves cathepsin-mediated 
degradation of ECM components, promoting metastasis (Kirkegaard and Jaattela, 
2009).  Alternatively, cathepsin release into the cytosol is associated with apoptotic cell 
death.  Lysosomal membrane destabilization (LMD) is the proposed mechanism of 
cathepsin release, leading to cytochrome c transport out of the mitochondria, causing 
downstream activation of caspases, specifically caspase-8 (Stoka et al., 2001).  LMD 
can be caused by such apoptotic stimuli as TNF, activation of p53, ROS production, and 
lysosomotropic agents (Halaby, 2015).  Treatment with CQ has been shown to cause 
lysosomal membrane damage, associated with recruitment of Galectin-3 to lysosomal 
sites and swelling of lysosomes up to a 3-fold increase in diameter.  Lysosomal 
membrane damage appears to be linked to glucose, as glucose starvation, regardless 
of serum concentration, could prevent CQ-induced lysosomal damage (Gallagher et al., 
2017).  Overall, the exact mechanism of LMD, its associated factor, and its involvement 
in apoptotic cell death remain unclear.   
Lysosomal Displacement of Drugs 
Another signature feature of lysosomes is their ability to sequester weakly basic 
chemicals, which, depending on how you look at it, poses a challenge or solution to 
many of the hurdles that must be overcome in cancer treatment.  Commonly referred to 
as “lysosomal trapping”, the highly acidic environment of the lysosome can protonate a 
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majority of weak bases that passively diffuse into it, massively reducing their rate of 
diffusion back into the cytosol by reducing their effective permeability.  This mechanism, 
as discussed previously for dibasic HCQ, causes lysosomes to serve as a drug sink for 
many other mono-, di-, and tri-basic drugs.  The actual extent to which bases are 
sequestered is a factor of both permeability as well as pKa.  Contributions of each factor 
were investigated by Ishizaki et. al. (Ishizaki et al., 2000) using three known 
lysosomotropic agents including imipramine, chlorpromazine, and propranolol.  They 
found that uptake of imipramine into isolated rat liver lysosomes was approximately 
140-fold higher than pH-partition theory predicted, attributing extra uptake to lipidic 
binding, and simulating this contribution with a simplistic mathematical model.  This 
concept was extended even further, differentiating between drugs whose permeabilities 
were reduced when ionized preferentially accumulating in the lysosome versus drugs 
whose permeabilities were not reduced preferentially accumulating in the mitochondria.  
Permeability-related lysosomal affinity was attributed to acid polysaccharides and 
glycolipids that make up the lysosome (Duvvuri et al., 2004; Duvvuri and Krise, 2005).  
Interplay between acidic macromolecule binding and drug pKa/permeability has been 
incorporated on a more general level into recently developed theories used in practice 
to predict drug-tissue partitions for pharmacokinetic modeling (Schmitt, 2008; Peyret et 
al., 2010).  
Concepts from these cell-based models of lysosomal-sequestering translate well 
when considering the role of lysosomes in tissue distribution, particularly in the case of 
known lysosomotropic (lysosomal-targeting) agents.  MacIntyre and Cutler (MacIntyre 
and Cutler, 1988) calculated that basic compounds would accumulate around 400 times 
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the concentration of the cytosol for monoacidic bases, and up to 16,000 times for 
diacidic bases.  Taking the volume fraction of lysosomes of the hepatocyte as 0.68%, 
the physical amount of drug in the lysosomal compartment would be roughly 3 or 1100 
times that of the cytosol, respectively.  This theory holds ground when comparing 
apparent volumes of distribution (VDss) between lysosomotropic compounds and other 
chemicals.  Assuming a VDss of 0.7 L/kg is representative of total body water (Obach et 
al., 2008) and VDss of 10 L/kg is indicative of very high tissue partitioning, in a panel of 
670 lipophilic drugs (logP = 2-4) the median unbound VDss (VDss/fu) was 13 and for 
very lipophilic drugs (logP > 4) was 77.  As a whole, basic drugs exhibited a median 
unbound VDss of roughly 9.  Of all 670 drugs screened, the lipophilic 
hydroxychloroquine showed an unbound VDss of roughly 1300 L/kg (Obach et al., 
2008).  Drugs exhibiting a VDss > 25 fit the profile for lysosomally-sequestered 
chemicals, as characterized in immortalized hepatocytes (Kazmi et al., 2013).   
The extent to which lysosomal ion trapping affects cellular uptake has been 
examined by numerous studies testing weakly basic lipophilic drugs in the presence of 
inhibitors of lysosomal trapping.  These include chemicals that deacidify the lysosome 
directly by acid-quenching (NH4Cl, CQ/HCQ, ionophores nigericin and monensin), or 
indirectly by inhibiting V-ATPase function (bafilomycin A1, omeprazole).  Ishizaki et. al. 
(Ishizaki et al., 2000) demonstrated dose-dependent neutralization of lysosomal pH with 
chlorpromazine, imipramine, propranolol, and NH4Cl within the low µM to low mM 
range, and were able to mathematically define lysosomal buffering capacity against 
basic drugs (Ishizaki et al., 2000).  The validity of this buffering capacity was verified by 
Yokogawa et. al. (Yokogawa et al., 2002) when mathematically-simulating and 
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validating the pretreatment of imipramine and methylamine with dose-escalating 
chlorpromazine, propranolol, and NH4Cl.  Additionally, Ishizaki et. al. showed tissue 
affinity of lipophilic basic drugs was decreased between 20-80% by NH4Cl treatment 
(Ishizaki et al., 2000).  Kazmi et. al. (Kazmi et al., 2013) examined this effect in 
immortalized hepatocytes using imipramine and propranolol, finding that uptake of these 
two drugs was inhibited >40% by NH4Cl, nigericin, and monensin, and >50% by CQ 
where non-lysosomotropic agents exhibited no effect on uptake.  Of particular note was 
the lengthy washout time required to reverse the CQ effect on imipramine and 
propranolol uptake compared to NH4Cl, representative of CQ’s long half-life in vivo 
(Kazmi et al., 2013).   For imipramine in particular, pretreatment with 2.5µM nigericin 
showed significantly decreased cellular uptake, whereas treatment with 1mM ATP 
caused massive increase in cellular uptake – likely due to the more readily available 
ATP source required by the V-ATPase pumps to maintain acidity of the lysosome. This 
was verified in that 10nM bafilomycin A1, a V-ATPase inhibitor, negated the effect of 
1mM ATP in increasing imipramine uptake (Ishizaki et al., 2000).  Examining the 
influence of lysosomal sequestration even further, a cell model representative of 
lysosomal uptake based on pH-perturbing, permeability-altering, and acidic 
macromolecule binding dynamics was developed and validated in lipophilic weak bases 
(Trapp and Horobin, 2005; Trapp et al., 2008), eventually looking directly at drug 
displacement dynamics by investigating displacement of the pH-dependent fluorescent 
lysosomal marker LysoTracker with four different lipophilic weakly basic drugs tested at 
therapeutically-relevant concentrations (Kornhuber et al., 2010).   
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A similar experimental method to characterize lysosomal sequestration of weak 
bases based off of chemical pKa was recently established by Schmitt and colleagues 
(Schmitt et al., 2019).  This methodology compared LCMS/MS concentrations from rat 
hepatocytes treated with different drugs to displacement of LysoTracker Red, 
correlating decreased fluorescence directly to an increase in lysosomal concentration of 
the agent described.  In rat hepatocytes the lysosomal pH was found to be a Gaussian 
distribution around mean pH of 5.53, suggesting the variation of pH that occurs 
throughout the endo/lysosomal system.  Overall, they observed lysosomal pH and 
lysosomal volume fraction of cells to be the most important factors in uptake of 
lysosomotropic agents.  On the basis of determining cellular uptake of drugs based on 
lysosomal profiles, it is of note that both lysosomal pH and lysosomal volume fraction of 
cells have been reported with an extremely large variation among cell types, with pH 
ranging from ~4.5-5.5 and volume fraction ranging from ~0.2-8% in cell lines (Schmitt et 
al., 2019).  Additionally, lysosome pH and lysosomal turnover is a dynamic process that 
is responsive to cellular intrinsic and extrinsic factors, adding another level of difficulty to 
characterizing drug/lysosome interplay.    
Mechanistically, the lysosomal drug sink effect is why a number of 
lysosomotropic drugs, like HCQ, exhibit their activity, but could also be a reason why 
other drugs actually exhibit diminished activity.  Lysosomal sequestration of weakly 
basic chemotherapeutics away from their target sites throughout the cell, effectively 
reducing their activity, has been identified as a form of MDR (Duvvuri and Krise, 2005).  
Numerous studies are involved with investigating the actual magnitude of this effect.  In 
comparison of drug sensitive versus resistant MCF-7 cells (MCF-7 vs. MCF-7/ADR), 
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DOX lysosomal sequestration was observed in resistant, but not sensitive cells.  This 
was correlated to a much more acidic lysosomal pH in the resistant cells, as well as the 
cytosolic pH being roughly 0.4 units lower in the resistant cells – a trend also observed 
in MDA-MB-231 and SW-48 cell lines.  Subsequent decreased DOX uptake/sensitivity 
was reversed by treatment with BafA1 and monensin (Altan et al., 1998).  This 
sequester-release effect of DOX and lysosome-targeting agents was also observed in a 
different study using CQ, OMZ, and BafA1 as alkalinizing agents.  Specifically, dose-
dependent lysosomal alkalization was shown with all three drugs, as well as increased 
uptake and sensitivity to DOX in MCF-7 and EMT-6 cells (mouse mammary carcinoma) 
(Lee and Tannock, 2006).  Another study looked at the lysosomal sequestering potential 
of palbociclib and ultimately showed that CQ was able to lower overall accumulation of 
palbociclib in the lysosome.  This ultimately increased the free amount of palbociclib in 
the cytosol, increasing sensitivity to the drug (Llanos et al., 2019).  Direct contribution of 
V-ATPase to this phenomena was analyzed through siRNA knockdown of ATP6L, a V-
ATPase subunit, resulting in a dramatic alkalinization of lysosomal pH as well as 
increased sensitivity/cellular relocation of DOX, 5-FU, and vincristine compared to 
control MCF7/ADR cells (You et al., 2009).   
 In some cases, MDR cells have been observed as having a higher lysosomal 
burden (volume * number) compared to drug-sensitive cells.  Interestingly, 
concentration of the basic lipophilic tyrosine kinase inhibitor sunitinib was found to be 
10-fold higher in resistant cell lines, which was connected with the increased expression 
of lysosomal-membrane protein 1 and 2 (LAMP1,2) (Azijli et al., 2015).  Continuous 
sunitinib exposure has also been shown to cause acquired resistance in HT-29 colon 
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and 786-O renal tumors, with resistant tumors accumulating 1.7-2.5 times more 
sunitinib.  This affect was associated with a significant increase in number and size of 
lysosomes (Gotink et al., 2011).  In a separate study using a panel of seven 
histologically-different cell lines, sunitinib resistance showed a striking linear relationship 
with lysosome number per cell (Zhitomirsky and Assaraf, 2015).  The role of lysosome 
size in resistance was shown using fluorescently-labeled sunitinib, which was shown to 
accumulate in lysosomes.  Resistance to sunitinib and sorafenib was observed in 
hepatocellular carcinomas with giant lysosomes versus those with normal sized 
lysosomes.  This group also observed ATP-binding cassette (ABC) drug efflux 
transporter expression on the lysosomal membrane, and were able to reverse drug 
resistance by treating with the ABC inhibitor verapamil (Colombo et al., 2014).   
Increased lysosomal burden can also be used advantageously, as was shown by 
treatment of MDR cells with the cytotoxic fluorochrome imidazoacridinone (IA).  IA 
readily accumulates in lysosomes, and was used to induce lysosome-rupture and 
subsequent deadly spikes in ROS by photodestruction of cells overexpressing MDR 
efflux transporters P-gp (ABCB1), MRP1, and BCRP.  This effect was not observed in 
non-MDR cell lines, and was actually reversed by treatment with lysosomal alkalinizing 
agents NH4Cl and BafA1 (Adar et al., 2012).  
 Some very recent studies have shown that the result of chemotherapeutic 
treatment and lysosomal disruption in cancer cells is markedly disconnected from the 
synergistic effects often associated with autophagy inhibition. Maycotte et. al.  
(Maycotte et al., 2012) observed this disconnect in the response of mouse breast 
cancer cells to cisplatin.  They showed induction of autophagy by cisplatin DNA 
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damage, and by treatment with autophagy inducers rapamycin, an mTOR inhibitor, and 
LY290042, a PI3K inhibitor.  While treatment with CQ sensitized cells to these 
autophagy induction treatments, knockout of the essential autophagy genes ATG12, 
BECN1, and treatment with BafA1 did not reproduce sensitization (Maycotte et al., 
2012).  A similar study was carried out in tongue squamous cell carcinoma, which are 
shown to have higher autophagic flux in comparison to normal tongue epithelial cells.  In 
this case, sensitization to cisplatin was caused by BafA1, attributed to reduced 
lysosomal trapping and increased cisplatin-DNA binding; however, this sensitization 
was not observed in combination with ATG5 knockout (Chu et al., 2018).  A third 
example investigated lysosomotropic sensitization in KRAS mutant cells, a cell-type 
thought to be autophagy-dependent.  KRAS mutant and wild-type cells actually showed 
equal sensitivity to CQ and Lys01, but ATG7 depletion did not cause a decrease in cell 
growth in vitro or in vivo even though autophagy was thoroughly inhibited.  Furthermore, 
cells with deleted ATG7 were equally sensitive to both CQ treatment and CQ/sunitinib 
or erlotinib combination as those still harboring ATG7 (Eng et al., 2016). 
Specific mechanisms behind this disconnect have been investigated, although 
the exact cause is unclear.  FGFR3-mutant bladder cancer is another reported CQ-
sensitive cell type in which the mechanism of death is independent of autophagy 
inhibition.  Knockout of ATG7, ATG13, ULK1, and VPS34 did not recapitulate CQ 
sensitivity, whereas cell death was actually shown to be lysosomally-mediated due to 
cathepsin-related caspase activation.  Interestingly, cholesterol treatment prevented 
CQ-triggered cell death, and blocking of cholesterol metabolism enhanced CQ-triggered 
cell death both pharmacologically through atorvastatin treatment, or directly through 
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siRNA KO (King et al., 2016).  Another study was able to characterize sensitivity of cell 
lines to CQ based on expression of the autophagy-unrelated genes alcohol 
dehydrogenase 1 family member A1 (ALDH1A1) and helicase like transcription factor 
(HLTF).  Increased expression of ALDH1A1 was shown to enhance uptake of 
lysosomotropic drugs, but is not directly related to autophagic flux or lysosomal 
disruption.  Increased expression of HLTF was shown to improve repair of ROS-based 
DNA damage.  Cell lines were effectively profiled into the CQ-sensitive (ALDH1A1high,low, 
HLTFlow) and CQ-insensitive (ALDH1A1low, HLTFhigh) categories (Piao et al., 2017).  To 
recapitulate – while treatment with autophagy inhibitors has been shown as an effective 
method of tumor sensitization to standard treatment methods, the actual mechanism of 
sensitization remains unclear and may be connected to some part of the lysosomal cell 
death pathway rather than (or in addition to) autophagy.   
Lysosomal Biogenesis in Response to Lysosomotropic Compounds 
 To further compound the lysosomal drug sequestering effect, lysosomal 
biogenesis is often triggered by lysosomal trapping and lysosomal disruption, which can 
exacerbate the effects of drug sequestration.  More specifically, multiple studies using 
lysosomal-accumulating drugs have been shown to trigger the activation of transcription 
factor EB (TFEB), which is often regarded as the master regulator of lysosomal 
biogenesis.  TFEB is a member of the MiT/TFE family of transcription factors, along with 
MITF, TFE3, and TFEC, and is a direct promoter of the coordinated lysosomal 
expression and regulation (CLEAR) network.  TFEB is located directly on the lysosomal 
membrane and is bound to mTORC1.  Under nutrient-rich conditions TFEB remains on 
the lysosomal membrane in the phosphorylated state, maintained by mTORC1 (Martina 
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et al., 2012).  Under autophagy-inducing conditions, namely starvation, lysosomal 
disruption, or mTORC1 inhibition, TFEB is subsequently dephosphorylated and 
translocated to the nucleus where it interacts with components of the CLEAR network to 
activate gene transcription related to lysosomal biogenesis, synthesis of lysosomal 
proteins, increased autophagy, and lysosomal exocytosis (Settembre et al., 2012; 
Napolitano and Ballabio, 2016).  This process can also be replicated by pharmacologic 
or genetic interventions (Roczniak-Ferguson et al., 2012; Settembre et al., 2012).  The 
general mechanism of TFEB activation is depicted in Figure 1.3.   
 
Figure 1.3. Mechanism of TFEB activation. Under normal nutrient and growth factor 
conditions (left) TFEB is actively phosphorylated by mTORC1 and remains bound to the 
lysosome.  Conditions inducing autophagy, like starvation, pharmacologic mTOR 
inhibition, or lysosomal disruption (right) cause mTORC1 to release its hold on TFEB by 
stopping its active phosphorylation (1), activating TFEB.  TFEB translocates to the 
nucleus where it activates components of the Coordinated Lysosomal Expression and 
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Regulation (CLEAR) network of genes, causing lysosomal biogenesis, autophagosome 
biogenesis, and autophagosome-lysosome fusion.   
 
TFEB has also been shown to be phosphorylated by master growth regulator 
ERK2/MAPK1, but details of the interaction are much less clear (Settembre et al., 2013; 
Napolitano and Ballabio, 2016).  Of note, components of the CLEAR network maintain a 
basal level of expression, meaning lysosomal turnover is always occurring – TFEB 
activation just works to increase this (Napolitano and Ballabio, 2016).  
 Another major player in TFEB activity is calcineurin.  As lysosomes serve as the 
calcium store for mammalian cells, autophagy inducing conditions cause release of 
intralysosomal Ca2+ stores by way of the mucolipin-1 (MCOLN1) channel.  This leads to 
activation of calcineurin, a phosphatase which also dephosphorylates TFEB (Medina et 
al., 2015).  
 The role of TFEB and the MiT/TFE family in autophagy is becoming increasingly 
clear.  TFEB has been shown to bind promoter regions of a handful of autophagy genes 
(Settembre et al., 2013), which causes effects such as biogenesis of autophagosomes, 
promotion of autolysosome formation, and autophagy substrate degradation steps 
(Settembre et al., 2011).  Cells overexpressing TFEB have shown increased 
autophagosome count and buildup of LC3, which is further enhanced by treatment with 
BafA1 and two other autophagy inhibitors, pepstatin and cysteine proteinase inhibitor 64 
(Settembre et al., 2013).  On the other hand, TFEB knockdown results in decreased 
LC3-II in both nutrient rich and scarce situations, an effect which was not altered by 
treatment with BafA1 (Settembre et al., 2013).  In addition, TFEB overexpressing cells 
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increased autophagy gene expression matching nutrient deprivation conditions with 
high significance (Settembre et al., 2013).  Results were recapitulated in the livers of 
transgenic mice (Settembre et al., 2013).   
 Due to the critical role of TFEB as a transcription factor, mutations or large 
changes in expression can have a significant impact on cellular function.  Mutations to 
the two serines governing phosphorylation status (Ser142 and 211), specifically Ser-Ala 
mutations, are shown to cause constant TFEB activation and residence in the nucleus 
(Napolitano and Ballabio, 2016).  As expected, TFEB overexpression has been shown 
to cause significant increase in the number of lysosomes and lysosomal enzyme activity 
(Napolitano and Ballabio, 2016).  Increased MiT/TFE family expression or alteration has 
been linked to tumorigenesis.  Amplification of MITF has been found to account for 
roughly 20% of melanomas (Stark and Hayward, 2007), as well as soft tissue tumor 
clear cell sarcoma survival and progression (Davis et al., 2006).  TFEB amplification has 
been linked with non-small cell lung cancer metastasis (Giatromanolaki et al., 2015) and 
pancreatic ductal adenocarcinoma (PDA) (Perera et al., 2015).  PDA solid tumors were 
noted to have roughly 15-fold higher lysosome number, significantly higher MiT/TFE 
gene expression (expression less than only melanoma and kidney), and autophagy 
dependence (Perera et al., 2015).  Knockdown of MiT/TFE in PDA resulted in 
lysosomes of roughly 3-fold larger in diameter, mimicked by BafA1 treatment.  Buildup 
of autolysosomes, wherein substrates have not completed digestion, elevated 
lysosomal pH, and lower autophagic flux were associated with TFE3 knockdown.  
Elevation of MITF or TFE3 expression was shown to activate lysosomal genes and 
autophagy, including a higher level of LC3-II which was further increased with CQ 
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treatment in PDA (Perera et al., 2015).  TFEB and lysosomal gene overexpression was 
also observed in stage 1 human breast cancer.  Specifically, upregulated TFEB was 
associated with genes like LAMP-2, cathepsin D, LC3-A, and, of particular interest, 
hypoxia-inducible factor 2α.  Additionally, TFEB overactivation in the nucleus was 
shown to be linked to increased glycolysis and acidic extracellular conditions 
(Giatromanolaki et al., 2015).  
 Overall, the role of the MiT/TFE family is still being investigated for its direct role 
in cell progression and survival, but indirect involvement is largely apparent as the result 
of some drug treatments as indicated by lysosomal biogenesis and other results from 
MiT/TFE stimulation.  Lysosomotropics primarily induce these effects that trigger 
lysosomal adaptation.  One particular study by Lu et. al. (Lu et al., 2017) heavily 
examined lysosome-related treatment effects of a small panel of eight clinically and 
chemically-diverse drugs in the immortalized retinal pigmented epithelium cell line, 
ARPE-19.  Drugs tested include autophagy inhibitor CQ, and autophagy inducers 
fluoxetine, imipramine (IMP), latrepirdine (dimebon), tamoxifen, chlorpromazine, 
amitriptyline, and verapamil; reporting comprehensive treatment effects as they relate to 
lysosome-related responses discussed previously in this chapter.  Lysosomal burden 
was reported to increase by 50% or greater by 24 hours for all drugs/doses (CQ highly 
dose-dependent at 25, 50, 100µM), as indicated by both LAMP-2 staining and mRNA 
expression.  Diminished staining of LysoTracker Red indicated pH-quenching between 
30-60 minutes for all drugs except IMP, followed by recovered staining between 4 and 
24 hours indicating pH-restoration.  Cathepsin B activity (Magic Red staining) was 
markedly increased with all drugs/concentrations at both 4 and 24 hour timepoints; 
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Cathepsin D (Bodipy FL-pepstatin A staining) showed the same trend only at 24 hours 
along with increased mRNA expression.  Regarding actual MiT/TFE factors, all drugs 
induced dose-dependent increases in TFEB, TFE3, and MITF nuclear translocation at 4 
and 24 hours – with CQ being effective as soon as 1 hour after treatment.  In the 
presence of TFEB and TFE3, but not MITF knockdowns, CQ still caused upregulation of 
TFEB and TFE3 mRNA expression along with increased LAMP-2 and cathepsin D.  
MITF knockdown and knockdown of all three was associated with reduced mRNA 
expression of LAMP-2 and cathepsin D.  CQ and dimebon treatment in the presence of 
the triple knockdown further decreased expression of LAMP-2 and cathepsin D, 
signifying that all three transcription factors are coherently involved in lysosomal 
response.   As it relates to autophagy inhibition, all drugs caused significant dose-
dependent increase of p62 (macroautophagy), membrane phospholipid 
(macroautophagy), and GAPDH (chaperone-mediated autophagy) at 24 hours.  
Additionally, an extracellular photoreceptor that is taken up and degraded by 
lysosomes, opsin, showed increase signaling for all drugs relative to control.  Results 
from these autophagy markers indicate that lysosomotropic-mediated lysosomal 
biogenesis does not necessarily result in a reduction of lysosomal dysfunction.  Finally, 
the importance of calcium signaling in lysosomal function was highlighted by 
pretreatment with BAPTA-AM, a permeable Ca2+ chelator.  A 1hr pretreatment with 5µM 
BAPTA caused 1) decreased lysosomotropic-induced nuclear translocation of 
TFEB/TFE3 but not MITF, 2) decreased lysosomotropic-induced lysosomal biogenesis, 
3) caused greater than additive combination cytotoxicity effects (Lu et al., 2017).   
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 While not as comprehensive, a handful of studies report similar lysosome-
biogenesis and related effects as a result of treatment with lipophilic weakly basic 
chemotherapeutics.  Vincristine treatment at 100nM over 24hr in HeLa and MCF-7 cells 
led to a significant increase in lysosomal burden, and massively sensitized the cells to 
the lysosomal destabilizer (causes cathepsin-mediated cell death) siramesine (Groth-
pedersen et al., 2007). Another study in MCF-7 observed TFEB translocation in 
response to nM concentrations of DOX and mitoxantrone.  Of particular note was that 
mitoxantrone was able to increase lysosomal burden by 2.7-fold at 10nM, 6% of the 
reported IC50, and as much as 16.4-fold at 30nM (Zhitomirsky and Assaraf, 2015).  In a 
study previously discussed with tongue squamous cell carcinoma, cisplatin resistance 
was attributed to cisplatin-induced lysosomal biogenesis mediated by TFEB-activation.  
Interestingly, this mechanism was regulated by c-ABL – a tyrosine kinase that 
modulates the key tumor suppressor p53 (Chu et al., 2018).  TFEB overexpression and 
knockdown was examined in the presence of DOX, finding that overexpression 
enhanced DOX autophagy activation while reducing sensitivity to DOX, whereas 
knockdown caused complete opposite effects.  ATG5 knockdown under these 
circumstances had the same effect of increasing DOX potency even during TFEB 
overexpression (Fang, 2017).  Additionally, the weakly basic MEK inhibitors trametinib 
and refametinib were associated with an increase in overall lysosome volume fraction of 
PDAC cells, which was further exacerbated the longer the cells were exposed to the 
drugs.  The lysosomal biogenesis was shown to be caused by TFEB activation, and 
knockdown of TFEB was able to prevent lysosomal biogenesis associated with MEK 
inhibition by trametinib and refametinib (Zhao et al., 2020).  
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A study investigating TFEB dynamics in response to lysosomotropic drugs 
showed that TFEB was significantly activated in the nucleus of cells in as little as 90 
minutes of exposure to agents including siramesine, sunitinib, mefloquine, and 
chloroquine (Zhitomirsky et al., 2018).  TFEB continued to increase in nuclear activity 
for the duration of the experiment, 180 minutes, and, specifically with siramesine, the 
study observes a disassociation of mTORC1 from the membrane.  This suggests that 
lysosomtropic agents activate TFEB through inhibition of mTORC1 (Zhitomirsky et al., 
2018).  
 In addition to autophagy inhibition, lysosomal disruption and lysosomal-mediated 
cell death play a role in augmenting primary chemotherapy.  Many cell lines thought to 
be autophagy-dependent due to their CQ/HCQ sensitivity have shown mechanistically 
that their sensitivity is due to other lysosomal-related pathways affected by CQ/HCQ 
treatment.  This highlights the need to clearly characterize mechanistic autophagy 
dependence versus sensitivity to lysosomal disruption.  To add complication, the two 
are highly connected as lysosomes are the primary autophagy mediator, and disrupting 
one tends to disrupt the other.  Additionally, a possible link to elevated levels of 
autophagy in response to chemotherapy treatment has been found in TFEB.  TFEB 
activation by cellular stress increases the autophagic and lysosomal burden of the cell, 
which promotes increased clearance of the primary chemotherapeutic from the cell, as 
well as increasing the effective lysosomal drug sink, pulling the chemotherapeutic away 
from its target within the cell.  This highlights the importance of CQ/HCQ and BafA1 in 
neutralizing this drug sink effect, in addition to their autophagy inhibiting capabilities.  
Lysosomal studies have provided an important link between autophagy inhibitors and 
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their role in overcoming drug resistance in tumor cells, and have revealed the role of 
TFEB as a key player in acquisition of this resistance.  Additionally, it is unclear what 
role TFEB activation may have in pharmacokinetic alterations of lysosomotropic agents, 
particularly over long periods of exposure both in vitro and in vivo.  
 
Autophagy and the Acidic Microenvironment in Cancer 
Extracellular acidification, response, and role in drug resistance – A Hallmark of Cancer 
 
One of the emerging hallmarks of cancer, particularly solid tumors, is altered pH 
homeostasis within the tumor microenvironment – particularly an acidified extracellular 
space and alkalinized intracellular space (Hanahan and Weinberg, 2011).  Due to the 
random organization of vasculature within the tumor microenvironment, hypoxic tumor 
subpopulations develop and must produce energy through glycolysis.  Induction of 
acidity in these subpopulations is due to the Warburg effect, which is a result of 
significantly higher glucose consumption in cancer cells, even in normoxic conditions – 
termed “aerobic glycolysis” (Hanahan and Weinberg, 2011).  Briefly, in cancer cells 
most glucose is converted to lactate through aerobic glycolysis, even in the presence of 
normal oxygen concentrations.  Lactate is a known inflammatory agent, and elevated 
levels of lactate have been linked to tumorigenesis and metastatic potential in the clinic 
(Walenta et al., 1997; Brizel et al., 2001).  Another byproduct of aerobic glycolysis is H+, 
which must be accounted for by the cell to avoid toxic cytosolic acidification.  A primary 
mechanism to account for rapid proton formation is an increase in cellular proton pump 
expression, wherein cellular membrane proton pumps/exchangers and V-ATPase play a 
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role.  Due to the higher metabolic demands of the cell, overexpression of proton pumps 
yields the characteristic tumor acidic extracellular space (pHe = 6.5-7.1) and alkaline 
intracellular space (pHi = 7.2-7.4) (Kato et al., 2013).  Acidic extracellular pH has been 
linked to metastasis as well, and the relationship has been shown by increased 
metastatic burden of melanoma cells pretreated with acidic media in vivo (Rofstad et al., 
2006).  
 Altered pH homeostasis in tumor cells is associated with several defining 
characteristics that pose a challenge from the treatment perspective.  First of all, 
increased metastatic potential is known to be associated with the cell-ECM relationship, 
particularly through proteolytic enzymes that remodel the ECM, and angiogenic 
promoters that accelerate metastatic potential (Lunt et al., 2009).  Additionally, 
chemoresistance in an acidic pHe is acquired through two mechanisms – induction of 
the drug efflux pump p-glycoprotein (P-gp), and reduced chemotherapeutic membrane 
permeability.  P-glycoprotein is a cellular membrane pump associated with efflux of 
chemotherapeutics, so having higher activity of this molecule means more drug will be 
pumped out of the cytosol and back into the extracellular space.  Higher levels of P-gp 
are associated with a multidrug resistant (MDR) phenotype (Lu et al., 2017c).  Reduced 
chemotherapeutic membrane permeability in an acidic pHe is another issue entirely.  It 
involves reduced fraction of drug that is able to diffuse across the membrane due to 
increased ionization as described by Henderson-Hasselbach fundamentals.  Briefly, 
many chemotherapeutic drugs are weakly basic molecules, meaning that a majority of 
the drug will be in the most permeable, unionized form at neutral pH.  As pH decreases, 
the fraction of unionized form of a weakly basic molecule decreases as well, meaning a 
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smaller fraction of that molecule can permeate the membrane – the same concept 
which applies to lysosomal trapping.   
 Another characteristic of MDR tumor cells involves higher prevalence of acidic 
organelles, and a larger pH gradient between them and the cytosol (You et al., 2009).  
The effect of this phenotype also involves reduced chemotherapeutic membrane 
permeability, as described above, except in the context of lysosomal trapping.  To 
reiterate the description in the previous chapter -  highly acidic organelles (pH ~4-5) 
exhibit an ion trap effect, meaning that once a weakly basic molecule permeates into 
the lumen a majority becomes ionized and cannot diffuse back into the cytosol.  This 
results in a natural “drug sink” that pulls weakly basic molecules away from their target 
site elsewhere in the cell.  In this case acidic pHe causes weakly basic drugs to 
protonate, preventing them from crossing the cell membrane.  This effect was observed 
in MCF7 cells, where mitoxantrone, daunorubicin, and doxorubicin (all weak bases) 
were significantly reduced in potency by 2-8 fold as media pH was decreased from 7.4-
6.8 (Mahoney et al., 2003).  Alternatively, weak acids increased in potency, and the 
zwitterion paclitaxel was not significantly affected by pH.  
 Another observed effect of acidic pHe is altered lysosomal trafficking, specifically 
from the perinuclear region to the cell periphery.  As discussed in the previous chapter, 
MDR and metastatic progression are associated with lysosomal relocation from the 
perinuclear region to the cell periphery.  This observation is recapitulated as increasing 
degree of lysosomal relocation to the periphery with acidic pH is associated with 
increased metastatic potential of a panel of cell lines (Glunde et al., 2003).  More so, 
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acidic pHe is associated with a significant decrease in lysosomal burden for poorly 
metastatic cells, and an increase in highly metastatic cells (Glunde et al., 2003).  
 In relation to altered lysosomal trafficking, several studies have shown elevated 
autophagy under hypoxic/acidic conditions, which acts as a protective mechanism. 
Exposure to acidic conditions (pH < 7.0) has been associated with increased LC3 in 
human melanoma cells, which is further increased with BafA1 treatment (Marino et al., 
2012).  Acidic media was shown to cause increased phosphorylation of AMPK and 
inhibition of mTOR, similar to glucose starvation.  Human melanoma cells also 
experienced slower growth rates with decreasing pH, which was significantly 
exacerbated by ATG5 knockdown (Marino et al., 2012).  A similar study observed two-
fold increase of LC3-II and p62 buildup as well as hypoxia-induced cell death in MCF7, 
PC3, and LNCaP cell lines.  This effect was also amplified with ATG7 and Beclin1 
knockdown, or pharmacologic V-ATPase inhibition by pantoprazole, which were 
recapitulated in xenografts.  Interestingly, this study noted increasing LC3 relative to 
increased hypoxia (based on distance from blood vessels), which was reduced 
significantly in ATG7 and BECN1 knockdown xenografts (Tan et al., 2016).  While these 
observations of autophagy dependence in hypoxic/acidic environments may make 
inhibiting autophagy seem like a good treatment option, acidic pHe has actually been 
shown to prevent autophagy inhibition by CQ (Pellegrini et al., 2014).  Acidic media 
completely prevented CQ-induced apoptosis and autophagy inhibition, where buffering 
acid-conditioned cells restored sensitivity to CQ.  Interestingly, in vivo tumor samples 
showed LC3 accumulation only in normoxic areas (Pellegrini et al., 2014).   
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 In addition to studies of acidity and hypoxia  in cell lines or tumor xenografts, 
3-D spheroids have shown to be a useful in vitro tool for mimicking these features of the 
tumor microenvironment.  Specifically, the larger the spheroid the more pronounced the 
microenvironmental effect.  Spheroids >500um in diameter can reflect 
microenvironmental factors observed in human solid tumors, particularly acidic and 
hypoxic gradients as well as a hypoxic core (Nath and Devi, 2016).  The paper by 
Nunes et. al. (Nunes et al., 2019) outlines three studies in spheroids that confirm the 
suspected mechanism of hypoxic gradient formation in spheroids, which indicates a 
higher consumption of oxygen by cell proliferation at the periphery of the spheroid, 
leading to lower oxygen concentrations in these regions compared to surrounding 
media.  This, coupled with the oxygen diffusion gradient, ultimately exacerbates the total 
oxygen gradient and leads to a hypoxic core (Mueller-Klieser and Sutherland, 1982; 
Mueller-Klieser, 1984; Grimes et al., 2014a; Grimes et al., 2014b).  Recapitulation of 
hypoxic factors, particularly of proteins of the hypoxia-inducible factor (HIF) have been 
shown to increase in cells cultured in 3-D spheroid format versus 2-D, particularly 
pronounced HIF-1α in Hela cells cultured in 3-D versus 2-D (Tian et al., 2010).  In MCF7 
cell spheroids HIF-1α was highly expressed, associated with an increase in P-gp which 
caused doxorubicin resistance and ultimately a decrease in doxorubicin uptake in MCF7 
spheroids relative to 2-D cultures which reproduced a known mechanism of MDR 
(Doublier et al., 2012).  
In addition to extrinsic microenvironmental features such as hypoxia, spheroids 
have been observed to mimic autophagy of the in vivo tumor microenvironment more so 
than in 2-D cultures.  Follo et. al. (Follo et al., 2016) investigated autophagic flux in 
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mesothelioma cell lines by quantitation of LC3 puncta for autophagy inhibition and 
ATG13 for autophagy initiation.  They observed an overall increase in autophagic flux in 
3-D when compared to 2-D.  Furthermore, the suggest that increased ATG13, i.e. 
increased autophagy initiation, is linked with a more positive outcome in patients.  In 
addition to overall autophagic flux, core autophagy transcription factors such as TFEB 
and FOXO3 are observed to be more highly expressed in spheroid cultures versus 2-D, 
and inhibition of core autophagy proteins such as BECN1, ATG5, and ATG7 or 
pharmacologic inhibition with CQ increases sensitivity of spheroid cultures to 
chemotherapeutic agents (Bingel et al., 2017).  Autophagy overactivation has also been 
observed in 3-D ovarian cancer cultures, associated with decreased proliferation with 
ATG KD (Wang et al., 2016). 
 Due to more in vivo similar microenvironments, spheroids can and have been 
used to study cellular uptake of drugs in the tumor microenvironment.  Moving further 
from the outer boundary towards the core, tumor spheroids have been shown to 
produce more lactate, which is linked to subsequent acidification of this region 
(Carlsson and Acker, 1988; Hirschhaeuser et al., 2010).  The oxygen gradient in 
spheroids is also associated with a pH gradient due to the inability of lactate to diffuse 
out of the spheroid center.  Spheroid extracellular pH has been shown to decrease 
proportional to depth, with large spheroids reaching acidic pH values in the range of 6.4-
6.8 (Swietach et al., 2012; McIntyre et al., 2016).  As might be expected, this gradient 
has been shown to contribute to decreased uptake of weakly basic drugs in deeper 
regions of the spheroid.  Of interest is the weakly basic compound, doxorubicin, which 
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was observed to decrease in overall uptake by 1.7x towards the core of the spheroid.  
This was associated with a decrease in sensitivity to the drug (Swietach et al., 2012).   
On the other hand, it may be possible to overcome the pH gradient observed in 
larger spheroids.  McIntyre et. al. (McIntyre et al., 2016) showed that treating spheroids 
with an inhibitor of sodium bicarbonate transporters could normalize pH throughout the 
entire spheroid, which was associated with an increase in core apoptosis.  This would 
be assumed to result in increased weak base drug uptake as well.  Additionally, the 
proton pump inhibitors omeprazole and lansoprazole were shown to increase 
doxorubicin uptake in spheroids cultured in acidic media, but not in neutral media 
(Paskeviciute and Petrikaite, 2019).  Multiple other studies have suggested the use of 
spheroids as an in vitro tool to more accurately investigate how drug response may look 
in vivo, specifically leveraging drug diffusion, MDR, generation of ROS, pH gradients, 
and cytotoxicity (Achilli et al., 2014; Mittler et al., 2017; Jove et al., 2019).   
Overcoming the Acidic Microenvironment 
 Attempts to overcome the pharmacologic treatment roadblocks and increased 
malignant potential correlated with acidic pHe involve targeting the tumor extracellular 
space for deacidification. Proton pump inhibitors (PPIs) are the current gold standard for 
neutralization of the extracellular space.  PPIs, such as omeprazole, esomeprazole, 
pantoprazole, lansoprazole, and rabeprazole, are clinically approved drugs primarily 
used to treat gastric ulcers by targeting the gastric H+/K+ ATPase (Shin and Sachs, 
2008).  PPIs are weakly-basic prodrugs that require acidic pH to activate.  They have 
short half-lives (1hr), but a pharmacodynamic effect of roughly 48 hours due to 
irreversible binding with the proton pump.  PPIs have characteristic high oral 
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bioavailability, but high interpatient variability attributed to Cyp3A4 metabolism (Shin 
and Sachs, 2008).  While PPIs are primarily used in gastric acidity-related issues, they 
have recently been found to inhibit other cellular proton pumps, including V-ATPase 
(Fais et al., 2007; Neri and Supuran, 2011).  In addition to their broader proton pump 
targeting, there is evidence of PPIs inhibiting P-gp, observed by altered digoxin efflux in 
Caco-2 cells (Pauli-Magnus et al., 2001).   
The idea that PPIs may serve as valuable tools in counteracting acidity of the 
tumor microenvironment has been significantly investigated in preclinical studies, which 
have led to a few recent clinical trials involving chemocombination therapy with PPIs.  
Regarding preclinical studies, the ability of PPIs to inhibit the V-ATPase, neutralizing 
lysosomal pH, has been shown using three clinically-approved PPIs in human 
melanoma and adenocarcinoma (Luciani et al., 2004).  24 hour pretreatment with PPIs 
were nontoxic and sensitized cell lines and xenografts to cisplatin, 5-FU, and vinblastine 
by up to 100x.  This was accompanied with notable drug relocation from the lysosome 
to their target site, along with increased extracellular and lysosomal pH.  Within the 
realm of chemocombination sensitization, another study investigated combo 
sensitization abilities of omeprazole (OMZ) and pantoprazole (PTZ) with gemcitabine 
and 5-FU in pancreatic cancer cells.  OMZ was effective on its own, with IC50 values 
between 2-120µM.  To put this in perspective, highest tolerable blood Cmax for 
pantoprazole was 85µM in clinical trials (Lu et al., 2017c). Omeprazole also reversed 
hormesis of 5-FU, and enhanced sensitivity to both 5-FU and gemcitabine dose-
dependently.  Lysosome-related effects of OMZ by increased LAMP-1 expression and 
altered cathepsin-D expression, but surprisingly not V-ATPase inhibition (Udelnow et 
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al., 2011).  Cytotoxic effects of PPIs, specifically esomeprazole (ESOM), were also 
shown in melanoma cells by increase of ROS through mitochondrial dysfunction.  
ESOM treatment shows autophagy inhibition capabilities through LC3-II accumulation, 
and sensitivity to treatment was significantly amplified by ATG5 and BECN1 (Marino et 
al., 2010).  PPI role in lysosomal targeting also causes lysosomal enzyme inhibition, 
specifically acid phosphatase and beta-n-acetylglucosaminidase in mouse spleen 
tissue.  Surprisingly, this was not recapitulated in liver tissue, likely due to significant 
first pass metabolism, which is also the primary driver of PK variability in these drugs 
(Liu et al., 2013).  An additional study showed both the pHe and pHlys targeting ability of 
OMZ.  Dose-dependent increase in endosomal pH with CQ, BafA1, and OMZ was 
observed, which directly correlated with increased cytotoxicity of DOX.  This did not 
result in significant cellular uptake of DOX, indicating it is not displaced to the lysosome 
anymore.  OMZ also increased penetration of DOX and mitoxantrone through multicell 
layers of tissue, where CQ and BafA1 did not (Lee and Tannock, 2006).  
While PPIs are sort of pan-specific when it comes to targeting, their role as 
clinically-approved V-ATPase inhibitors can be emphasized by studies directly 
interrupting the V-ATPase. Knockdown of the protein TM9SF4, which is an activator of 
V-ATPase, showed increased sensitivity to 5-FU, reducing malignant characteristics, 
and acidifying the cytosol while alkalinizing the extracellular space and lysosomes 
(Lozupone et al., 2015).  Another study knocked down the ATP6L sub-unit of V-
ATPase, which was associated with similar effects – sensitization and cellular relocation 
of 5-FU, DOX, VCR; and neutralization of lysosomal pH (You et al., 2009). 
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Overall, PPIs are safe and widely used drugs whose possible application to 
cancer therapy is being investigated clinically.  A study in human osteosarcoma 
observed the expected effects with 24hr pretreatment of 60µM ESOM followed by 
cisplatin in human osteosarcoma cells, and complete tumor regression was observed in 
xenografts using 24hr pretreatment of 25mg/kg ESOM followed by 5mg/kg cisplatin.  
This study was coupled with a prospective phase 2 clinical trial in human patients, using 
two-day pretreatment of 40-120mg/day ESOM before regimens involving methotrexate, 
cisplatin, and doxorubicin.  The outcome involved increased patient response compared 
to historical control, and while not quite statistically significant (p = 0.07, n = 61 in 
chondroblastic osteosarcoma) the toxicity profiles remained unchanged by ESOM 
pretreatment (Ferrari et al., 2013).   
 The indication of PPI efficacy in preclinical studies along with no observed 
toxicity exacerbation in initial clinical trials have led to multiple phase I/II clinical trials 
evaluating the efficacy of PPIs for use in treating cancer patients, including two in 
companion animals.  One preliminary retrospective study in breast cancer patients 
showed OMZ treatment augmented chemotherapy and significantly improved survival, 
and the trial is aimed at examining the mechanism of sensitization (NCT02595372).   
Three other trials are investigating optimal dosing (NCT01163903), and role of high 
dose PPI (NCT01748500, NCT01069081) in augmenting primary chemotherapy of 
patients with various solid tumor types (Koltai, 2016).  Results from the two phase I/II 
clinical trials in companion animal patients have led to overall positive results, with 
tumor regression for most animals observed.  To recapitulate results from the phase I/II 
study in animals with chemoresistant tumors (Spugnini et al., 2011): 19/28 dogs 
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experienced varying degrees of response (including 9/11 lymphoma dogs on the 
Wisconsin CHOP Protocol), whereas only 2/10 control dogs experienced partial 
response.  4/28 dogs experienced GI side effects (vomiting and diarrhea). 6/7 cats 
responded, two of which had complete remission.  2/7 cats in the control group showed 
partial response.  Overall response in PPI patients was 68% whereas control was 17% 
(with no patients showing complete remission).  Dosing was 5 mg/kg lansoprazole for 3 
consecutive days with chemotherapy administration.  Clinical trial results thus far have 
shown dose tolerance up to 240mg/day, giving a serum Cmax of roughly 85µM (Lu et al., 
2017c) which is similar to cytotoxic concentrations observed in vitro.  This high dosing 
strategy is consistent with Zollinger-Ellison-Syndrome patients who are treated with 
OMZ as much as 120mg x 3/day, resulting in uncommon mild side effects (Frucht et al., 
1991) and no reported long-term side effects (Thomson et al., 2010). 
 Overall PPIs appear safe to use, accompanied by good evidence showing their 
ability to augment chemotherapy strategies.  This is being investigated in early phase 
clinical trials and has shown positive results thus far.  Due to neutralization of the tumor 
extracellular environment, PPIs may serve as a useful treatment strategy to augment 
HCQ treatment efforts in the clinic, as a likely mechanism of HCQ nonresponse is due 
to hypoxic subpopulations in solid tumors (Pellegrini et al., 2014; Tan et al., 2016).  
Additionally, PPIs have been shown to inhibit autophagy and augment primary 
chemotherapy treatments in a similar manner as HCQ.  The combination of increased 
and homogenous HCQ uptake throughout the tumor microenvironment, compounded 
autophagy inhibition, and additive tumor cell cytotoxicity provide solid hypothetical 
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grounds for further investigation of treatment regimens including a combination of these 
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Hydroxychloroquine:  A Physiologically-Based Pharmacokinetic Model in the 




Hydroxychloroquine (HCQ) is a lysosomotropic autophagy inhibitor being used in over 
50 clinical trials either alone or in combination with chemotherapy.  Pharmacokinetic 
(PK) and pharmacodynamic (PD) studies with HCQ have shown that drug exposure in 
the blood does not correlate with autophagy inhibition in either peripheral blood 
mononuclear cells (PBMCs) or tumor tissue.  To better explain this PK/PD disconnect a 
physiologically-based pharmacokinetic model (PBPK) was developed for HCQ 
describing the tissue-specific absorption, distribution, metabolism, and excretion as well 
as lysosome-specific sequestration.  Using physiologic and biochemical parameters 
derived from literature or obtained experimentally the model was first developed and 
validated in mice, and then adapted to simulate human HCQ exposure in whole blood 
and urine through allometric scaling and species-specific parameter modification.   The 
human model accurately simulated average steady-state concentrations (Css) of those 
observed in five different HCQ combination clinical trials across seven different doses, 
which was then expanded by comparison of the Css distribution in a virtual human 
population at this range of doses.  Value of this model lies in its ability to simulate HCQ 
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PK in patients while accounting for PK modification by combination treatment 
modalities, drug concentrations at the active site in the lysosome under varying pH 
conditions, and exposure in tissues where toxicity is observed.     
 
Introduction 
Hydroxychloroquine (HCQ) is a 4-aminoquinoline class molecule traditionally 
used as an anti-malarial medication, but currently being investigated in over 50 cancer 
clinical trials either alone or in combination with chemotherapy (ClinicalTrials.gov).  
HCQ’s putative mechanism of anticancer activity is through the inhibition of autophagy, 
a naturally occurring metabolic process that involves the digestion of a cell’s own 
organelles, proteins, and other cellular debris in the lysosome.  HCQ is the current “gold 
standard” for autophagy inhibition in a clinical setting as it exhibits similar potency yet 
less toxicity in long-term dosing compared to other clinically approved autophagy 
inhibitors, such as chloroquine (Shi et al., 2017).  There is significant evidence that 
autophagy is heavily upregulated in certain tumor types, acting as a survival mechanism 
against both the harsh tumor environment and chemotherapy treatments (Levy et al., 
2017, Yang et al., 2011).  Inhibition of this process by augmenting the primary treatment 
method with HCQ has been shown to re-sensitize tumors to a resistant therapy regimen 
or enhance response to a current treatment regimen (Amaravadi et al., 2011, Barnard et 
al., 2014, Carew et al., 2012, Levy et al., 2014).    
 Mechanistically, HCQ is a weakly basic compound that alkalinizes the highly 
acidic lysosome, preventing the autophagosome-lysosome fusion step of autophagy (de 
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Duve, 1983, Lu et al., 2017).  This mechanism drives its pharmacokinetics (PK), 
primarily through an ion-trap accumulation observed in lysosomes and other acidic 
compartments. Overall, HCQ PK has been well characterized in multiple species, and 
the PK profile appears to scale linearly with dose escalation, though exhibits a 
significant amount of intersubject variability (Fan et al., 2015, Furst, 1996, Lim et al., 
2009, McChesney, 1983, Tett et al., 1988).  Sources of variability are likely due to the 
fact that these studies have been done by different research groups over the course of 
decades as well as variance in absorption, distribution, metabolism and elimination 
(ADME) factors related to the physicochemical properties that drive its PK. 
 HCQ is typically administered as an oral tablet, in doses ranging from 100 mg to 
1200 mg daily by which it is readily absorbed within 2-4 hours (Browning, 2014).  The 
fraction absorbed is estimated to be 74 ± 13% (Browning, 2014, Tett et al., 1989).  HCQ 
blood concentration peaks shortly after the absorption phase, and falls relatively quickly 
due to rapid partitioning into organs.  Accumulation in lysosomes appears to drive the 
large volume of distribution in plasma, while binding to melanin contributes to the long 
terminal half-life (Tett et al., 1990).  It is roughly 50% bound to plasma protein in the 
blood (Furst, 1996).  Metabolism appears to be the primary driver of HCQ clearance.  It 
occurs in the liver through CYP3A4 and CYP2C3 driven dealkylation to form 
desethylhydroxychloroquine, desethylchloroquine, and bisdesethylchloroquine, the 
former which exhibits therapeutic activity and PK thought to be comparable to HCQ 
(Browning, 2014, Kim et al., 2003, McChesney et al., 1965, Qu et al., 2015).  Rate of 
metabolism varies tremendously across species, leading to significant cross-species 
differences in half-life that ranges from hours in mice to days in humans (Tett et al., 
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1988).  Excretion takes place primarily in the kidneys, accounting for roughly 22% of 
HCQ total blood clearance, with liver clearance assumed to account for the rest (Tett et 
al., 1988).  Mean renal clearance from plasma is reported as 3 to 4 times greater than 
GFR corrected for protein binding, suggesting the drug is secreted in addition to 
filtration (Tett et al., 1988). 
 In the context of cancer treatment, HCQ blood exposure correlates with neither 
tumor exposure nor pharmacodynamic (PD) markers of autophagy inhibition in both 
peripheral blood mononuclear cells and tumor tissue (Barnard et al., 2014).  To 
investigate the PK/PK and PK/PD disconnect observed in HCQ treatment, as well as 
the high inter-individual patient variability in PK studies, a physiologically-based 
pharmacokinetic model (PBPK) serves as a powerful investigative tool.  This model 
allows for simulation of patient profiles and study of relationships between drivers. 
Developed around key tissues as well as physiologic and biochemical properties 
associated with the ADME profile, this PBPK model of HCQ can simulate exposure in 
tissues associated with toxicity as well as therapeutic effect.  It can also investigate the 
variability in tumor pH that may contribute to the disconnect between exposure in the 
blood and autophagy inhibition in the tumor, specifically the inverse relationship 
between HCQ uptake and extracellular pH (Pellegrini et al., 2014).  
 The PBPK model described for HCQ was developed using biochemical and 
physiologic parameters adapted from literature or obtained experimentally, with 
significant focus on the pH-based aspect of PK.  Tissues represented in the model are 
involved with absorption, metabolism, excretion, binding, or are subject to toxicity.  
Model output simulates single intraperitoneal dose tissue exposure in mice.  
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Biochemical and physiologic parameters were then adjusted accordingly to simulate 
whole blood exposure in humans.  Simulation output across multiple dosing regimens 
and across different species matches well with experimental PK data, indicating that key 
drivers of HCQ PK are accounted for by the PBPK model.  
 
Materials and Methods 
PK Study in Mice 
Protocols for the mouse studies were approved by the Institutional Animal Care 
and Use Committee at Colorado State University. Female BALB/c mice were treated 
with a single intraperitoneal dose (IP) of 20, 40, or 80 mg/kg HCQ (Sigma-Aldrich, 
H0915). Tissues and whole blood were collected from 3 mice for each dose at 3, 6, 12, 
24, 48 and 72 hours (n = 54). Levels of HCQ and dHCQ in whole blood and tissues 
were determined via a previously validated liquid chromatography-tandem mass 
spectrometry (LC-MS/MS) assay (Barnard et al., 2014).  Briefly, 100μL of tissue 
homogenate was added to a micro centrifuge tube along with 10μL of Milli-Q water, 
10μL 50/50 acetonitrile/Milli-Q, 10μL of 2.5μg/mL CQ (internal standard), and 100μL of 
acetonitrile.  Samples were vortexed for 5 minutes and centrifuged for 10 minutes at 
13,300 RPM.  80μL of this mix was transferred to an autosampler vial and mixed with 
120μL of Milli-Q water prior to mass spectrometer analysis.  Standards and quality 
controls were prepared in an identical manner.  Data points below the LLOQ of 1 ng/mL 
for HCQ and 10 ng/mL for dHCQ were excluded.  Non-compartmental analysis (NCA) 
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measured exposure, as determined by area under the drug concentration versus time 
curve (AUC0-inf), to both HCQ and dHCQ. 
HCQ Microsomal Metabolism Studies 
Metabolism rate constants for the human PBPK model were obtained through 
microsomal incubation.  Pooled mixed gender human liver microsomes at 20 mg/mL 
were obtained from XenoTech and were split into 100 μL aliquots prior to beginning 
microsomal incubations.  Briefly, microsome stocks were diluted to 0.5 mg/mL in 
100mM phosphate buffer and pre-incubated with an NADPH regenerating system for 5 
minutes.  100x HCQ (Sigma-Aldrich H0915) was spiked in to the microsome mix and 
incubated for up to 3 hours. Reactions were terminated by addition of 100 μL of 
acetonitrile, vortexed for 5 minutes, and centrifuged at 14,000 rpm for 5 minutes to 
pellet the microsomal protein.  Prior to analysis by HPLC the samples were mixed 50:50 
with the internal standard of 500 ng/mL camptothecin dissolved in MilliQ water.  Rate of 
metabolism was determined by rate of n-desethylhydroxychloroquine formation, the 
primary metabolite of HCQ (Browning, 2014).  Analysis of samples was done using the 
liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay mentioned in the 
previous section. Standards and quality control samples were prepared in an inactive 
microsomal homogenate matrix in the same way as samples and containing identical 
amounts of internal standard. Key structural and physicochemical properties of HCQ are 




Figure 2.1. HCQ molecular structure with key physicochemical properties  
 
Lysosomal Quantification in Mouse Tissue 
Lysosome contents of the various tissues incorporated in the model were 
determined by analyzing acid phosphatase enzyme activity.  It was assumed that 
lysosome volume fraction of the tissue was directly proportional to the acid phosphatase 
activity in that tissue.  Tissues were extracted from BALB/c mice, diluted to 100 mg/mL 
in 0.2 M acetic acid buffer (pH = 5.0), and homogenized in a Bullet Blender Storm 2400 
at max speed for 5 minutes.  Samples were centrifuged at 5000 rpm for 10 minutes at 
4°C and homogenate was collected and transferred to new tubes.  Homogenate was 
vortexed, and 150 μL was transferred to a cuvette followed by 600 μL of acetic acid 
buffer to this same cuvette.  The cuvette was then incubated at 37°C for 10 minutes to 
inactivate additional enzymes.  After incubation, 250 μL of 32 mM p-nitrophenol 
dissolved in water was added to the cuvette.  Cuvette was inverted and read 
immediately on a DU 800 Spectrophometer at 420 nm for 5 minutes to collect 
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absorbance data.  Absorbance data at the 5 minute time point was normalized to the 
total protein content of the homogenate, as determined by comparison with a bovine 
serum albumin standard curve.  Acid phosphatase enzyme activity was reported as 
moles/min/mg protein, and values for each organ were compared to a fixed fraction for 
kidney (Kawashima et al., 1998, Sewell et al., 1986). 
PBPK Model Development 
Base Model Development 
The PBPK model for HCQ is represented by eight distinct, flow-limited tissue 
groupings that could describe HCQ PK based on physiologically-derived metabolism, 
renal elimination, absorption, macromolecule binding, and lysosomal sequestration.  
Key features that the model aimed to capture were melanin binding to investigate cases 
of retinal toxicity, and lysosomal uptake kinetics to model intracellular PK at the active 
site.  Figure 2.2 depicts a schematic describing the system of these key tissues involved 
in HCQ PK.   
Typically administered orally, HCQ absorption occurs rapidly in the gut lumen, 
followed by transport to the liver where it undergoes first pass metabolism.  From there 
it is distributed to the rest of the body.  Key tissues include the kidney, the site of renal 
excretion, as well as eyes and skin, major sites of melanin binding, and the heart, due to 
observed instances of cardiomyopathy.  The rest of the body is lumped into the slowly 
perfused compartment, consisting of bone, fat, and muscle, as well as the rapidly 
perfused compartment which is composed of the remaining viscera.  Additionally, a 




Figure 2.2. Schematic of model describing key organs involved in HCQ ADME 
after oral dosing.  Absorption occurs in the gut, metabolism in the liver, and excretion 
in the kidneys.  Skin and eyes exhibit unusual PK properties due to extensive binding to 
melanin.  Heart is included due to cardiomyopathy as an observed side-effect in some 
cases.  The rest of the organs are split into slowly perfused (muscle, fat, bone) and 
rapidly perfused (internal viscera).  
 
tumor. Each compartment of the model is further described by a lysosomal sub-
compartment discussed in the next sub-section . 
 Mass balance of a typical tissue observed in the bulk portion of the model is 
described by equation (1) 
                    (1) 
76 
 
where mt is the amount of HCQ within the tissue, Qt is the blood flow rate to that tissue, 
Ca is the unbound arterial plasma concentration carried to the tissue, Ct is the free 
concentration within the compartment, Pt is the partition coefficient of that tissue, At is 
the lysosomal surface area, and ΔJlys is the net flux between the cytosol and lysosome.  
The only tissue with an exception to equation (1) is the liver, wherein arterial 
concentration is set to include free drug as well as bound drug due to dissociation of 
HCQ and protein occurring in the hepatic space (Meijer and van der Sluijs, 1989).   
 For tissues involved in clearance of HCQ an additional term is added to equation 
(1). For kidney, a renal clearance term is added and is represented by equation (2).  In 
the case of liver, a metabolism term is added and is represented by equation (3) for 
mouse and equation (4) for human.   
                  (2) 
                            (3) 
              (4) 
The first term of equation (2) accounts for renal filtration where GFR represents 
glomerular filtration rate, QK¬ represents blood flow to the kidney, and CA represents 
arterial blood concentration.  The second term represents active secretion where VK 
represents kidney volume, and Vmax and Km represent Michaelis-Menten constants for 
secretion.  Equation (3) describes the amount of HCQ metabolized in mouse and is 
represented by VL and CL, the volume and concentration of liver, respectively.  It is also 
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represented by Vmax and Km, Michaelis-Menten rate constants for metabolism.  
Equation (4) describes the amount of HCQ metabolized in human and is represented by 
the linear rate constant Met.  Melanin  binding is the other driving factor of distribution in 
the model, and so the amount of free HCQ unbound to melanin, applying to skin and 
eyes, is represented by equation (5).  
                                          (5)  
where mfree is the amount of unbound drug in the cytosol, mcyt is the total amount in 
the cytoplasm, Tmel – a function of melanin/HCQ binding ratio (MelBR) and melanin 
concentration in the tissue (Ctmel), is the binding capacity of melanin for HCQ, Kmel is 
the binding affinity of HCQ to melanin, and Ct is the free concentration in the cytosol.  
Values for Tmel and Kmel were estimated from a previous study on HCQ binding 
(Schroeder and Gerber, 2014) and melanin concentrations for skin and eye have been 
reported (Browning, 2014, Durairaj et al., 2012).  The parameters for the PBPK model 
can be found in Table 2.1 along with the source of each variable.  
ADME Parameters 
Tissue volumes and blood flows were standard, fixed values as previously 
described (Brown et al., 1997). The only exception was eye, which came from multiple 
sources (Choi et al., 2012, Zhi et al., 2012). 
 Absorption parameters were obtained from a prior study (Tett et al., 1989).  
Specifically, the absorption rate constant (KA) was modeled as linear uptake that 
achieved near full absorption within an average of 3 hours.  Fraction absorbed was set  
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Table 2.1. PBPK Model Variables 
Tissue Volume Symbol Mouse Human Reference 
Kidney % body 
weight 
1.7 0.4 Brown et al., 1997 
Heart  0.5 0.5 Brown et al., 1997 
Eye  0.034 (g) 15 (g) Mou – Experimental; Hum - 
Brittanica 
Skin  16.5 3.7 Brown et al., 1997 
Gut  4.2 1.4 Brown et al., 1997 
Liver  5.5 2.57 Brown et al., 1997 
Blood  4.9 7.9 Brown et al., 1997 
Slowly Perfused  56.1 75.7 Brown et al., 1997 




    
Kidney % cardiac 
output 
9.1 17.5 Brown et al., 1997 
Heart  6.6 4.0 Brown et al., 1997 
Eye  0.0566 0.0016 Mou – Zhi et al., 2012; Hum – 
Choi et al., 2012 
Skin  5.8 5.8 Brown et al., 1997 
Gut  14.1 18.1 Brown et al., 1997 
Liver  2.0 4.6 Brown et al., 1997 
Slowly Perfused  34.2 28.5 Brown et al., 1997 




    
Kidney PK 50 50 Wei et al., 1995 
Heart PH 44 44 Wei et al., 1995 
Eye PE 33 33 Wei et al., 1995 
Skin PS 26 26 Wei et al., 1995 
Gut PG 35 35 McChesney et al., 1967 
Liver PL 193 193 Wei et al., 1995 
Blood PB 7.2 7.2 Tett et al., 1988 
Slowly Perfused PSP 10 10 Wei et al., 1995; McChesney 
et al., 1967 
Rapidly Perfused PRP 150 150 Wei et al., 1995 
 
Metabolismb 
    














    
Plasma Protein 
Binding 
% bound 0.45 0.45 Browning, 2014 
Glomerular 
Filtration Rate 
GFR 0.125 0.11 Mou – Qi and Breyer, 2009 
Secretion Affinity Kmsec 
(μM) 









    
Absorption Rate KA (hr-1)  0.5 Tett et al., 1989 
Absorption 
Fraction 
FA  0.75 Tett et al., 1989 
 
Melanin Bindingd 
    
Melanin Affinity Kmmel 
(μM) 
 217 Schroeder and Gerber, 2014 










 300 Browning, 2014 
 
a. Most partition coefficients were optimized from Wei et al., 1995, McChesney et al.,  
1967, and Tett et al., 1998. Slowly perfused was an average value of adipose from Wei 
et al., 1995 and McChesney et al., 1967 
 
b. Values for mouse were calculated from liver PK data; Human rate constant was 
calculated from human liver microsomes and optimized to meet the ratio of metabolism 
vs. clearance reported by Tett et al., 1988 and 1989 
 
c. Total renal clearance was a function of plasma protein binding and GFR, with 
secretion coefficients optimized to meet total renal clearance values in tandem with 
metabolism reported by Tett et al., 1988 and 1989 
 
 d. Melanin binding parameters were taken from a bunch of sources and optimized for 
human.  Skin melanin is for an average person of light colored skin. The value 




to an average of 0.75 ± 0.13 of the dose, as described by human urine and blood data. 
First pass hepatic effect was deemed insignificant in this study as well, and was 
calculated at only 6% of the total dose.   Biliary secretion was initially considered, as 
fecal excretion of HCQ in rat was cited as 25% of total dose (McChesney, 1983); 
however, ratio of metabolite vs. parent were not observed.  Biliary secretion was tested 
in the model, assuming complete absorption, and was representative of a model lacking 
biliary clearance with 0.85-0.9 fraction absorbed.  As this fell within the range of 
absorption fraction observed in humans, biliary secretion was not considered a major 
driving factor of HCQ PK and was omitted from the model.   
 Distribution of the bulk model was primarily described by partition coefficients, 
the concentration ratio between plasma and tissue at steady state.  The partition 
coefficient values were derived and optimized using previously published data 
(McChesney et al., 1967, Tett et al., 1989, Wei et al., 1995). 
 Metabolism values for mouse were obtained and optimized from liver PK data by 
determining the Michaelis-Menten relationship that represented the compartmental 
clearance of this region.  The human metabolism rate constant was obtained by 
incubating HCQ with activated human liver microsomes, as described in the microsome 
section of materials and methods, and optimized to best fit human PK data.  Intrinsic 
scaling of in vitro to in vivo metabolism for CYP450 enzymes as previously described 
(Chiba et al., 2009) was not considered since moderate optimization of the microsome-
derived metabolism rate yielded clearance that fit the clinical data well, and satisfied the 
hepatic clearance portion observed in human patients (Tett et al., 1988).  Intestinal 
metabolism was considered negligible due to the significantly lower CYP3A and 2C 
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levels observed in intestine compared to liver as well as low first pass metabolism 
(Thelen and Dressman, 2009).  
 Excretion was modeled as filtration and secretion, since mean renal clearance 
was found to be 3-4x greater than GFR (Tett et al., 1990, Tett et al., 1988, Tett et al., 
1989).  GFR was set to 0.125 for mouse (Qi and Breyer, 2009) and 0.11 for human of 
the unbound plasma flow to the renal tubules.  The Km and Vmax for renal secretion 
were optimized using the Nelder-Mead method to best fit the data, accounting for 3-4x 
GFR as secretion as well as the ~3:1 ratio of non-renal clearance (assumed to be liver 
clearance) to total renal clearance upon scaling from mouse to human (Furst, 1996, Tett 
et al., 1990). 
Lysosomal Compartment Development 
Within each tissue compartment was a lysosomal sub-compartment that was 
mathematically described as separate from its parent compartment.  The sub-
compartment was modeled to represent the ion trap effect that causes HCQ 
accumulation to millimolar concentrations in acidic regions, primarily the lysosome.  A 
schematic of lysosomal sequestration is represented in Figure 2.3, which depicts HCQ 
and HCQ+ moving freely across membranes at physiologic pH, but upon entering the 
acidic lysosome a majority of HCQ is in the 2+ state where it can no longer permeate 
the membrane and becomes trapped.  
 The mass balance of the lysosomal sub-compartment for each tissue is 





Figure 2.3. Intracellular mechanism of HCQ PK with pH dependence.  HCQ crosses 
membranes readily, but accumulates in acidic compartments due to being non-
permeable in the +2 state.   
 
                                  (6) 
where At represents the lysosomal surface area and ΔJlys represents the net flux 
between the cytosol and lysosome compartments.  The flux portion was adapted from 
the cell model proposed by Trapp et al. that describes lysosomal drug uptake on a 
cellular pharmacokinetic level. It was validated using a select handful of drugs with a 
variety of pKa and lipophilicity (Kow) values, one of which was chloroquine (Trapp and 
Horobin, 2005, Trapp et al., 2008).  The overarching principle in their cell model was 
application of Fick’s 1st law of diffusion with the Nernst-Planck equation, which 
incorporates electric charge into the movement of molecules through a biological 
environment.  Fick’s 1st Law of Diffusion, which only applies to the neutral form of HCQ 
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(Jn), is depicted by equation (7), and the combined Fick’s-Nernst-Planck version of 
diffusion (Jd) is equation (8).  These equations are combined to yield equation (9) 
                            (7)      
                       (8) 
                                                 (9)  
where fn represents the fraction of freely dissolved neutral HCQ, described by equation 
(10) (or reference equation 6 from (Trapp et al., 2008) for a more derived description). 
Pn and Pd represent the permeabilities of neutral and ionic HCQ states, Dz is the 
Henderson-Hasselbach activity ratio, C is the total HCQ concentration in the 
compartment (applying to either cytosol or lysosome), and N is the Nernst equation. 
Equation (7) and (8) represent HCQ flux in the neutral and ionic states, and are 
combined to give the net flux between both compartments in equation (9).  The fraction 
of freely dissolved HCQ in this equation is represented by fn, and is described by 
equation (10): 
                (10) 
which represents the fraction of HCQ in the system that is available to move.  This 
description has been well described previously (Trapp et al., 2008), but briefly it 
represents the fraction available to move by taking into account lipid binding, sorption, 
and ionic activity.  W represents water fraction in the compartment, L represents lipid 
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fraction in the compartment, Kn and Kz are sorption coefficients of neutral and ionic 
HCQ, and gammas represent the ionic activity coefficients for the compartment.   
 The effect of charge on lipophilicity (Kow) of a molecule, which sets the 
framework for the ionic sorption coefficents (Kz) and ionic permeability has been 
previously described (Trapp et al., 2008).  The equation for charged lipophilicity is 
shown in equation (11)  
               (11)  
where z is the charge HCQ.  Equation (11) is applied to the permeability equation (12) 
and sorption equation (13) to represent these properties of charged HCQ 
                (12) 
                      (13)  
Additionally, equation (8) incorporates the Henderson-Hasselbach activity ratio, Dz, 
which represents the ratio between neutral and ionic fractions of the molecule.  Dz is 
represented by equations (14) for the 1+ state and equation (15) for the 2+ state.    
                        (14) 
                        (15) 
All values of physicochemical properties of HCQ and lysosomal properties used in 
equations related to this section of the model can be found in Table 2.2 along with the 
source of these values (Ishizaki et al., 2000, Kawashima et al., 1998, Trapp et al., 2008, 
Warhurst et al., 2003).  
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Table 2.2.  Physicochemical properties of HCQ and lysosomal properties 
Drug Constants Symbol Value Reference 
Molecular Weight MW 335.872  
Lipophilicity Log10(Kow) 3.84 Warhurst et al., 2003 
1st Dissociation Constant pKa1 9.67  
2nd Dissociation Constant pKa2 8.27  
Lysosomal Parameters    
Lysosomal Lipid Fraction L 0.05 Trapp et al., 2008 
Lysosomal Water Fraction W 0.95 Trapp et al., 2008 
Neutral Activity Coefficient γN 1.23 Trapp et al., 2008 
1st Activity Coefficient γ1 0.74 Trapp et al., 2008 
2nd Activity Coefficient γ2 0.3 Trapp et al., 2008 




β (mM) 46 Ishizaki et al., 2000 
Lysosomal pH pHlys 5.0 Trapp et al., 2008 
Cytosolic pH pHcyt 7.2 Trapp et al., 2008 




Heart  0.1  
Eye  0.015  
Skin  0.1  
Gut  0.1  
Liver  0.05  
Slowly Perfused  0.1  
Rapidly Perfused  0.2  
 
a. Starting values from Kawashima et al., 1998; Sewell et al., 1986.  Final values 
determined from acid phosphatase and optimization 
 
 An additional component to consider at the cellular scale is the effect of 
lysosomal HCQ accumulation on pH. Previous studies have demonstrated the pH 
neutralization effect of weak base accumulation in lysosomes (Ohkuma and Poole, 
1978), and this has been taken into account in more recently developed cellular models 
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(Ishizaki et al., 2000, Kornhuber et al., 2010). Equation (16) was used to describe the 
dynamic pH of the lysosome compartment  
                       (16)  
where Clys is the free lysosomal concentration and β is the buffering capacity as 
previously described (Ishizaki et al., 2000).  Dynamic pH affects the free fraction of HCQ 
in each ionic state, which causes net flux to approach an equilibrium as lysosome pH 
becomes more neutral.  Dynamic pH based on buffering capacity was not considered 
for the cytosolic compartment.  Initial pH values for lysosome and cytosol compartments 
were the same for all tissues and were set to 5.0 and 7.2, respectively.  
 Volume of the lysosome compartment for each tissue was determined by total 
acid phosphatase activity in the tissue.  Acid phosphatase activity was assumed to 
correlate directly with total lysosomal volume fraction of the tissue.  Acid phosphatase 
activity / lysosome volume fraction was compared between tissues on a ratio basis 
using a set value for kidney lysosome volume fraction, and optimized to fit the mouse 
model (Kawashima et al., 1998, Sewell et al., 1986).  Lysosome size was set to a 
constant spherical volume using a radius of 275nm. 
Data Analysis 
The ability of the model to accurately predict concentration-time profiles was 
analyzed by comparing PBPK simulation pharmacokinetic variables to those of actual 
data, as well as through calculation of the median absolute performance error (MAPE%) 
and the median performance error (MPE%).  The performance error (PE) of the model 
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was calculated as the difference between the measured and simulated concentrations 
normalized to the simulated concentration as shown in equation (17): 
                  (17)  
The MAPE%, which measures prediction accuracy, was calculated by equation (18): 
                            (18) 
where N represents the total number of samples for the given tissue.  The MPE%, 
which is a measure of positive or negative prediction bias, was calculated by equation 
(19):  
                           (19)   
Computer Simulation and Software 
PBPK model development and simulation was done in Advanced Continuous 
Simulation Language Xtreme (acslX) version 3.1.4.2. from Aegis Technologies Group, 
Inc.  Pharmacokinetic evaluation of simulated and clinical data was done on Phoenix 64 
build 7.0.0.2535.  
 
Results 
HCQ Model Simulations in Mice 
PK data from mice was generated following a single intraperitoneal (IP) dose of 
20, 40, or 80 mg/kg HCQ.  Tissues and whole blood were collected from mice at 3, 6, 
12, 24, 48, and 72 hours after dosing.  The PBPK model was developed from the 
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following tissues in this study: whole blood, liver, kidney, and gut.  Figure 2.4 shows the 
HCQ PK profile from these mice compared to PBPK generated simulation data.   
 
Figure 2.4. Mouse PK data compared to PBPK simulation.  Mice were treated with a 
single IP dose of HCQ at 20, 40, and 80 mg/kg (left, middle, and right columns) and 
data was collected at 3, 6, 12, 24, 48, and 72 hours from whole blood (A), liver (B), 
kidney (C), and gut (D).  Circles represent tissues from treated mice (three replicates 




In addition to whole tissue PK, the contributions of lysosomal sub-components were 
examined and are found in Supplementary Figure 2.1. Lysosomal HCQ PK profiles 
were similar between tissues and simulated concentrations peaked between 20-40 mM, 
which are consistent with lysosomal concentrations of lysosomotropic agents reported 
in previous studies (Browning, 2014).  
The ability of the model to accurately predict the concentration-time profile of 
HCQ was determined through calculation of median absolute prediction error (MAPE%) 
and median prediction error (MPE%) presented as a percentage for tissues and whole 
blood, shown in Table 2.3.   
 
Table 2.3. Measure of Predictive performance of the PBPK model  
 
Dose Tissue/Patient MAPE% MPE% 
20 mg/kg Blood 27.25 -11.06 
 Liver 73.25 -41.16 
 Kidney 33.89 -25.28 
 Gut 39.35 -31.87 
40 mg/kg Blood 23.93 -23.93 
 Liver 71.31 -46.90 
 Kidney 27.48 8.17 
 Gut 18.52 8.08 
80 mg/kg Blood 37.01 -37.01 
 Liver 43.80 -24.80 
 Kidney 24.19 5.90 
 Gut 23.52 9.90 
200 mg (oral) 4 (blood) 18.64 14.79 
 5 (urine) 15.53 -3.34 
200 mg (IV) 4 (blood) 33.51 -11.58 
 5 (urine) 20.99 9.55 
 1 (blood) 42.13 17.36 





MAPE% is a method of determining model accuracy, while MPE% indicates 
under or over prediction bias (Sheiner and Beal, 1981). Overall, MAPE% for each 
dosing cohort were within similar ranges.  The ranges were 27-73%, 19-71%, and 24-
44% for 20, 40, and 80 mg/kg respectively.  Upper bounds of this range were skewed 
by the deviation of model simulation from actual PK data for liver after 24 hours due to 
the concentration-time profile for HCQ PK dropping to zero after 24 hours. The model 
prediction follows the actual data well for the first 24 hours, after which it predicts a 
slower decline at these later time points.  Removing the liver MAPE% drops the ranges 
to 27-39%, 19-27%, and 24-37%. Comparing this range of MAPE% to the variation in 
actual PK data, determined by the range of average coefficient of variation (CV) for 
each dosing cohort, is a strong indicator of whether or not model prediction is within the 
dispersion of the actual data.  CV values for the PK cohorts are 16-43%, 9-20%, and 8-
28% for 20, 40, and 80 mg/kg, respectively, which are quite similar to the MAPE% for 
the respective cohorts.  This suggests that the model accounts for a majority of natural 
variation within the clinical data.  Taking into account MPE%, the model tends to slightly 
over-predict blood and liver concentrations in each dose cohort.  Kidney and gut are 
over-predicted in the 20 mg/kg cohort, but slightly under-predicted in the 40 and 80 
mg/kg mice indicating no significant bias in over- or under-prediction of the model. An 
additional method of determining the model’s predictive capability was through 
comparison of simulation vs. actual pharmacokinetic variables generated through 





Table 2.4. NCA parameter comparison between PK and PBPK data 






20 mg/kg Blood Actual 24.09 ± 
8.84 
10.84 ± 0.63 1.87 0.97 
  Simulated 12.91 11.22     





  Simulated 6.84 107.9     
 Kidney Actual 15.12 ± 
0.72 
72.25 ± 2.69 1.17 0.73 
  Simulated 12.96 99.01     





  Simulated 12.97 131.80     
40 mg/kg Blood Actual 11.2 ± 
1.49 
19.50 ± 0.66 0.88 0.89 
  Simulated 12.67 21.89     





  Simulated 6.00 198.19     





  Simulated 12.74 175.82     





  Simulated 12.76 222.82     
80 mg/kg Blood Actual 10.51 ± 
0.52 
33.27 ± 2.25 0.84 0.75 
  Simulated 12.45 44.17     





  Simulated 5.07 400.70     
 Kidney Actual 13.77 ± 
0.76 
339.17 ± 4.11 1.10 1.05 
  Simulated 12.53 322.20     





  Simulated 12.43 385.13     
Human       
200 mg – 
Patient 4 
(oral) 
Blood Actual 77.47 5.57 1.00 1.01 
  Simulated 77.24 5.54   
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200 mg – 
Patient 4 (IV) 
Blood Actual 84.90 5.85 1.16 0.78 
  Simulated 73.45 7.51   
200 mg – 
Patient 1 (IV) 
Blood Actual 54.58 5.23 0.70 0.89 
  Simulated 77.76 5.86   
400 mg – 
Patient 1 (IV) 
Blood Actual 117.50 10.01 1.72 0.80 
  Simulated 68.25 12.55   
 
 The NCA variables compared for blood and each tissue were terminal half-life 
(t½) and area under the curve (AUC). Values of each were determined over the 72 hour 
interval and compared ratiometrically (actual/simulated).  Overall, the AUC ratios were 
very close to one, indicating a high degree of accuracy within the model.  Half-lives 
were also relatively close except for liver 20 and 40mg/kg cohorts, which, as noted with 
MAPE%, is due to the lack of a terminal phase in the actual liver data.  While half-life 
ratios were low for each dosing cohort, the ratios near one for AUC indicate that the 
model predicts overall liver exposure with a high degree of accuracy.   
HCQ Model Simulations in Human 
After validating the simulation in mice, the model was scaled to human patients 
by adjusting appropriate physiologic parameters, which are compared in Table 2.1. 
Concentration-time data for individual humans were used (Tett et al., 1988, Tett et al., 
1989) and included both oral and IV infusion doses of 200mg and 400mg HCQ sulfate.  
Whole blood data was available for two patients (patient 1 and 4) from this study, and 
cumulative urinary excretion of HCQ was available for another (patient 5).  The 
concentration-time profile between simulation and actual data were compared over a 72 




Figure 2.5. Human whole blood and urine concentrations of HCQ.  Whole blood 
concentrations of patient 4 from the studies, was simulated after a single 200mg oral 
dose (A).  Urinary excretion of HCQ was simulated in patient 5 from the studies 
following 200mg oral and IV doses (B).  Whole blood concentrations of patient 4 from 
the studies were simulated after a single 200mg IV infusion (C) and of patient 1 after 
200mg and 400mg IV infusions (D). HCQ (points) were compared to PBPK simulation 
(lines) (Tett et al., 1988 and 1989).   
 
concentrations were simulated following these dosing schemes as well and can be 
found in Supplementary Figure 2.2.  Simulated PK profiles for each of the dosing routes 
were notably different from each other, specifically in that liver and gut peak 
concentrations were roughly 2-3x higher, and kidney much lower, in patients receiving 
oral vs. IV infusion dosing due to the absorption phase.  Lysosomal PK for these human 
tissues were also simulated following these dosing schemes and can be found in 
Supplementary Figure 2.3.  Peak concentrations are similar to those in mice, at 20-30 
mM in liver and gut, and as low as 6 mM in kidney following 200 mg oral dosing.   
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 As individual physiologic data was not available for the human patients, generic 
human physiologic parameters were assumed (see Table 2.1) for patient 4 and patient 
5 (Brown et al., 1997).  After fitting the model to these patients through optimization of 
absorption, metabolism, and renal clearance parameters, the model was fit to patient 1 
by simply increasing body weight from 70 to 85kg.   For the human model the MAPE% 
range, presented in Table 2.3, for whole blood was between 19-42% and for urine was 
between 16-21%, indicating strong predictive power of the model.  As this was 
individual patient data, the coefficient of variation was not reported for comparison with 
these patients.  MPE% indicated a slight under prediction of the actual PK profile for all 
those compared except patient 4 IV infusion, which was a slight over prediction.   
 NCA parameters were also compared for human whole blood data, and can be 
found in Table 2.4.  Overall the actual/simulation ratios of t½ and AUC indicated strong 
predictive power of the model.   
 To investigate the toxicity-related aspect of HCQ regarding retinopathy, HCQ 
exposure was simulated in human eyes at 200, 600, and 1200 mg/day of oral dosing 
and can be found in Supplementary Figure 2.4.  Single dose HCQ at these levels 
generate relatively low concentrations in the eye relative to the other tissues shown in 
Supplementary Figure 2.2, although eyes continue to retain HCQ as blood levels 
decline.  After 30 days of once daily dosing, it is clear that 1200 mg/day causes 
significantly higher accumulation of HCQ within the eyes, roughly 10-fold more than 200 
mg/day.  It is of note that even two months after dosing is discontinued the 
concentration of HCQ in the eyes decreases only slightly, indicating an extremely long 
half-life.  60 days of once daily dosing show a similar trend as 30 days, although 
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concentration buildup begins to taper off.  Concentrations in the human eyes at 1200 
mg/day are close to those observed in the eyes of hooded rats dosed at 40 mg/kg for 6 
days/week over the same timeframe (McChesney, 1983).  
Simulated Steady State Concentration and Clinical Trial Comparison 
After the model was validated for single dose HCQ in human patients, the dosing 
interval was extended out to investigate predictive capability over a much longer period 
of time.  Using generic human PBPK parameters as listed in Table 2.1, the model was 
used to simulate once-daily oral dosing of 100, 200, 400, 600, 800, 1000, and 1200mg 
HCQ for a 30 day period.  The steady state concentration (Css) was taken as the 
average whole blood concentration occurring after 20 days.  Simulated Css for each 
dosing regimen was compared to the patient Css distribution of the corresponding 
dosing regimen in five different cancer clinical trials using HCQ in combination with 
another treatment in Figure 2.6 (Mahalingam et al., 2014, Rangwala et al., 2014a, 
Rangwala et al., 2014b, Rosenfeld et al., 2014, Vogl et al., 2014).   
 The trials reported reaching the concentration distribution depicted by the 
following days:  Temsirolimus at 15 days, Vorinostat at 20 days, Bortezomib at 21 days, 
Temozolomide Glioblastoma did “not distinctly represent steady state” and the time was 
not reported, and Temozolomide Solid Tumor/Melanoma was at 16 days. The depicted 
range in all trials represents concentrations falling within the second and third quartile of 
patient data, except for Vorinostat which represents the mean ± standard deviation.  Of 
all trials examined, only the Temozolomide Glioblastoma patient population had a 
regression line statistically significant from the PBPK simulation.  The regression line for 




Figure 2.6. Whole blood concentrations of HCQ at steady state. Data comparison 
between five different human cancer clinical trials and PBPK model output at varying 
doses. The combination trials represented include (A) Temsirolimus (Rangwala et al., 
2014a), (B) Vorinostat (Mahalingam et al., 2014), (C) Temozolomide in glioblastoma 
patients (Rosenfeld et al., 2014), (D) Bortezomib (Vogl et al., 2014), and (E) 
Temozolomide in advanced solid tumor and melanoma patients (Rangwala et al., 
2014b). Clinical trial data represents steady state concentrations between the second 
and third quartile of patients, except for the Vorinostat trial (B) which represents the 
mean ± standard deviation.  Steady state concentrations from the PBPK model were 
taken as the average concentration occurring at 20 days of once daily oral dosing.  
Black lines represent the regression lines for clinical trial data, dotted black lines 
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represent the 95% confidence interval, and grey lines represent the regression line for 
PBPK simulated data.  The only trial that had a regression slope statistically different 
from the PBPK simulation was the Temozolomide glioblastoma trial (C). 
 
compared to the regression line of the PBPK simulation which had a mean slope of 2.2. 
The Vorinostat patient population did not undergo regression analysis due to only two 
daily doses of HCQ (400 and 600mg) used in the trial, but the slope of this line was 1.7 
compared to the PBPK simulation of 2.2.  Of all trials tested against the PBPK 
simulation average Css from the model human fell within the bounds of the 2nd and 3rd 
quartile for all dosing regimens except for the Temozolomide Glioblastoma 800mg and 
Temsirolimus 400mg.   
Simulation of HCQ in a Virtual Population 
Once model simulated Css was found to be in good agreement with clinical trial 
Css distributions, the model was tested in a virtual population of humans.  250 males 
and 250 females were generated from the physiological parameters for PBPK modeling 
(P3M) database using PopGen (McNally et al., 2015).  Briefly, P3M is a massive 
database of U.S. patient records containing their associated physiologic data, and was 
developed by The Lifeline Group.  Using PopGen to extract from this database, a virtual 
population of individuals was generated using available demographic data from the 
Bortezomib/HCQ combination phase I clinical trial (Vogl et al., 2014).  This was 
assumed to generate a population representative of a general cancer clinical trial.  Css 
was then simulated for this population at each dosing regimen, and the simulated 
distribution was compared to the actual distribution observed in the clinical trials 
referenced.  Each dose from 100-1200mg dosed once-daily was simulated in each of 
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the 500 total patients to generate a realistic range of steady state concentrations.  The 
results of this simulated patients compared to the actual distribution from each trial are 
shown in Figure 2.7. 
 
Figure 2.7. Distribution of steady state whole blood concentrations of HCQ.  Css 
(at 20 days) for patients in different dosing cohorts was compared as simulated data vs. 
actual patient data from four clinical trials.  Plots in grey represent the PBPK model 
simulation of HCQ in a virtual population of 500 patients (half male and half female) 
randomly generated using demographic data from the Bortezomib Trial.  Plots in white 
represent the whole blood HCQ concentration distribution for patients in one of the four 
clinical trials, including (A) Bortezomib (Vogl et al., 2014), (B) Temozolomide in 
glioblastoma patients (Rosenfeld et al., 2014), (C) Temozolomide in patients with solid 
tumors or melanoma (Rangwala et al., 2014b), and (D) Temsirolimus (Rangwala et al., 
2014a). Virtual Population was generated for 250 males and 250 females using the 




 The model captured the distribution of steady state whole blood concentrations in 
the simulated patient population extremely well at low doses. The higher doses in the 
clinical trial population exhibited much more distributional variability between trials. This 
was expected due to the more prominent effect that variability in physiologic parameters 
will have at higher doses.  Additionally, the clinical trial patient populations were 
relatively small, especially in comparison to the 500 virtual patients simulated by the 
model, which is another likely contributor to the distributional variability between trials.    
 
Discussion 
 PBPK modeling is a relatively well-established concept, dating back to the first 
modern model of methotrexate in 1971 (Bischoff et al., 1971).  Cancer therapy is a 
major field for development of these models due to the ability to simulate multiple 
dosing regimens in a relatively short period of time with the purpose of maintaining 
therapeutic efficacy while minimizing toxicity.  This includes PBPK models for some 
drugs that have been used in clinical trials in combination with HCQ, including three of 
those discussed in this paper (Ballesta et al., 2014, Gustafson et al., 2002, Zhang and 
Mager, 2015).  Although the utility of PBPK models appears increasingly clear, their use 
in a clinical setting is not well established.   With treatment including, but not limited to 
malaria, lupus, rheumatoid arthritis, and now cancer, HCQ is a prime candidate for use 
of PBPK models in a personalized-medicine setting.  Due to the widespread use of this 
drug, accounting for sources of PK variability from easily monitored driving parameters, 
such as GI absorption, CYP3A4 and CYP2C3 metabolism, and renal clearance could 
be a quick method of accounting for the broad range of patient PK profiles observed in a 
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clinical setting.  This would concurrently improve prediction of exposure in areas that 
are more difficult to monitor, such as melanin binding in the eye or variation in 
lysosomal content of a target site.   
 The described PBPK model for HCQ successfully predicts blood and tissue 
disposition in both mice and humans in single dose oral, IP, and IV scenarios.  More so, 
it is capable of establishing a population distribution at doses ranging from 100-1200mg 
for long-term daily oral dosing in a human population representative of a general cancer 
clinical trial.  This model was developed based on flow-limited uptake for the bulk 
compartments with perfusion-based uptake for the lysosomal compartment, and 
accounts for specific binding to melanin and non-specific binding to plasma protein. It is 
built based off of physiological and biochemically relevant parameters for eight 
compartments, three of which are validated by clinical PK data.  These validated 
compartments consist of gut, liver, and kidney, along with whole blood.  Gut and liver 
were included due to absorption and metabolism, respectively.  Kidney is involved in 
renal clearance through filtration and secretion.  There is evidence of reabsorption, but 
that mechanism was not considered in this model due to the lack of clinical data 
available relating urine pH to renal clearance of HCQ.   Melanin binding was the primary 
reason for including eyes, specifically with regards to retinopathy observed in higher 
doses of HCQ used in cancer clinical trials.  Accumulation of HCQ in the eyes was 
simulated to investigate the difference dosing levels may have on retinal exposure to 
this drug.  While actual concentrations associated with retinopathy are unknown, 
patients classified as high risk are categorized as those receiving >6.5 mg/kg/day for >5 
years (Pandya et al., 2015).  The model can be used to simulate and avoid HCQ retinal 
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accumulation thresholds observed within these high risk dosing levels. Heart was 
included due to rare incidence of irreversible cardiomyopathy that could possibly be 
exacerbated during long term dosing of combination therapies that also exhibit some 
level of cardiovascular toxicity (Al-Bari, 2015).  Treatments associated with 
cardiomyopathy are extremely rare, with only 42 known cases as of 2014 and reported 
mean cumulative doses of 1843 g (Yogasundaram et al., 2014).  Remaining tissues 
were grouped into the rapidly perfused compartment, consisting of remaining viscera, 
and the slowly perfused compartment which consists of bone, muscle, and adipose.    
 The model was initially developed in mice and began with gathering of relevant 
biochemical and physiological parameters.  After this step, parameter effect on model fit 
to actual data was assessed.  This was followed by optimization to maximize model 
accuracy across dosing regimens.  Scaling to humans involved modifying relevant 
physiological parameters and biochemical parameters as seen in Table 2.1, and 
optimizing the model to fit human data.  Validating against multiple types of human PK 
data offers the predictive power to simulate HCQ PK in patients while accounting for PK 
modification by combination treatment modalities, drug concentrations at the active site 
in the lysosome under varying pH conditions, and exposure in tissues where toxicity is 
observed.  Interindividual variability in response is one of the primary concerns in 
treatments with HCQ.  From a PK perspective, of all parameters the ones that the blood 
portion of the model are most dependent on are body weight, rate of metabolism, and 
blood partitioning and protein binding.  Contribution of these factors to model 
performance are not dose dependent, i.e. linear with dose escalation.  Patients with 
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impaired liver or kidney function would likely be exposed to higher concentrations of 
HCQ, which would need to be accounted for in application of this model.   
 Primary value of this model is found through accurate simulation of HCQ PK in 
mice and humans while taking into account exposure in tissues, especially those where 
toxicity or clinical efficacy may be observed.  Mice were the species chosen to begin 
model development due to the option of PK/PD investigation in whole organs.  Between 
the mouse PK data, PD data (not yet published), and the likelihood that mice will be 
used in future preclinical studies with HCQ or next generation analogues, this model will 
prove a valuable tool to make connections between exposure and response in a 
preclinical setting.  This is especially relevant in the context of lysosomal uptake and the 
effect of these various factors on the PK/PD of HCQ and next generation 
lysosomotropic autophagy inhibitors.  Being a major driver of HCQ PK, it is important to 
note that lysosomes are a dynamic system undergoing effects such as swelling, 
biogenesis, pH modulation, and turnover that is not well characterized from a 
quantitative perspective in the presence of HCQ (Lu et al., 2017, Zhitomirsky and 
Assaraf, 2015).  As pH is the driver for lysosomal accumulation it plays an important 
role, especially in a tumor context where acidic conditions can dramatically affect HCQ 
uptake (Pellegrini et al., 2014, Zhitomirsky and Assaraf, 2015). The cellular model of 
lysosomal uptake applied in our PBPK model (Kornhuber et al., 2010, Trapp and 
Horobin, 2005, Trapp et al., 2008) serves as a strong base of modification to begin 
describing whole tissue PK based on the pH-lysosome relationship.  Further 
advancement of this PBPK model will require stronger prediction power in a tumor 
setting.  Achieving this involves further characterization of these natural and HCQ-
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influenced lysosomal dynamics, and how they are related to intra and extracellular pH in 
a tumor setting.   
 In addition to its use as a tool for further characterization of autophagy-
dependence and preclinical study, this model has proven its utility in predicting 
exposure in human patients as well.  The model was validated in humans by accurately 
simulating blood exposure and urinary clearance of HCQ over a 72 hour period 
following oral and IV administration of two different doses.  Additionally, it captured the 
distribution of steady state concentrations at seven different dosing levels in a larger 
population of patients.  Overall, it is able to simulate both early time points and steady 
state values of patients at all concentrations used in a cancer clinical trial setting.  This 
validation, in conjunction with the physiologic nature of the model, makes it a powerful 
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Lysosomes act as a cellular drug sink for weakly basic, lipophilic (lysosomotropic) 
xenobiotics, with many instances of lysosomal trapping associated with MDR.  
Lysosomotropic agents have also been shown to activate master lysosomal biogenesis 
transcription factor EB (TFEB), and ultimately lysosomal biogenesis.  We investigated 
the role of lysosomal biogenesis in the disposition of hydroxychloroquine (HCQ), a 
hallmark lysosomotropic agent, and observed that modulating the lysosomal volume of 
human breast cancer cell lines can account for differences in disposition of HCQ.  
Through use of an in vitro pharmacokinetic (PK) model we characterized total cellular 
uptake of HCQ within the duration of static equilibrium (1 hour), as well as extended 
exposure to HCQ that are subject to dynamic equilibrium (>1 hour) wherein HCQ 
increases the size of the lysosomal compartment through swelling and TFEB-induced 
lysosomal biogenesis.  In addition, we observe that pretreatment of cell lines with TFEB-
activating agent Torin 1 contributed to an increase of whole cell HCQ concentrations by 
1.4 to 1.6-fold, which were also characterized by the in vitro PK model.  This 
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investigation into the role of lysosomal volume dynamics in lysosomotropic drug 
disposition, including the ability of HCQ to modify its own disposition, advances our 
understanding of how chemically-similar agents may distribute on the cellular level, and 
examines a key area of lysosomal-mediated MDR and DDI. 
 
Introduction 
Hydroxychloroquine (HCQ) has been investigated in over 50 cancer clinical trials 
and countless preclinical studies through the past decade as an additive compound to 
primary chemotherapy treatment. Mechanistically, HCQ acts to inhibit autophagy, which 
has been identified as a mechanism of tumor cell resistance to chemotherapy and a key 
pathway to survival within the tumor microenvironment. While next generation 
autophagy inhibitors are in preclinical stages of development, HCQ remains the only 
clinically approved autophagy inhibitor. Overall HCQ is generally effective and safe as a 
treatment but suffers from various pitfalls within the pharmacologic space – specifically 
in terms of predictability of patient likelihood of response and reliable pharmacokinetic 
(PK) and pharmacodynamic (PD) metrics. There is a general disconnect between HCQ 
PK in the tumor and blood; creating a challenge when optimizing dosing strategies to be 
confident that target concentrations of HCQ are achieved within the tumor (Barnard et 
al., 2014). Characterization of HCQ PK properties on a cellular level may provide insight 
towards tumor-specific factors that would promote this disconnect. 
Cellular uptake of HCQ is driven primarily through lysosomal ion-trapping due to 
its weakly basic and lipophilic properties that characterize it as a hallmark 
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lysosomotropic agent. HCQ readily diffuses through neutral spaces, but becomes 
diprotonated in the lysosome, whose acidic environment facilitates accumulation. This 
results in concentrations significantly higher than other compartments within the cell 
(Duvvuri and Krise, 2005). Key mechanisms contributing to pharmacokinetics have 
been considered and consolidated into in vitro mathematical models to describe cellular 
uptake of compounds with similar physicochemical properties to HCQ, namely weakly 
basic and lipophilic (Ishizaki et al., 2000; Trapp et al., 2008; Kornhuber et al., 2010; 
Schmitt et al., 2019). These models assume the cell behaves as a static 
system of compartments, but recent evidence suggests that lysosomotropic compounds 
induce changes in the lysosome itself. 
Lysosomes swell in response to chloroquine (CQ) exposure, which is 
mechanistically and pharmacokinetically similar to HCQ. Near clinically-relevant doses 
of CQ have been observed to cause a 3-fold increase in relative lysosomal volume after 
multiple days of exposure to the drug (King et al., 2016), and recruitment of galectin-3 to 
sites on these swollen lysosomes, indicating membrane damage (Gallagher et al., 
2017). In addition to an increase in lysosomal size, an increase in lysosomal number 
has also been reported in response to a panel of lysosomotropic agents, including CQ, 
over the course of 4 and 24 hours (Lu et al., 2017). This increase in lysosomal number 
was linked to an increase in nuclear translocation of master lysosomal biogenesis 
transcription factors, TFEB, TFE3, and MITF. TFEB activation of the CLEAR network of 
genes has been described as the master regulation system of lysosomal biogenesis 
(Settembre et al., 2012; Settembre et al., 2013). Lysosomotropic agents cause 
activation of this network by inducing lysosomal stress, and has been shown to activate 
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as early as 90 minutes of exposure to CQ (Zhitomirsky et al., 2018). The results of 
lysosomal swelling and TFEB activation by lysosomotropic agents may be linked to their 
long-term tissue PK. Extended dosing of HCQ is characterized by a consistent increase 
in HCQ concentrations in rat tissue over the course of 3 months of daily dosing. In some 
tissues (spleen, kidney, liver, heart) HCQ concentrations continued to increase out to 
the latest timepoint measured at 7 months (McChesney, 1983). This long-term PK 
profile is noted by McChesney to be similar to other lysosomotropic drugs such as 
chlorpromazine. 
Due to the frequent, high doses of HCQ used in cancer clinical trials we 
characterized this lysosomal adaptation response on a cellular level and investigated 
the extent to which it may influence cellular disposition of the drug. The data described 
herein suggests that baseline cell uptake of HCQ is associated with different baseline 
lysosomal profiles between cell lines, which were integrated into a lysosome cellular PK 
mathematical model (Trapp et al., 2008; Kornhuber et al., 2010) to accurately model 
whole cell HCQ PK to chemical kinetic equilibrium. Small, but consistent increases in 
whole cell uptake of HCQ over an extended time period were also observed, and 
attributed to an increasing volume of the lysosomal compartment. The in vitro PK profile 
of HCQ was thus broken up into a short-term kinetic equilibrium portion, within 1 hour of 
exposure, and a long-term dynamic portion, out to 24 hours of exposure for all cell lines. 
This data was used, in conjunction with observed differences in baseline lysosomal 





Materials and Methods 
Cell Lines 
Human breast cancer cell lines including MDA-MB-231, MDA-MB-468, T47D, 
and MCF7 human breast cancer cell lines were purchased from Cell Culture Services at 
University of Colorado Anschutz Medical Campus (Aurora, CO). For cell 
pharmacokinetic experiments, all cell lines were stably transfected with Incucyte 
NucLight Red Lentivirus (Sartorius, Cat. 4476) prior to experimentation. 
Cell lines were cultured in Dulbecco’s Modified Essential Medium (Corning, 10-
017-CV) supplemented with 10% fetal bovine serum (Peak Serum, PS-FB3), 1% 
penicillin/streptomycin (Fisher, 30-002-CI), and 1% sodium pyruvate (Fisher, 25-000-CI) 
at 37°C and 5% CO2 in a humidified incubator. 
Chemicals and Reagents 
Hydroxychloroquine (HCQ) sulfate was purchased from SigmaAldrich (St. Louis, 
MO). Monensin (MN) was purchased from VWR (Radnor, PA). Torin1 (T1) was 
purchased from Fisher (Hampton, NH). Hoechst 33342 20mM solution (62249) and 
CellLight Lysosomes-GFP, BacMam 2.0 (C10507) were purchased from ThermoFisher 
(Waltham, MA). ETP, a pH-insensitive lysosomal lumen dye applicable for live and fixed 
cell imaging, was received as a gift from Dr. Yi Pang at the University of Akron 





Cell Uptake Experiments 
4 human breast cancer cell lines were used to perform experiments. The first 2, 
MBA-MB-231 and MDA-MB-468, are mechanistically sensitive to autophagy inhibition 
through gene knockdown (Maycotte et al., 2014; Towers et al., 2019) and 
pharmacologically sensitive to hydroxychloroquine. The second 2, MCF7 and T47D, are 
insensitive to both methods (Maycotte et al., 2014). 
Cell lines were cultured in standard DMEM supplemented with 10% FBS, 1% PS, 
and 1% sodium pyruvate in an incubator at 37°C and 5% CO2. T47D and MCF7 cell 
lines required supplementation of 8μg/mL of insulin to maintain growth. For acidic media 
experiments with MDA-MB-231 cells, DMEM without sodium bicarbonate was 
purchased, and bicarbonate was added to achieve an incubator-conditioned media pH. 
Culture media buffers other than sodium bicarbonate, such as HEPES, were purposely 
omitted as HEPES has been shown to activate the MiT/TFE network, resulting in 
lysosomal biogenesis (Tol et al., 2018). 
Cell lines were plated, allowed to adhere overnight, and treated at roughly 70% 
confluence. All cell lines stably expressed NucLight Red, and cell counts were 
measured by counting red fluorescent nuclei on an Incucyte ZOOM (Sartorius; 
Gottingen, Germany) prior to treatment with drug. For 4 hour and 24-hour timepoints 
cells were counted immediately prior to harvesting, as the doubling time for these cell 
lines is between 16-20 hours. Experiments were not extended past 24 hours to avoid 
cell line growth inhibition in response to HCQ. For treatment, culture media was 
aspirated and replaced with fresh, incubator-conditioned media containing 10μM HCQ 
and placed in a 37° C incubator until the designated timepoint. At the timepoint cell 
115 
 
media containing HCQ was aspirated and cells were washed with HBSS, then 
trypsinized for 5 minutes. Trypsinized cells were washed off the plate with additional 
culture media at a ratio of 4:1 media:trypsin. Cells were then pelleted at 1600 rpm for 5 
minutes, media was carefully aspirated, and the cell pellet reconstituted in MilliQ-water 
and frozen until LCMS extraction and analysis. 
LC/MS-MS analysis follows methods described in (Barnard et al., 2014), but 
briefly – cell pellets were vortexed and lysed for 10 minutes in a sonication water bath. 
Acetonitrile (ACN) was then added to the cell pellets to yield a final solution of 50% ACN 
+ 50% MilliQ-H2O. Cells were vortexed for 10 minutes, then centrifuged at 13,300 rpm 
for 10 minutes. Supernatant was transferred to polypropylene inserts. Chloroquine (CQ) 
was used as an internal standard. Concentrations of supernatant obtained on LC/MS-
MS were normalized to the cell counts obtained for each sample from an Incucyte 
ZOOM, and samples were then normalized to cell volume, obtained for each cell line 
from suspended cell diameter measured on a Countess system (n=4), to obtain HCQ 
concentration (μM) in each cell. 
For experiments with monensin (MN), cells were pretreated with 25μM MN for 30 
minutes prior to adding HCQ. After 30 minutes 10μM HCQ was added for the duration 
for of the 1hr exposure. For experiments with Torin1 (T1), cells were pretreated with 
250nM Torin1 for 16 hours prior to adding HCQ. All cell uptake experiments were 






For all imaging experiments cells were plated at 10,000 cells/well on an 8-well 
glass chamber slide (Cellvis, C8-1.5H-N) and allowed to adhere overnight. 
To determine lysosomal volume, live cells were treated with 1μM of ETP 
(Abeywickrama et al., 2019), and incubated for 30 minutes. Excess dye was removed 
by washing twice with warm media, and incubated with 10μM of Hoescht 33342 for 10 
minutes. Cells were then washed twice with PBS and fixed for 10 minutes in 2% PFA. 
PFA was washed off twice with PBS and cells were imaged on an Olympus IX83 
microscope with a Plapon 60x Objective, NA = 1.42 on Cy3 and DAPI confocal 
channels. 43 z-stacks of 0.24μm step-size were captured on Cy3 and DAPI channels. 
Lysosomal volume fraction of cells was determined using an in-house image processing 
pipeline which is described briefly as follows: Raw confocal image stacks were 
converted to .tif files and imported into Python version 3.7.6. A reference image was 
created by compressing the stack by its maximum pixel intensity. Each slice of each 
image stack was analyzed to determine the peak signal to noise ratio (PSNR) relative to 
the reference image using the sewar module (https://pypi.org/project/sewar/). A .csv file 
containing the top 10 PSNR slices for each image stack was generated and imported 
into a FIJI macro that calculated the Cy3 (lysosome) area for each raw .vsi image slice 
based on an algebraic threshold of mean intensity. The area for each slice was 
multiplied by the step size (0.24μm) to generate a volume, and then volumes from the 
10 slices per image stack were summed to generate a lysosomal volume for the image. 
The lysosomal volume was normalized to the cell count of each image, and the cell 
count was normalized to the experimentally determined cell volume for each cell line to 
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generate a lysosomal volume fraction per cell. 5-10 images were obtained for each 
experimental replicate, and lysosomal volume fraction is presented as the mean ± 
standard deviation of each replicate (n=3) for each cell line. Imaging of cell lines for 
GFP-LAMP-1 expression followed the same imaging process, except cells were 
incubated with 1μL of the baculovirus overnight prior to treatment with HCQ. 
For drug treated conditions, single plane images were captured at 20x using the 
same microscope, but an Uplsapo 20x objective, NA = 0.75 on Cy3 and DAPI LED 
channels. To determine a change in lysosome content of the cell, cells were treated with 
the same drug treatment conditions as described in the cell uptake experiments section. 
Chamber slides were prepared in the same way as described above. Images were 
quantitated using a FIJI macro with an algebraic threshold of the mean intensity, and 
data was calculated as Cy3 area / DAPI area. Roughly 10 images were obtained for 
each experimental replicate, and data is reported as the mean ± standard deviation of 
each replicate (n=4). Statistical significance was calculated as a one-way ANOVA with 
Dunnett’s multiple comparisons test relative to the control, where P < 0.05 was 
significant. 
TFEB Activation 
TFEB activation by HCQ was determined with 2 different kinds of methods 
including gene set enrichment analysis (GSEA) of the TFEB-regulated CLEAR network, 
and through a TFEB transcription factor activity assay (RayBiotech, TFEH-TFEB). Gene 
expression microarray data was prepared for all 4 hBC lines following cell culture 
preparation steps as outlined in the cell uptake experiments section. Cell lines were 
treated with 20μM HCQ, for 24 hours prior to harvesting for gene expression 
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preparation in triplicate. Prepared cell extraction homogenate was run on an 
HG_U133_Plus_2 chip. CEL file data was extracted and prepared for GSEA using the 
Affymetrix Bioconductor package in R, and normalized using RMA. Expression data 
was then analyzed using the GSEA 4.0.3 software provided by the BROAD Institute. 
Gene sets from the 4 cell lines, treated with HCQ or vehicle, were analyzed in GSEA 
using a gene set representative of TFEB lysosome targets (Palmieri et al., 2011) and 
run in tandem with the Hallmarks of Cancer gene set database version 7.1 provided in 
the GSEA software. The run was set for 1000 permutations following a “gene_set” 
permutation type. Data is reported as the NES value and significance determined by 
FDR q-value generated in the run. Raw .CEL files are available in the supplement. 
TFEB nuclear activation was performed in duplicate and was determined using the 
human TFEB transcription factor activity assay following manufacturer’s instructions. 
TFEB activity data is expressed as mean ± standard deviation, and was analyzed by 
one-way ANOVA with Dunnett’s multiple comparison test relative to control with 
significance as P < 0.05. 
Cell Pharmacokinetic Mathematical Modeling and Simulation 
To simulate the lysosomal uptake of HCQ into cells a previously published base 
model of lysosomal uptake was used (Trapp et al., 2008; Kornhuber et al., 2010). 
Lysosomal volume fraction for each cell line was determined by imaging methods 
described above. Extracellular pH was determined by measuring the pH of incubator-
equilibrated media in a pH meter (7.6), and then testing the change in cellular uptake of 
HCQ at the 1hr timepoints in a media of decreased pH (7.0). The influence of the 
lysosome and cytosolic pH were determined experimentally by pretreating MDA-MB-
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231 cells with monensin (MN), a lysosome-selective ionophore (Grinde, 1983), and 
simulating the experimental uptake of HCQ in cells after pre-treatment. The model 
values of cytosolic pH of roughly 7.0 and lysosomal pH of 5.0 worked well with the cell 
lines used, which are similar to what has been previously reported for MCF7 cytosolic 
pH (Belhoussine et al., 1999), and MCF7 and MDA-MB-231 lysosomal pH values 
(Montcourrier et al., 1994). It is noted that the range of the pH values from different 
literature reports is quite broad, with lysosomal pH values reported around 4.2 for MDA-
MB-231 cells (Ndolo et al., 2012), 4.5 for MCF7 and MDA-MB-231 cells (Wang et al., 
2019), and 5.1 for MCF7 and MDA-MB231 cells (Montcourrier et al., 1994). Cytosolic 
pH exhibited a similar trend from literature, with reported values around 6.9 for MCF7 
(Belhoussine et al., 1999), 7.3 for MCF7 (Persi et al., 2018), and 7.4 for MDA-MB-231 
and MCF7 (Wang et al., 2012). From the studies using multiple human breast cancer 
lines, that were also used in this work, the lysosomal and cytosolic pH were not very 
different between each cell line and so we chose to use fixed values for these 
parameters across all 4 cell line models. 
Evaluation of Model Fit 
Model fit versus experimental data was evaluated by comparing the experimental 
AUC0-1hr or AUC0-24hr to the simulated value for each cell line. Additionally, model 
accuracy was analyzed by calculating the performance error (PE), median performance 
error (MPE%) to investigate positive/negative bias, and mean absolute performance 
error (MAPE%) to determine overall model fit (Gustafsson et al., 1992). These 




Computer Simulation and Software 
Intracellular PK model simulation was done in MATLAB, version R2020a 
(Mathworks; Natick, MA) and the intracellular compartmental system was solved using 
the ode45 package. Image selection was done in Python, version 3.7.6, using sewar 
and tqdm packages. Image analysis was done in ImageJ, version 1.52p using methods 
described above.  
 
Results 
Whole Cell Uptake of HCQ is Proportional to Basal Lysosomal Volume Fraction 
The in vitro PK of HCQ was assessed in 4 human breast cancer cell lines (hBC), 
MDA-MB-231, MDA-MB-468, T47D, and MCF7 by collecting total cell homogenate at 1, 
5, 15, 30, 60, 240, and 1440 minutes after incubating with 10µM HCQ. This 
concentration of HCQ was chosen as it is clinically achievable.  HCQ concentration 
within the whole cell was determined by normalizing total HCQ in the homogenate to the 
total cell volume in the homogenate outlined in Supplementary Figure 3.1.  We 
observed different concentration levels of HCQ for each cell line, which mostly followed 
the ranking of MDA-MB-231 > MDA-MB-468 > T47D > MCF7 (Fig. 3.1A).  For all 4 hBC 
lines the HCQ total cellular concentrations increased the longer the cell lines were 
exposed to the drug up to total cellular concentrations peaking between 0.58-2.67mM, 
which were 58-267x the extracellular concentration of HCQ, and are consistent with 
steady-state partition coefficients of HCQ tissue:plasma from previous in vivo studies 
(McChesney et al., 1967; McChesney, 1983; Wei et al., 1995).   
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As acidic organelles are suggested to account for a majority of cellular 
distribution of diprotic lipophilic compounds, we investigated the total lysosomal volume 
fraction of each cell line using microscope imaging methods outlined in Supplement Fig. 
3.2.  We observed lysosomal percent volume of total cellular volume ranging from 0.50  
 
Figure 3.1. Whole cell uptake of HCQ is proportional to basal lysosomal volume 
fraction.  The in vitro whole cell PK of HCQ was assessed in 4 human breast cancer 
cell lines (hBC), MDA-MB-231, MDA-MB-468, T47D, and MCF7 at 1, 5, 15, 30, 60, 240, 
and 1440 minutes after incubating with 10µM HCQ (A).  Cell lysosomal volume fraction 
was calculated as outlined in Supplementary Figure 2 (B).  Lysosomal volume fraction 
closely followed the ranking of AUC0-24hr of the whole cell PK data (C).  Mean whole cell 
HCQ concentrations at each timepoint, except 1 minute, was significantly correlated 
with cellular lysosome volume fraction (D).  This correlation was also significant when 
comparing the mean AUC0-24hr of each cell line to the cellular lysosome volume fraction 
(E).  Applicable data is shown as mean ± sd, and significance is defined as P < 0.05.   
 
± 0.19% in MCF7 cells to roughly 3.67 ± 1.09% in MDA-MB-231 cells (Fig. 3.1B), which 
followed roughly the same trend as total cellular uptake of HCQ based on AUC0-24hr 
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(Fig. 3.1C). Overall, mean total cell uptake concentrations of HCQ showed a significant 
Pearson correlation with lysosomal volume fraction for timepoints 5, 15, 30, 60, 240, 
and 1440 minutes (Fig. 3.1D).  The 1 minute timepoint was not significant, likely due to 
insufficient time for HCQ to diffuse into the lysosomal compartment.  Total exposure to 
HCQ, as calculated by AUC0-24hr, also had a strong correlation (P=0.032, R2=0.936) with 
cellular lysosomal volume fraction (Fig. 3.1E).   
Basal Lysosomal PK Model of HCQ Accounts for Uptake by Adjusting Lysosomal 
Volume Fraction 
To further investigate the in vitro PK of HCQ in the 4 hBC lines we used a base 
pharmacokinetic (PK) model of lysosomotropic drug uptake (Trapp et al., 2008; 
Kornhuber et al., 2010), and modified it to be specific to the 4 cell lines in the study with 
experimentally determined lysosomal volume fractions.  HCQ in vitro PK was modeled 
as a diffusion-based 3-D system where net flux of HCQ across membranes is driven by 
the permeability of each ionization state, and ionization state (0, 1+, 2+) is a function of 
pH described by the Henderson-Hasselbach activity ratio.  The model consisted of 3 
compartments representative of in vitro settings, which include culture media, cytosol, 
and lysosomes (Fig. 3.2A).  Trafficking between compartments was driven by net flux. 
The lysosomal compartment had a dynamic pH (∆pH) term that was a function of 
lysosomal HCQ concentration, as HCQ is suggested to neutralize the acidic lysosomal 
pH.  Model parameters are listed in Supplementary Table 3.1.  
 By adjusting the lysosomal volume fractions for each cell line, we simulated the 
in vitro PK experiment of HCQ administered at 10µM for each cell line out to 1 hour (Fig. 
3.2B).  For all cell lines except T47D, the experimentally-derived mean lysosomal 
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volume fraction allowed the simulation to capture the mean concentration of HCQ with a 
strong fit. The simulation was also run using the 95% CI bounds for the experimentally-
derived lysosomal volume fractions to investigate variability due to this parameter. The 
simulation suggested that the system reaches equilibrium around 30 minutes; however, 
 
 
Figure 3.2. Basal Lysosome PK Model of HCQ Accounts for Uptake by Adjusting 
Lysosomal Volume Fraction.  To further investigate the in vitro PK of HCQ in the 4 
hBC lines we used a previously published base model of lysosomotropic drug uptake 
into cells.  The compartmental model is outlined, where compartments considered are 
culture media, cytosol, and lysosome, with the lysosome contained within the cytosolic 
compartment (A).  Mathematically, the 3 compartments are separate, where HCQ 
diffuses freely from Media → Cytosol → Lysosomes, and diffusion is represented 
by a net flux term (∆J) that is the sum of permeability of each HCQ ionization state 
(neutral, 1+, 2+).  The lysosomal compartment has a dynamic pH feedback term that 
was representative of the proposed mechanism of HCQ to increase the pH of the 
lysosome based on free drug concentration.  The model was used to simulate HCQ 
uptake in each cell line based on lysosomal volume fractions and other parameters in 
Table 1.  The output of the model simulation for each cell line is shown as the observed 
mean ± 95% CI bounds in conjunction with the simulated mean ± 95% CI bounds of the 
cellular lysosomal volume fraction (B).  The model only considered timepoints out to the 
first hour, which were labeled as short-term static equilibrium.  In the experimental data 
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it is observed that concentrations continue to increase after 1 hour, which is 
characterized as the long-term dynamic system (C), and investigated in later figures.   
 
the experimental PK data for all 4 cell lines suggests that HCQ concentrations in the cell 
continue to increase steadily at 1, 4, and 24 hours (Fig. 3.2C). Early timepoints were 
characterized by chemical kinetic equilibrium, where the cellular physiologic parameters 
are static, followed by later timepoints where the system physiologic parameters are 
dynamic.  The dynamic system is investigated further in later figures. The model fit for 
each of the cell lines out to 1 hour is characterized by the ratios of simulated/observed 
AUC (Table 3.1), as well as measures of predictive performance PE, MAPE%, and 
MPE% (Supplementary Table 3.2).   
Table 3.1. Static Model Metrics (AUC) 
AUC Summary (0-1hr) Experimental Simulated Ratio 
Cell line Mean Mean Mean Sim / Exp 
MDA-MB-231 1239 1160 0.936 
MDA-MB-468 551 549 0.995 
T47D 588 354 0.602 
MCF7 276 270 0.980 
 
Using a previously determined range of 0.5-2.0 as acceptable ratios for AUC of 
simulated/experimental, the model captured MDA-MB-231, MDA-MB-468, and MCF7 
very closely (0.936, 0.995, 0.980).  T47D was underpredicted, but still fell within the 
acceptable range (0.602).  In comparing the model performance error (PE), the model 
underpredicted early timepoints (1, 5 minutes) for all cell lines except MCF7. Timepoints 
between 15-60 minutes were predicted with good accuracy, aside from T47D.  MAPE%, 
a metric of model accuracy, suggests that the model predicts individual timepoints in 
MDA-MB cell lines with about 30% error, T47D around 60%, and MCF7 about 6.5%.  
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Overall, the model underpredicts concentrations (MPE%) by 18.4 and 8.6% in the MDA-
MB cell lines, although this is biased by early timepoints error, 64% in T47D, and 
overpredicts by only 1.3% in MCF7.  Observations from these metrics suggest that 
T47D cell uptake of HCQ may be better explained by the upper CI bound of its 
lysosomal volume fraction (1.16%), rather than its mean (0.78%).  Model metrics also 
suggest that early timepoints (1, 5 minutes) in MDA-MB cell lines were either 
underpredicted based on uptake kinetics, or there was time-based experimental error 
exacerbated by early timepoint sampling.   
We also investigated the influence of the pH parameters on total cellular uptake 
of HCQ in MDA-MB-231 cells.  We measured the pH of incubator-conditioned culture 
media (5% CO2, 37°C) used in the previous experiments at 7.6, and made acidic 
culture media at an incubator-conditioned pH of 7.0. As stated in the methods section, 
we opted out of using culture media buffers other than sodium bicarbonate, such as 
HEPES, as it has been suggested to activate the MiT/TFE pathway which ultimately 
results in lysosomal biogenesis (Tol et al., 2018).  As the model accurately captured 
MDA-MB-231 cell lines under neutral conditions, they were exposed to 1 or 10µM HCQ 
in the conditioned culture media for 1 hour, and the resulting decrease in total cellular 
uptake of HCQ associated with decreasing media pH was quite dramatic. We observed 
a 6.4-fold decrease in HCQ uptake at the treated concentrations when switching the 
media pH from 7.6 to 7.0, such that in most cases the 10µM HCQ uptake at pH of 7.0 
was nearly equivalent to the 1µM HCQ uptake at pH of 7.6 (Supplementary Figure 
3.3A).  The shape of the simulated kinetics uptake curve was not visibly modified by 
extracellular pH out to the 1 hour timepoint tested (Supplementary Figure 3.3B).  
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Interestingly, lysosomotropic drug partition into cells and tissues has been suggested to 
be significantly reduced by acidic extracellular pH (Wojtkowiak et al., 2011), causing a 
subsequent resistance of cells to growth inhibition by HCQ.  We tested the effect of 
acidic culture media in blunting HCQ growth inhibition in MDA-MB-231 cells and 
observed an almost complete reduction in growth inhibition (Supplementary Fig. 3.3C), 
similar to the trend described by with CQ (Pellegrini et al., 2014).  In addition to testing 
the influence of extracellular pH directly, we also investigated the contribution of 
lysosome and cytosol pH gradient indirectly by treating cells with MN prior to HCQ in 
order to eliminate the gradient.  In MDA-MB-231 cells pretreatment with 25µM MN for 
30 minutes prior to HCQ caused a reduction in total cellular uptake of HCQ by 93.2% at 
1 hour.  We simulated this experiment using the model by changing the lysosomal pH to 
7.0 and comparing to the model with lysosomal pH of 5.0 (Supplementary Fig 3.3D).  
Overall, the model captured the decrease in total cellular uptake well, with simulated 
MN (+) / MN (-) concentration ratio of 0.078 versus observed MN (+) / MN (-) 
concentration ratio of 0.068. 
HCQ Increases the Size of the Lysosomal Compartment 
 While the model captures early timepoint in vitro PK (<1hr) of HCQ, as well as 
variabilities in influential model parameters along the pH gradient, it fails to capture later 
timepoints as the simulation suggests the system reaches equilibrium when the 
observed concentrations actually continue to gradually increase out to 24 hours (Fig. 
3.2C).  Recent reports suggest that many weakly basic lipophilic compounds, including 
CQ, activate lysosomal biogenesis by activating the transcription factor EB (TFEB) (Lu 
et al., 2017; Zhitomirsky et al., 2018; Zhao et al., 2020), which ultimately increases the 
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lysosomal volume fraction of treated cells and should allow them to sequester even 
more drug than their original baseline (Ruzickova et al., 2019).  CQ has been observed 
to activate TFEB and increase lysosomal content of the cell, so we investigated the 
capability of HCQ to do the same.  Treatment of all 4 hBCs with either HCQ for 24 hours 
or TFEB-activator Torin1 for 16 hours, caused a significant increase in TFEB activity in 
the nucleus (Fig. 3.3A), suggesting it is released from the lysosome and translocated to 
the nucleus after HCQ treatment.  In addition, gene microarray data on all 4 cell lines 
treated with HCQ or vehicle for 24 hours showed a significant enrichment in expression 
of the TFEB-associated direct targets in lysosomal function (Fig. 3.3B) as characterized 
by the Ballabio group (Palmieri et al., 2011).  Treatment of all 4 cell lines with HCQ or 
Torin1 caused an increase in the relative volume of the lysosome compartment.  MCF7 
cells had the most visually-distinct increase in lysosomal burden with both drugs (Fig. 
3.3D).  Quantitation of the increase in lysosome-positive area per nuclei suggests a 
relative increase in 1.59 to 14.93-fold (average 5.90-fold) in the cell lines with 24 hour 
treatment with HCQ, or Torin1 caused a 2.25 to 10.7-fold (average 5.55-fold) (Fig. 
3.3C). This increase in lysosomal burden by HCQ may have some contribution 
independent of TFEB as well, as CQ has been shown to induce swelling in lysosomes 
at higher doses, which is visually apparent in images comparing Torin1 increase in 
lysosomal burden versus HCQ increase in lysosomal burden in MCF7 (Fig. 3.3D), and 
the other 3 cell lines (Supplemental Figure 3.4). To further investigate lysosomal 
swelling by HCQ we transfected MDA-MB-468, T47D, and MCF7 cells with a GFP 
baculovirus for lysosomal associated membrane protein 1, LAMP-1, as it more clearly 
defines the membranes of individual lysosomes, and imaged cells after treatment with 
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10μM HCQ for 24 hours. MDA-MB-231 cells would not express the virus and were 
omitted from this experiment. In the 3 cell lines we observed a dramatic increase in size 






Figure 3.3. HCQ Increases the Size of the Lysosomal Compartment.  We 
investigated the ability of HCQ to change the size of the lysosomal compartment.  TFEB 
activity in the nucleus was significantly increased in all cell lines treated with 10µM HCQ 
for 24 hours, and with 250nM Torin1, a molecular TFEB activating agent, for 16 hours 
(A).  Gene set enrichment analysis (GSEA) of all four cell lines treated with 20µM HCQ 
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for 24 hours also caused a significant enrichment of TFEB lysosome targets (B).  
Fluorescence microscopy imaging of all 4 cell lines with ETP showed a significant 
increase in lysosome accumulation within all cell lines treated with 10µM HCQ for 24 
hours, or 250nM Torin1 for 16 hours (C).  Representative images of MCF7 cells imaged 
with ETP under the treatment conditions are shown in in (D).  Zooming in on MCF7 cells 
treated with HCQ shows a visual increase in lysosomal size in comparison with the 
Torin1 treatment.  To prepare figures for publication the raw image threshold was 
adjusted to the same upper and lower bounds across the entire image for all images 
shown.  
 
Dynamic Lysosomal Volume Accounts for Simulation Error 
 The original model with a static lysosomal volume compartment was able to 
capture total cell uptake of HCQ out to 1 hour, but significantly underpredicted 4 and 24 
hour timepoints.  To account for this error, we incorporated lysosomal biogenesis into 
the model by adding a dynamically-growing lysosomal volume fraction represented by 
the proposed mechanism outlined in Figure 3.4.  The growing compartment is 
represented as a linear increase in lysosomal volume fraction as a function of time: Vflys 
(t) = Vflys_0*(1+x*t). We found that a 1.5 to 3-fold total increase in lysosomal volume 
fraction by 24 hours in the dynamic lysosomal model accounted for the underprediction 
of 4 and 24 hour timepoints predicted by the static lysosomal model (Fig 3.5A). The 
simulated 1.5-3 fold increase in lysosomal volume fraction over 24 hours of HCQ 
exposure was within the 95% CI of the experimentally observed increase due to HCQ in 
the 4 cell lines shown in Figure 3.3C, except for T47D.  As such, for T47D, we tested an 
increase of 2.5-fold in lysosomal volume starting from the upper bound of the 95% CI 
(1.155%), which resulted in a better model fit to 24 hours. Incorporation of this time-






Figure 3.4. Proposed Mechanism of HCQ Altered Uptake.  This figure outlines the 
process by which HCQ increases its volume of distribution within the cell.  HCQ is 
initially added to the cell culture (1), after which it immediately begins to accumulate 
within the lysosomes of the cells until it reaches chemical equilibrium between 30 to 60 
minutes (2).  After reaching chemical equilibrium, the lysosomes begin to swell and 
simultaneously activate TFEB (3).  TFEB triggers the formation of new lysosomes, 
which undergo the same swelling process under static extracellular concentrations of 
HCQ (4).  This hypothesized mechanism describes the rapid chemical equilibrium of 
HCQ within the cell, until it starts causing a dynamic increase in the size of the 
lysosome compartment, ultimately leading to this positive feedback loop where HCQ 






Figure 3.5. Dynamic Lysosome Volume Accounts for Simulation Error in Long-
Term HCQ Uptake 
To investigate HCQ whole cell uptake past 1 hour, we incorporated a growing lysosomal 
component into the model for all cell lines.  Lysosomal growth is represented by a linear 
increase as a function of time, out to a maximum lysosomal volume of the fold-increase 
observed with HCQ treatment for each cell line in Figure 3C.  The dynamic system 
model is shown (A) for MDA-MB-231, MDA-MB-468, T47D, and MCF7, respectively.  
MDA-MB-231 and MDA-MB-468 simulated uptake are shown as the mean increase in 
experimental lysosomal volume after HCQ treatment, the upper value of the lysosomal 
volume, and with no growth incorporated.  T47D is shown as the mean, upper, and 
lower increase in lysosomal volume as well as the value we would expect based on the 
PK data (realistic) and no growth.  MCF7 is shown as the mean, upper, lower, and no 
growth.  It should be noted that the time-based increase in lysosomal volume in the 
dynamic model does not affect earlier timepoints, and thus would not affect model fit 




 The model fit, as characterized by the ratios of simulated/observed AUC0-24hr, is 
shown in Table 3.2, and measures of predictive performance PE, MAPE%, and MPE% 
are shown in Supplementary Table 3.3.  Overall, the model captured the early 
Table 3.2. Dynamic Model Metrics (AUC)  
AUC Summary (0-24hr) Experimental Simulated 
 
Cell Line Mean Mean Mean Sim / Exp 
MDA-MB-231 55660 46753 0.84 
MDA-MB-468 26922 22085 0.82 









early timepoints of the cell lines with good performance, as the AUC and ratios were 
close to 1. PE followed the same trend to the static model for timepoints 0-1hr, with 4-24 
hour timepoints being slightly underpredicted for all cell lines except MCF7 and T47D at 
24hr.  MAPE% suggests the model fits overall timepoints for all cell lines between 7.53-
45.21%, and MPE% suggests a slight underprediction bias for the model.  Overall, this 
experimental data and model simulation suggests that HCQ creates a positive 
feedback-loop within the cell-lysosomal compartment causing it to increase its own 
distribution within the cell over time.  
Torin1 Increases Size of Lysosomal Compartment Which Increases Cell Uptake of HCQ 
 While HCQ appears to be able to modify its own distribution, we investigated the 
capability of direct modification of the cell lysosomal volume fraction to increase HCQ 
uptake capacity.   In Figure 3.4D we observed that Torin1 increased the relative 
lysosomal burden by 2.25-10.7 fold.  In this experiment we repeated the HCQ cell 
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uptake experiments out to 24 hours, but first pretreated cells with Torin1 (+) or (-) for 16 
hours prior to administering HCQ.  Pretreatment with Torin1 resulted in a mean increase 
in cellular uptake of HCQ at all timepoints in all cell lines of 1.4-1.6 fold (Figure 3.6A).   
 
Figure 3.6. Torin1 Increases Size of Lysosomal Compartment, Increasing Whole 
Cell Uptake of HCQ.  Cell lines were pretreated with Torin1 (T1) using the same 
concentration and time as in Figure 3.  After Torin1 pretreatment HCQ, the PK studies 
from 1min-24hr were repeated in Torin1 (+) vs. Torin1 (-) cells.  Torin1 pretreatment 
resulted in an average increase of HCQ whole cell concentrations at all timepoints by an 
average of 1.4 to 1.6-fold.  The mathematical PK model of HCQ was tested at basal 
lysosomal volume fractions versus Torin1-modified starting lysosomal volume fractions 
by multiplying the basal lysosomal volume fraction in each cell line by the mean 
increase by Torin1 treatment from Figure 4D (A).  MDA-MB-231 (A, top-left) fit the data 
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well using mean values of Torin1.  MDA-MB-468 used the starting lysosomal volume 
fraction value of the lower 95% CI (0.753%) and mean value of Torin1 i6ncrease (A, 
top-right).  T47D used the mean starting Vflys (0.783%), and was tested against the 
mean Torin1 increase in lysosomes (10.5x) as well as the lowest observed ratio within 
the replicates (3x) (A, bottom-left).  MCF7 was tested against the mean lysosomal 
increase by Torin1, and the lowest observed ratio within the replicates (3.8x) (A, bottom-
right).  To test if the increase in uptake by Torin1 was only due to the increase in 
lysosomes MDA-MB-231 HCQ uptake was tested at 1 hour with no pretreatment, Torin1 
pretreatment, monensin pretreatment, or Torin 1 and monensin pretreatment.  No 
significant change in the ratio between T1/ctrl and MN+T1/MN HCQ uptake was 
observed (B) with a two-tailed unpaired t test (p = 0.573).  Comparing the simulated 
lysosomal concentrations versus the whole cell uptake concentrations in MDA-MB-231 
cells with T1 (+) or (-) show a minimal difference in lysosomal concentration in both 
scenarios (C).   
 
To test this in the context of the in vitro PK model, we changed the cell line base 
lysosomal volume fraction at time 0 based on the mean fold increase of lysosomal 
fraction by Torin1 from Figure 3.3, and simulated the dynamic lysosome PK model 
(Figure 3.6A).  The dynamic lysosome PK simulation suggested that this change in 
initial lysosome starting fraction accounts for the increased uptake of HCQ in the cells.  
For the new data set, the MDA-MB-468 T1 (-) uptake data was simulated against the 
lower CI basal Vflys (0.835%) and the T47D against the mean starting Vflys  (0.783%) 
from Figure 3.1B.  In MDA-MB-231 and 468 cells the mean increase of lysosomes by 
Torin1 accounted for the increased cell uptake of HCQ in the simulation.  In T47D and 
MCF7, the experimental mean increase in lysosomes by Torin1 from Figure 3.3C was 
very high, and so the ratio from the lowest replicate was used to show the increase the 
model would account for.  Comparison of observed versus simulated AUC0-24hr are 
shown in Table 3.3.  All simulation/experimental ratios except the T47D and MCF7 
mean T1 were within the range of 0.5-2.0; however, T47D and MCF7 simulations using 
the lowest T1/ctrl lysosome ratio from a replicate did fall within this range.  Model 
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performance metrics are shown in Supplementary Table 3.4.  The model for each cell 
line followed similar performance error (PE) trends to the earlier versions of the models.  
MAPE% for all cell lines suggests that the model fits overall timepoints between 15.48-
61.69%, and MPE% suggests an even spread of over and underprediction of the model 
across the cell lines.  
Table 3.3. Torin1 Dynamic Model Metrics (AUC)  
AUC Summary (0-24hr) Experimental Simulated 
 
Cell Line Mean Mean Mean Sim / Exp 
MDA-MB-231 (Ctrl) 56214 46753 0.83 
MDA-MB-231 (T1) 104084 99813 0.96 
MDA-MB-468 (Ctrl) 18490 13141 0.71 
MDA-MB-468 (T1) 29517 30276 1.03 
T47D (Ctrl) 17692 15304 0.87 
T47D (T1) 28044 119838 4.27 
T47D (T1 - lower) 
 
39299 1.40 
MCF7 (Ctrl) 12849 10284 0.80 
MCF7 (T1) 21471 49679 2.31 




In addition, we ran the same experiment in MDA-MB-231 cells, except pretreated 
cells with T1, T1 + MN, or MN alone prior to treatment with HCQ for 1 hour.  We 
observed that the ratio of T1/ctrl was not statistically significant from the ratio of MN-T1/ 
MN-ctrl (1.6), suggesting that this increase in cell uptake of HCQ is due to only the 
increase in lysosomal volume fraction induced by T1 (Fig. 3.6C).  In MDA-MB-231, 
model simulation of the T1 (+) vs. T1 (-) scenarios represented an increase in total 
cellular uptake of HCQ, but also showed that the lysosomal concentrations in both 
conditions was roughly the same (Fig. 3.6D).  This suggests that even though the 
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quantifiable concentration of HCQ from a PK study, whole cell or tissue homogenate, 
may change, the concentration in the lysosome may be the same.  This observation 
could have implications for PK:PD correlations as the lysosome is the target site of HCQ 
for autophagy-inhibition.  
 
Discussion 
 Lysosomes have been observed as a drug sink for many lysosomotropic agents, 
including many prescribed drugs like doxorubicin, vinblastine, imipramine, and a variety 
of TKIs, like gefitinib (Skoupa et al., 2020), imatinib (Burger et al., 2015), and sunitinib 
(Ruzickova et al., 2019).  In a recent study by Ruzickova et. al. the lysosomotropic 
agent sunitinib was shown to be capable of increasing overall lysosomal sequestration 
of the TKIs tested, although this effect was insufficient in reducing sensitivity to the TKIs 
by the hypothesized mechanism of sequestering them away from their mechanistic 
target sites as the concentrations tested in culture maintained a static extracellular 
concentration.  The in vitro PK model of HCQ supports this finding, and would suggest 
the same observation as the direct increase of lysosomal volume fraction by pretreating 
with Torin1 (Fig. 3.6C) barely increases HCQ concentration in the lysosome even 
though the whole cell concentration is higher.  This observation sheds light onto one 
commonly suggested hypothesis for HCQ growth-inhibition synergism with other 
lysosomotropic agents in cell culture, which is that HCQ displaces drugs from the 
lysosome, reducing overall sequestration, and increasing concentration at target sites 
elsewhere within the cell.  This work in conjunction with other recent findings would 
suggest that under static extracellular concentrations this hypothesized mechanism is 
138 
 
unlikely, as an overall reduced cellular uptake of lysosomotropic drugs may be due to 
displacement by HCQ, but would not result in a subsequent increase in concentration at 
the drug’s mechanistic target.  This does not eliminate this hypothesized mechanism in 
vivo though, as extracellular concentrations are not constant. 
 Many drugs have been shown to activate TFEB in vitro in recent publications (Lu 
et al., 2017; Zhitomirsky et al., 2018; Zhao et al., 2020), most of which are weakly basic 
lipophilic agents that would be physicochemically characterized as lysosomotropic.  If 
lysosomotropism is a major factor in the PK of these drugs, as it is for HCQ, then the 
distribution of these drugs might be altered by their effect on the lysosome as we have 
observed for HCQ.  Our findings emphasize care in cell-level PK studies of drugs with 
weakly-basic lipophilic structures, especially when attempting to correlate concentration 
with response.  This is especially important when using multiple lysosomotropic agents 
in combination. 
 Regardless, the possibility of occurrence of this lysosome-altered distribution is 
supported by in vitro studies in other lysosomotropic agents, whether it be through the 
activation of lysosomal biogenesis or through lysosomal fusion that is independent of 
biogenesis (Skoupa et al., 2020), but with limited data to suggest it may occur in vivo.  
HCQ is somewhat unique in this context because of its long half-life combined with 
often prolonged dosing regimens, which means that tissue will be exposed to relatively 
high concentrations of the drug for an extended duration.   Extended duration of 
exposure to tissues might exacerbate the lysosomotropic effects due to HCQ, that may 
not necessarily be prevalent with other drugs that are dosed more short term.  We are 
unaware of any long term preclinical PK studies involving HCQ that investigate multiple 
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timepoints aside from the work by McChesney, EW (McChesney, 1983).  This study 
looked at a variety of different tissues in rats that were treated with HCQ 6 days/week 
for months, with timepoints at 1, 2, 3, and 7 months.  The key observation from this 
study is that HCQ concentrations continually increase up to 3 months, where dosing is 
discontinued in the first study.  In the 7 month study, HCQ only starts to reach tissue 
steady-state between 3-7 months in lung, eye, and muscle, but continues to gradually 
increase in concentration for other tissue.  This is particularly interesting as the plasma 
half-life of HCQ in rats has been observed at around 10.6 hours (Moore et al., 2011), 
suggesting a disconnect between plasma and tissue steady-state values.  The study by 
Wei et. al. also investigated HCQ dosing in rats, sampled multiple timepoints of blood 
over the course of 10 weeks, but only sampled tissue at the 10 week mark (Wei et al., 
1995).  Interestingly, of the 3 dosing regimens applied to both male and female rats (6 
conditions total), only the 8mg/kg regimen in male rats appeared to increase in blood 
concentration after the first timepoint at 3 weeks, but remained steady after that.  For 
the rest of the dosing regimens, HCQ appeared to remain constant which would 
suggest that steadily increasing tissue concentrations of HCQ would be undetected by 
the traditional PK sampling of blood in clinical studies.   
 This work has implications in HCQ PK, both in vitro and in vivo, particularly in the 
context of the cancer clinical trial in solid tumors by Barnard et al., where there was no 
correlation between HCQ concentrations in the tumor and plasma (Barnard et al., 
2014).  Further data is needed to investigate the concentration/time relationship of this 
effect and possible maximum values of lysosome volume fractions that are achievable 
in vitro.  For this study we modeled the lysosomal compartment as increasing linearly 
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with time, although it is more likely that this effect follows a hyperbolic trend – increasing 
rapidly, and leveling off to eventually reach a pseudo-maximum.  It is also likely that this 
effect is due to overall exposure to HCQ (AUC) rather than time or concentration alone, 
but to investigate that a significant number of timepoints and concentrations are 
necessary in conjunction with subsequent PK analysis to maintain a connection 
between the lysosomal biogenesis mechanism and PK outcome.  In addition, a 
comprehensive PK/PD study connecting increasing tissue concentrations over the long 
term with an increase in lysosomal volume of tissues is warranted to truly confirm 
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HCQ, while the only clinically-approved autophagy inhibitor used in cancer clinical trials, 
suffers from clinical shortcomings revolving around pharmacokinetic predictability and 
contextual efficacy.  As discussed earlier, there is a significant disconnect between 
blood and tumor concentrations of HCQ, creating a challenge in predicting if target 
concentrations are reached within the tumor in clinical settings.  This is likely due to a 
combination of tumor intrinsic and extrinsic factors specific to lysosomotropic agents.  
Intrinsic factors are focused around the lysosomal sequestering capacity of specific 
cells, and the ability of HCQ to modulate this sequestering capacity, creating a dynamic 
volume of distribution within the cell.  Extrinsic factors are primarily attributed to pH 
variability.  Solid tumors are associated with a non-homogenous acidic 
microenvironment, which blunts HCQ permeability into cells, and creates acidic niche 
populations of cells which will not be affected by HCQ due to decreased cell uptake.  
These intrinsic and extrinsic factors together contribute to alterations in HCQ PK in vitro, 
and are likely involved in in vivo variabilities in overall tumor exposure to the drug.  As 
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no solution to address these variabilities has been effective when in conjunction with 
HCQ, the logical next step is to investigate next generation CQ-like autophagy inhibitors 
that may overcome them.  Lys05 (DC221) and DC661 were investigated in a 
comparative study with HCQ, to determine their susceptibility to such intrinsic and 
extrinsic factors.  Lys05 and DC661 were found to modulate their own cellular volume of 
distribution by induction of lysosomal biogenesis, similar to HCQ; however, were shown 
to be less dependent on the lysosomal:cytosolic pH gradient than HCQ.  Lys05 and 
DC661 total cell uptake were less affected by acidified extracellular pH (<2-fold) relative 
to HCQ (6-fold), which was associated with less of a reduction in cellular growth 
inhibition.  The in vivo PK of Lys05 and DC661 suggest higher exposure relative to 
dose, and maintained concentrations for a longer duration relative to HCQ.   Overall, 
Lys05 and DC661 have advantages over HCQ regarding intrinsic and extrinsic factors 
related to drug exposure, but still suffer from the same shortcomings, albeit to a lesser 
degree.   
 
Introduction 
 In the past two decades many compounds have been discovered that function as 
autophagy inhibitors, generally categorized by the different steps within the 
macroautophagic pathway in which they exert activity.  Most drugs that have been 
applied in vitro to study stream-points in mechanistic autophagy inhibition have been 
largely unsuccessful in vivo in the context of cancer treatment (Onorati et al., 2018).  
Currently, inhibition of the endpoint of autophagy, where the lysosome fuses with the 
autophagosome, has shown the most promise in vivo.  Along those lines, the only FDA 
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approved inhibitor of autophagy for clinical cancer treatment is hydroxychloroquine 
(HCQ), which inhibits the fusion of the lysosome and autophagosome by alkalinizing the 
lysosomal pH.  HCQ has shown moderate success in cancer clinical trials, with positive 
outcomes including improved patient response rate (Barnard et al., 2014; Mahalingam 
et al., 2014; Rangwala et al., 2014a; Rangwala et al., 2014b; Boone et al., 2015) and 
overcoming acquired resistance when used in combination with other therapies (Levy et 
al., 2014), but has not been successful in monotherapy treatment (Wolpin et al., 2014).   
 HCQ as an anti-cancer treatment suffers from various pharmacologic 
shortcomings both in vitro and in vivo.  In clinical trials, HCQ has been observed to 
cause only a small increase in autophagy inhibition at the highest doses (600 mg b.i.d.), 
as observed in peripheral blood mononuclear cells (PBMCs), but has also not been 
observed to have any marker of pharmacokinetic (PK) accumulation within the tumor 
(Barnard et al., 2014).  HCQ (and mechanistically-similar chloroquine (CQ)) 
concentrations in tissue are dramatically decreased in cells if the extracellular pH is 
physiologically-acidic (pH < 7.0), which is a hallmark of solid tumors (Hanahan and 
Weinberg, 2011).  This is associated with a loss in the ability of the drug to inhibit 
autophagy in vivo (Pellegrini et al., 2014).  In addition, HCQ lacks potency in terms of 
single agent growth inhibition as well as autophagy inhibition.  Typical concentrations of 
HCQ used in autophagy inhibition assays are 10µM or higher for an extended duration 
(4-24hr) (Klionsky et al., 2016).  As a single agent for inhibiting cancer cells in vitro it 
has a broad range of IC50 values generally falling between 1-40µM.  For context, 
clinically-achievable concentrations of HCQ reach a maximum around 10µM (Collins et 
al., 2018), so to have single agent efficacy it would only affect a population of cancer 
148 
 
cells if one assumes that partitions between the 10µM concentrations correlate directly 
to in vivo concentrations.  Unfortunately, this is unlikely as extracellular pH in cell culture 
assays tends to be much higher (7.4-7.6) than what is observed in solid tumors in vivo 
(6.3-7.0).   
 As lysosomal inhibition is, so far, the most promising method of inhibiting 
autophagy in vivo, we have focused on investigating drug properties of HCQ further, 
and comparing directly to dimeric CQ analogues, Lys05 and DC661, that would make 
them more potent in terms of autophagy inhibition and single agent growth inhibiting 
potential.  Lys05 (DC221) and DC661 are dimeric versions of CQ that contain the same 
4-aminoquinoline nucleus, and are connected through a tertiary amine linker of varying 
carbon chain lengths (DC221 = length 2, DC661 = length 6).  Both drugs are shown to 
be significantly more potent than CQ/HCQ in inhibiting autophagy and growth inhibition.  
These drugs also have single agent antitumor activity when administered to mice 
(McAfee et al., 2012; Rebecca et al., 2019).  Lys05 is also shown to overcome 
decreased activity in the presence of acidic extracellular pH in comparison to HCQ 
(Pellegrini et al., 2014).  While these drugs, along with CQ/HCQ, have recently been 
shown to molecularly target PPT1 (Nicastri et al., 2018; Rebecca et al., 2019), their 
accumulation at the active site in the lysosome is likely due to extracellular: cytosolic:  
lysosome pH gradient, as they share similar physicochemical properties to CQ.  Lys05 
and DC661 are likely to accumulate more preferentially in the lysosome due to a more 
dramatic shift in membrane permeability between neutral and ionized states.  This is 
driven by the presence of 3 weakly basic amine subgroups, compared to HCQ which 
only has 2, resulting in increased potency.  We do not know if PPT1 plays a role in drug 
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localization and uptake within the lysosome, but observations discussed herein suggest 
it likely does.   
 In this work we investigate how Lys05 and DC661 interact with intrinsic and 
extrinsic aspects of the in vitro system in comparison to HCQ.  We observe that Lys05 
and DC661 are more potent than HCQ in a panel of 8 cell lines, with correlations 
between sensitivity across cell lines that suggest they inhibit growth in the same way.  
Lys05 and DC661 in vitro PK are similar to HCQ in that they are driven by lysosomal 
uptake, modulate their own PK similar to HCQ, and can be manipulated by altering the 
lysosomal volume of the cell.  Lys05 and DC661 are much less affected by acidic 
extracellular pH in comparison to HCQ, which can be characterized primarily by 
physicochemical differences, and suggests they would be more viable alternatives to 
HCQ in overcoming the acidic tumor microenvironment.  Furthermore, we characterize 
Lys05 and DC661 in vivo PK in mice in liver, kidney, intestine, brain, and blood.  Both 
drugs are retained in tissue for a significantly longer duration than HCQ and neither 
were observed in brain tissue, which have significant considerations for drug use in 
preclinical testing.  We investigate the ability of these drugs to inhibit autophagy in 2-D 
microenvironments, and how autophagy inhibiting potential is affected by acidic 
extracellular pH.  Overall, this work highlights important features of Lys05 and DC661 
pharmacologic characterization, which will be important in predicting their use in vivo as 





Materials and Methods 
Cell Lines 
Human breast cancer cell lines including MDA-MB-231, MDA-MB-468, and 
MCF7 were used in experiments.  For cell pharmacokinetic experiments all cell lines 
were stably transfected with Essen NucLight Red Lentivirus prior to experimentation.  
For autophagic flux experiments cell lines were stably transfected with the mCherry-
GFP-LC3 reporter construct, received as a gift from Dr. Andrew Thorburn at Colorado 
University Anschutz Medical Campus.  
Cell lines were cultured in Dulbecco’s Modified Essential Medium (DMEM; 
Corning, 10-017-CV) supplemented with 10% fetal bovine serum (FBS; Peak Serum), 
1% penicillin/streptomycin (PS; Fisher), and 1% sodium pyruvate (Fisher) at 37°C and 
5% CO2 in a humidified incubator.   
Chemicals and Reagents 
Hydroxychloroquine (HCQ) sulfate was purchased from Sigma Aldrich.  
Monensin (MN) was purchased from VWR.  Torin 1 (T1) was purchased from Fisher.  
Hoechst 33342 20mM solution was purchased from ThermoFisher.  Lysosome Dye 1 
(ETP), a pH-insensitive lysosomal lumen stain applicable for live and fixed cell imaging, 
was a received as a gift from Dr. Yi Pang at the University of Akron (Abeywickrama et 
al., 2019).  Lys05 and DC661 were gifts from Drs. Jeffrey Winkler and Ravi Amaravadi 
at University of Pennsylvania.  Drug structures of CQ, HCQ, Lys05, and DC661 along 




Figure 4.1. Structures of chloroquine analogues. 
 
Cell Growth Inhibition Experiments 
Cells were plated in 96-well plates at 5,000 cells/well and allowed to adhere 
overnight.  Drug was dissolved in fresh, warm media and then added to cells for the 
duration of the experiment (96 hr).  For acidic media experiments, cells were plated in 
culture media and culture media was replaced with acidic media containing the drug.  
Immediately after adding drug the cells were imaged on an Incucyte ZOOM every 3 
hours for the duration of the experiment to count red fluorescent nuclei.  Cell growth 
inhibition was calculated using a concentration survival curve following the Chou-




Cell Uptake Experiments 
3 human breast cancer cell lines were chosen to perform experiments.  The first 
2, MBA-MB-231 and MDA-MB-468, are mechanistically sensitive to autophagy inhibition 
through gene knockdown (Maycotte et al., 2014; Towers et al., 2019) and 
pharmacologically sensitive to hydroxychloroquine.  The third, MCF7, is insensitive to 
both methods (Maycotte et al., 2014).  Cell drug uptake experiments were conducted 
using the same methods as those described in Chapter 3.   
Lysosomal Imaging 
Experiments involving the change in relative lysosomal volume of cells used the 
same dye and imaging methods described in Chapter 3.   
Cell Pharmacokinetic Mathematical Modeling and Simulation 
Modeling exercises followed the same methods as those described in Chapter 3.  
Cell starting parameters were identical to those in Chapter 3 for MDA-MB-231, MDA-
MB-468, and MCF7.  The model developed by Trapp and colleagues (Trapp et al., 
2008; Kornhuber et al., 2010) was only designed to characterize mono and dibasic 
compounds.  To account for tribasic compounds a third Henderson-Hasselbach activity 
radio (D3) was added to account for fraction of drug in the third ionization state.  In 
addition, the activity coefficient of the 3rd ionization state, gamma 3, was derived using 
the same methods described (Trapp et al., 2008).  Briefly, the third activity coefficient 
(γ3) was estimated from the Davies approximation of the modified Debye-Huckel 
equation at a concentration of 0.1M, which value of γ3 = 0.07 for triprotic ions.  The base 
lysosomal PK model developed by Trapp et. al. was only validated against molecules of 
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0, +1, and +2 ionic states.  In testing the model with the derived γ3, it was found that the 
model overpredicted cell uptake for Lys05 under neutral conditions as the predicted 
acid-phospholipid binding free fraction of Lys05 was only 7.38% as opposed to 31.58% 
for HCQ.  This allowed Lys05 to build up to a much higher extent in the lysosome 
without neutralizing the pH (as only the free fraction is assumed to neutralize lysosomal 
pH).  This allowed Lys05 to accumulate to dramatically high concentrations as the pH-
feedback loop in the lysosome was minimally-impactful.  In addition, using the derived 
value of γ3 did not characterize cellular uptake of Lys05 due to perturbations in media 
pH very well.  Thus, the model for triprotic molecules that incorporated the derived γ3 did 
not capture cell uptake of Lys05 very well based on the physicochemistry of the 
molecule as it did for HCQ.  To bypass this mathematical modeling road-block I 
assumed that γ3 was similar to a diprotic molecule, and used the same value as γ2, 0.3 
instead of 0.07.  This assumption allowed the model to capture in vitro PK of Lys05 with 
much better accuracy. 
Mouse Pharmacokinetic Study 
Mice were dosed intraperitoneally with 5 or 10 mg/kg Lys05 or 3 mg/kg DC661.  
Mice were grouped by timepoint with n=3 mice per timepoint.  Timepoints included 4, 
10, 24 hr, and 2, 3, 4, 8, and 12 days.  At the designated timepoint, mice were 
anaesthetized and sacked.  Tissues were immediately harvested, and flash frozen in 
liquid nitrogen.  Tissues included liver, kidney, intestine, and brain.  Whole blood was 
also harvested by cardiac stick, and kept on ice until freezing fully.  For LC-MC/MS 
analysis, tissue was homogenized and diluted 1:10 in Milli-Q water.  For Lys05 in tissue, 
drug was extracted by adding 50µL of tissue homogenate to 150µL of acetonitrile 
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(ACN).  This mixture was vortexed on high for 10 minutes, centrifuged for 10 minutes at 
13,300 rpm, and supernatant transferred to polypropylene inserts for analysis.  For 
DC661 in tissue and blood, and Lys05 in blood, drug was extracted by adding 50µL of 
blood and 5µL of 20% NH4OH to a tube and vortexed on high for 5 minutes.  Then 
1000µL of MTBE/EtOAc was added to the tube and vortexed on high for another 5 
minutes.  Samples were spun at 13,300 rpm for 20 minutes, and then 900µL of 
supernatant was transferred to a 2mL tube.  Samples were dried down on a speed 
vacuum for 45 minutes on medium speed.  Samples were reconstituted in 100µL of 
90:10 ACN w/ 0.5% Formic Acid, vortexed for 20 minutes, and transferred to 
polypropylene inserts for analysis.  DQ661 was used as an internal standard and the 
LLOQ of the method was 10ng/mL.  Quantitative chemical analysis was done on a 
Shimadzu HPLC system coupled to a 3200 Q-TRAP triple quadrupole mass 
spectrometer (Applied Biosystems, Inc., Foster City, CA) with an Atlantis HILIC Silica 
5µm, 4.6 x 150mm column (Part No. 186002028).  Noncompartmental analysis of the 
data was done on Phoenix WinNonlin.   
Autophagy Pharmacodynamic Studies 
To investigate the role of HCQ, Lys05, and DC661 in endpoint autophagy 
inhibition in MB231, MB468, and MCF7 cell lines, cells were stably transfected with a 
GFP-mCherry-LC3 reporter construct.  The GFP part of the probe is pH-sensitive, and 
so under normal conditions will be quenched in the acidic lysosome.  Endpoint 
autophagy inhibition by preventing the autophagosome, where LC3 is located, from 
fusing with the lysosome should therefore prevent GFP from being quenched and 
ultimately result in higher GFP/mCherry fluorescence in autophagy inhibited cells.  All 3 
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cell lines were tested for endpoint autophagy inhibition of the drugs, under both neutral 
and acidic conditions. Cells were treated with the indicated drug condition for 24 hours, 
and then live cells were imaged on GFP and Cy3 channels at 40x magnification on an 
LED microscope described in Chapter 3.  To compare treatment conditions, the image 
fluorescence per area was presented as a ratio of GFP/Cy3 and statistical significance 
was determined using one-way ANOVA with Dunnett’s multiple comparison test relative 
to the control.   
Computer Simulation and Software 
Intracellular PK model was done in MATLAB, version R2020a (MathWorks, Inc.) 
and solved using the ode45 package.  Image analysis was done in ImageJ, version 
1.52p using methods described above.  Noncompartmental analysis was done in 
Phoenix WinNonlin.   
 
Results 
Growth Inhibition Trends Between HCQ, Lys05, DC661, and BafA1 
Lys05, DC661, and Bafilomycin A1 growth inhibition was tested in a panel of 8 
cell lines which included MDA-MB-231 (human breast cancer), MDA-MB-468 (human 
breast cancer), SK-BR-3 (human breast cancer), H292 (human lung cancer), U2OS 
(human osteosarcoma), SJSA-1 (human osteosarcoma), Gracie (canine 
osteosarcoma), and Moresco (canine osteosarcoma).  The Dm96hr is reported for all 3 
drugs for all cell lines, except SK-BR-3 for DC661.  
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Cell Dm96hr for Lys05 and DC661 had a significant Pearson correlation across cell 
lines (P = 0.034) (Fig 4.2A.).  HCQ Dm96hr values for the cell lines were not readily 
available, but all cell lines had been previously characterized as HCQ sensitive (S) or 
resistant (R).  Cell lines Dm96hr for Lys05 fell within the range of 0.5-2µM, where HCQ 
(S) cell lines were more sensitive to Lys05 and HCQ (R) cell lines were less sensitive 
(Fig. 4.2B).  DC661 followed a similar pattern, although the range of Dm96hr was 
narrower (0.2-0.5µM) which made it difficult to tell if cell lines followed the same 
grouping, though it appeared they did (Fig. 4.2B-C).   
Cell Dm96 of Bafilomycin A1 was also tested in all cell lines except SK-BR-3.  The 
range of BafA1 Dm96hr values fell between 2-15nM, but did not show any correlation 
when compared to cell sensitivities of Lys05 and DC661 (Fig. 4.2D, E).  BafA1 
sensitivities also did not appear to follow the same ranking as HCQ (S) vs. (R) cell lines 
(Fig. 4.2F).  Taken together, this data would suggest Lys05, DC661, and HCQ cause 
growth inhibition in cells in a similar manner.  BafA1, which is a V-ATPase inhibitor, 
deacidifies the lysosome as the three CQ drugs are suggested too, however the manner 




Figure 4.2. Growth inhibition between CQ analogues follows a similar trend 
across cell lines.  Cell lines Dm96hr values are shown for Lys05 vs. DC661 (A).  
Distribution of Lys05 and DC661 cell Dm96hr values is shown for cells classified as HCQ 
sensitive (S – blue) or resistant (R – red) (B, C).  Lys05 (D) and DC661 (E) Dm96hr 
compared to Bafilomycin A1 Dm96hr. Distribution of Bafilomycin A1 cell Dm96hr values is 
shown for cell lines (F).   
 
Intracellular PK of Lys05 and DC661 Exhibits Similar Behavior to HCQ 
The intracellular PK of Lys05 and DC661 were determined in MDA-MB-231 cells 
at 1µM and 0.5µM, respectively, following experimental methods described in Chapter 
3.  Lys05 was observed to have a similar trend to HCQ, with rapid equilibrium uptake 
out to 1 hour, followed by consistent steady uptake at 4 and 24 hours (Fig. 4.3A).  Total 
whole cell concentration of Lys05 was increased by a mean of 1.90x at each timepoint 
when cells were pretreated with 250nM Torin1 for 16hr, suggesting that its PK is 
lysosomally-driven.  By 1hr, 1µM Lys05 treated whole cell concentrations reached 
587µM, which compared to 10µM treated HCQ of 2670µM (Fig. 4.3C).  DC661 whole 
cell PK was also similar to HCQ, although exhibited a drop at 1hr followed by recovery 
158 
 
and increase at 4 and 24hr (Fig. 4.3B).  Total whole cell concentration of DC661 was 
increased by a mean of 1.65x at each timepoint when cells were pretreated with 250nM 
Torin 1 for 16hr hours, suggesting it is also lysosomally-driven, yet seems less 
perturbed in comparison to Lys05 and HCQ.   
 
Figure 4.3. Intracellular PK of CQ analogues.  MDA-MB-231 cells were treated with 
Lys05 at 1µM (A), DC661 at 0.5µM (B), and HCQ at 10µM (C) for timepoints ranging 
from 1 minute to 24 hours (black) or pretreated with Torin1 prior to drug administration 
(grey), and whole cell concentrations were determined.  Lysosome content of cells was 
probed at 24 hours in MDA-MB-231 and MCF7 cell lines after 24 hours of exposure to 
the drugs (D).  Whole cell concentration ratios of MDA-MB-231 cells pretreated with 
lysosome ionophore, monensin (MN) or vehicle, prior to 1 hour administration of drugs 
(E).   
Lys05 and DC661, like HCQ, increased the relative lysosome volume in MDA-
MB-231 and MCF7 cell lines after 24 hours of exposure (Fig. 4.3D).  This suggests that 
they may also be able to activate the lysosome positive feedback loop which allows 
them to increase their whole cell concentration over extended exposure times.  From 
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the intracellular PK data illustrated, Lys05 would appear to follow this feedback loop 
(Fig. 4.3A), whereas DC661 is less apparent (Fig. 4.3B).   
MDA-MB-231 cells were pretreated with 25µM MN prior to 1hr exposure to all 3 
drugs, and interestingly the decrease in drug uptake of each drug in MN pretreated vs. 
vehicle pretreated was 0.14 for HCQ,  0.19 for Lys05, and 0.69 for DC661 (Fig. 4.3E).  
This may indicate that Lys05 and DC661 are less dependent than HCQ on the 
cytosolic:lysosomal pH gradient to accumulate in cells, suggesting there may be some 
other binding affect playing a role – potentially due to PPT1 affinity.   
Mathematical Modeling of Intracellular PK 
To investigate the role of lysosomally-driven PK in the intracellular distribution of 
Lys05 and DC661, the mathematical model of weakly-basic drug accumulation 
validated for HCQ from Chapter 3 was applied with appropriate parameters modified.  
Lys05 and DC661 physicochemical properties have not been determined 
experimentally, so for the purpose of simulation they were estimated computationally 
and presented in Table 4.1.  LogP values of both drugs were determined using either 
Molinspiration or ChemDraw.  The pKa values were determined by Jaguar through 
sequential or standard pKa estimation methods.  Values used the in the PK simulation 
were optimized from the estimated values and 2 different combinations were used for 






Table 4.1. Physicochemical properties used in CQ analogue simulations. 




pKa (est) pKa (opt) 
HCQ 335.87 3.84 3.84 9.67, 8.27 9.67, 8.27 




9.57, 7.90, 7.293 
9.57, 8.61, 8.614 
9.57, 7.90, 7.29cond5 
9.57, 8.61, 8.01cond6 




9.83, 8.40, 7.803 
9.83, 8.40, 8.404  
9.83, 8.40, 8.40cond1 
9.83, 8.40, 7.80cond3 
1 – value estimated by molinspiration 
2 – value estimated by Chemdraw 
3 – empirical sequential pKa estimated by Jaguar 
4 – empirical standard pKa estimated by Jaguar 
 
Simulated versus observed PK of Lys05 and DC661 using the two combinations 
of pKa and lipophilicity values are shown for MDA-MB-231 cells in Figure 4.4A and B, 
respectively.  With the adjustments made to the base model, outlined in the methods 
section, the static model of conditions 5 and 6 captured Lys05 uptake kinetics fairly well, 
aside from 4 and 24 timepoints as was the case in HCQ.  DC661 followed a similar 
pattern.   
To investigate the role of the lysosomal pH gradient in uptake of the drugs, I 
tested the model simulation against conditions representative of MN pretreatment 
wherein the lysosomal pH is equilibrated with the cytosol (pH = 7.0).  Simulated drug 
treatment with 1µM Lys05 (cond5) and 0.5µM DC661 (cond1) resulted in a lysosomal 
pH increase to 5.1 and 5.2, respectively (Fig. 4.4C-D).  Simulating the MN condition 
resulted in a whole cell MN (+) / (-) ratio of 0.0026 for Lys05 and 0.00317 for DC661, 
which were significantly lower than the observed values of 0.19 and 0.60 presented in 
Figure 4.3E.  This again suggests that Lys05 and DC661 whole cell uptake may not be 




Figure 4.4. Mathematical simulation of acidic ion trap kinetics for Lys05 and 
DC661.  MDA-MB-231 whole cell concentrations of Lys05 and DC661 from Fig. 4.3. 
compared to simulated cell uptake using Lys05 conditions 1 & 2 (A) and DC661 
conditions 1 & 2 (B).  Simulation data looking at whole cell uptake and lysosomal uptake 
of drugs in MN (+) versus (-) conditions for Lys05 (C) and DC661 (D).   
 
Dimeric CQ analogue cell uptake is blunted less by acidic extracellular pH compared to 
HCQ 
Cell interaction with the 3 drugs was tested under standard (N) and more 
acidified (A) media pH of 7.0 and 7.6, respectively.  Drugs were treated at 1 and 10µM 
for 1 hour in MB231, MB468, and MCF7 cell lines.  HCQ whole cell uptake was 
significantly blunted by the more acidic culture media (Fig. 4.5A) compared to Lys05 
and DC661 (Fig. 4.5B-C), such that the concentration of HCQ 1µM (N) was similar to 
HCQ 10µM (A) for most cell lines.  Ratiometric comparisons, presented in Table 4.2, 
show that the HCQ uptake is decreased by roughly 6.0-fold, where Lys05 and DC661 
are decreased by roughly 2-fold.  This more pronounced effect for HCQ is observed in 
cell sensitivity to the drugs in MB231 cells, where HCQ growth inhibiting ability is 
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completely inhibited (Fig. 4.5D), whereas Lys05 and DC661 maintain some potency 
under acidic conditions (Fig. 4.5E-F).  Simulation of all conditions tested in Figure 4.5A-
C show that the mathematical model accounts for reduced uptake of HCQ in most 
cases for MDA-MB-231, MDA-MB-468, and MCF7 cell lines (Supplementary Figure 
4.1A-C).  Lys05 conditions 5 and 6 simulation captured the timepoints well at 1µM 
concentrations in the cell lines, but began to lose accuracy at the higher dose of 10µM 
(Supplementary Figure 4.1D-F).  For DC661, only condition 1 captured the lower 
concentrations well, but also started to lose accuracy at the higher dose of 10µM 
(Supplementary Figure 4.1G-I).   
 
Figure 4.5. Blunting of CQ analogue cell uptake by acidic extracellular pH.  Whole 
cell drug uptake of MDA-MB-231, MDA-MB-468, and MCF7 cell lines treated with 1 or 
10µM HCQ (A), Lys05 (B), or DC661 (C) for 1 hour under acidic or neutral media 
conditions.  Cell growth inhibition curves were probed under the same conditions for 






Table 4.2. Ratios for cell lines at different concentrations and pH values 
Drug Conc. Ratio MB231 MB468 MCF7 Mean Std. dev 
HCQ 1N/1A 8.32 6.80 6.94 7.35 0.84 
10N/10A 6.38 2.07 5.24 4.56 2.24 
Lys05 1N/1A 2.47 1.72 1.94 2.04 0.38 
10N/10A 2.33 1.11 2.05 1.83 0.64 
DC661 1N/1A 2.98 2.70 1.79 2.49 0.62 
10N/10A 1.36 1.69 1.37 1.47 0.19 
 
To comparatively evaluate the three drugs against each other, simulated uptake 
of 10µM was tested in MB231 cells for extracellular pH values of 7.6, 7.0, and 6.5 (Fig. 
4.6).  HCQ cell and lysosomal uptake were significantly decreased the more the 
extracellular pH was decreased (Fig 4.6A-B), where any alkalinization of lysosomal pH 
was lost at pH 7.0 (Fig 4.6C).  Both conditions for Lys05 had slightly decreased cell and 
lysosomal uptake between pH 7.6 and 7.0, and more dramatically at pH 6.5 (Fig. 4.6D-
E).  Condition 5 appeared less blunted by pH between 7.0 and 7.6.  Both simulated 
conditions were able to alkalinize lysosomal pH to some extent under pH 7.0 and 7.6, 
though condition 6 more so, but most of this was lost at pH 6.5 (Fig. 4.6F).  Both 
simulated conditions for DC661 were barely affected between pH 7.6 and 7.0, but were 
affected at pH 6.5 (Fig. 4.6G-H).  DC661 simulated pH alkalinization suggests that 
condition 3 is better at alkalinizing lysosomal pH at extracellular pH of 7.6 and 7.0; 
however, both conditions lose the ability to alkalinize lysosomal pH at extracellular pH of 
6.5 (Fig. 4.6I).   
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Figure 4.6. Simulation of CQ analogues at different extracellular pH.  MDA-MB-231 
cell uptake of drugs was simulated at pH 7.6 (blue), 7.0 (red), and 6.5 (green).  
Simulations were run for HCQ whole cell (A), lysosome (B), and lysosome pH (C); 
Lys05 whole cell (D), lysosome (E), and lysosome pH (F); DC661 whole cell (G), 
lysosome (H), and lysosome pH (I).   
 
Mouse Tissue PK of Lys05 and DC661 
To investigate the in vivo PK of Lys05 and DC661, both drugs were administered 
to mice intraperitoneally.  Lys05 was tested at 5 and 10mg/kg, and DC661 was tested at 
3mg/kg, with both drugs tested out to 288hr (12 days).  The tissue PK of both drugs 
were compared to PK data with HCQ at 20, 40, and 80mg/kg from Chapter 2.  Lys05 
and DC661 were retained in tissue for significantly longer than HCQ (Figure 4.7), and 
achieved much higher tissue concentrations relative to the dose administered in 
comparison to HCQ.  Lys05 and DC661 were not detected in the brain (Figure 4.7).  
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Noncompartmental analysis (NCA) of Lys05 and DC661 in Table 4.3 suggest that 
DC661 is retained in tissue and blood significantly longer than Lys05, despite having 
mostly lower Cmax and AUC values for only a slightly lower dose.  Comparing half-lives 
to HCQ, Lys05 was retained in blood 4 times longer and in tissue 4-13 times longer, and 
DC661 was retained in blood 11 times longer and in tissue 7-61 times longer (Table 
4.4).   
 
Figure 4.7. Mouse tissue PK of CQ Analogues.  Mice were treated with 20, 40, or 
80mg/kg HCQ (blue, red, green); 5 or 10mg/kg Lys05 (grey, black); or 3mg/kg DC661 
(purple).  Tissue were collected between 3-72 hr (HCQ) or 4-288 hr (Lys05, DC661), 
and concentrations are shown for whole blood (A), kidney (B), liver (C), intestine (D), 







Table 4.3. Noncompartmental analysis of Lys05 and DC661 PK data.  
Tissue Cohort Half-life (hr) Cmax (ng/g) AUC (hr*ng/mL) 
Mean Std. dev Mean Std. dev Mean Std. dev 
Blood Lys05 
5mg/kg 
57.7 7.1 9.28E+02 6.32E+01 3.87E+04 4.84E+02 
Lys05 
10mg/kg 
65.6 7.0 1.60E+03 2.01E+02 8.43E+04 9.39E+03 
DC661 
3mg/kg 
179 67.8 2.05E+02 2.49E+01 2.04E+04 7.72E+03 
Liver Lys05 
5mg/kg 
44.9 3.7 4.01E+04 5.78E+03 2.81E+06 1.27E+05 
Lys05 
10mg/kg 
48.7 5.9 6.59E+04 6.85E+03 4.87E+06 7.00E+04 
DC661 
3mg/kg 
182.9 32.1 5.46E+03 2.09E+02 4.11E+05 8.66E+04 
Gut Lys05 
5mg/kg 
68.9 10.3 1.13E+04 1.28E+03 1.18E+06 6.53E+04 
Lys05 
10mg/kg 
83.3 20.0 2.05E+04 8.73E+02 2.21E+06 1.09E+05 
DC661 
3mg/kg 
369.1 96.1 2.49E+03 1.34E+02 9.19E+05 3.34E+05 
Kidney Lys05 
5mg/kg 
158.5 23.3 1.92E+04 7.76E+02 3.96E+06 5.22E+05 
Lys05 
10mg/kg 
163.6 34.6 3.22E+04 4.14E+03 7.86E+06 1.17E+06 
DC661 
3mg/kg 
283 101.2 7.30E+03 9.81E+02 3.34E+06 1.35E+06 
 
Table 4.4. Average tissue half-lives of CQ analogues. 
Tissue HCQ Lys05 DC661 
Blood 15.3 61.7 179.0 
Liver 3.6 46.8 182.9 
Kidney 15.0 161.0 101.2 
Intestine 17.4 65.40 369.1 




Pharmacodynamic Analysis of HCQ, Lys05, and DC661 
To investigate the role of HCQ, Lys05, and DC661 in endpoint autophagy 
inhibition, the MDA-MB-231 cell line was stably transfected with a GFP-mCherry-LC3 
reporter construct.  The GFP part of the probe is pH-sensitive, and so under normal 
conditions will be quenched in the acidic lysosome.  Endpoint autophagy inhibition by 
preventing the autophagosome, where LC3 is located, from fusing with the lysosome 
should therefore prevent GFP from being quenched and ultimately result in higher 
GFP/mCherry fluorescence in autophagy inhibited cells.  Cells were treated with 10 or 
50µM HCQ, 1 or 5µM Lys05, 0.5 or 2.5µM DC661, or 100nM Bafilomycin A1 as a 
positive control under neutral or acidic extracellular conditions for 24 hours prior to live 
cell imaging.  Under neutral conditions 24hr treatment with HCQ 10 and 50µM caused a 
significant increase in GFP/RFP ratio (Figure 4.8).  Lys05 did not cause any significant 
change, nor did DC661 at 0.5µM; however, DC 2.5µM did.  BafA1 did have a significant 
change relative to control and was most visually apparent.   
Under acidic conditions the GFP/mCherry fluorescence ratio comparisons 
between images were barely changed versus control (Figure 4.9).  Lys05 1µM and 
BafA1 were the only significant conditions.  While the quantitative data for most of the 
dimerics were not significant, they were higher in value relative to HCQ.  Visibly, the 
overall fluorescence in acidic control cells was quite low and the puncta seemed more 
sparse than neutral control cells.  Also, of note is that the overall number of puncta in all 
acidic treated conditions appeared higher than the control, which may not have been 





Figure 4.8. MDA-MB-231 LC3-mCherry-GFP cells treated with CQ analogues 
(neutral).  MDA-MB-231 cells transfected with LC3-mCherry-GFP were treated with the 
indicated drug and concentration in neutral pH culture media for 24 hours prior to live 
cell imaging at 40x magnification in PBS.  Integrated fluorescence density of GFP / 
mCherry was calculated for each image and condition.  Statistical comparisons were 
made using one-way ANOVA with Dunnett’s multiple comparison test relative to control 
with significance as P<0.05.  To prepare images for display an equivalent threshold for 





Figure 4.9. MDA-MB-231 LC3-mCherry-GFP cells treated with CQ analogues 
(acidic).  MDA-MB-231 cells transfected with LC3-mCherry-GFP were treated with the 
indicated drug and concentration in acidic pH culture media for 24 hours prior to live cell 
imaging at 40x magnification in PBS.  Integrated fluorescence density of GFP / mCherry 
was calculated for each image and condition.  Statistical comparisons were made using 
one-way ANOVA with Dunnett’s multiple comparison test relative to control with 
significance as P<0.05.  To prepare images for display an equivalent threshold for each 






 In this chapter I attempt to characterize differences between HCQ and dimeric 
CQ analogues mainly in the context of pharmacokinetics, and attempt to broadly link 
pharmacokinetic trends to cytotoxicity and pharmacodynamics.  In addition, I attempt to 
characterize the intracellular pharmacokinetics of dimeric CQ analogues in the same 
manner as HCQ – based on their physicochemical properties and interactions with the 
lysosomal system.  
 All in all, HCQ is similar to Lys05 and DC661 in some regards, but dissimilar in 
others.  The major takeaway is that the behavior of these drugs cannot be mostly 
characterized by their physicochemical properties, as is the case for HCQ.  Under 
standard conditions, in which these drugs are developed and tested in vitro, HCQ, 
Lys05, and DC661 appear to follow a predictable pattern of cytotoxicity and the trend 
between cell lines remains the same, i.e. the way the drugs cause growth inhibition 
appears to be similar.  The proposed mechanism is through PPT1 inhibition, which has 
been identified as the putative target of these drugs (Rebecca et al., 2019).  
Interestingly, bafilomycin A1 did not follow the same growth inhibition sensitivity trends 
in cell lines as the CQ analogues, suggesting that growth inhibition is not directly related 
to endpoint autophagy inhibition by lysosomal pH alkalinization.   
 Pharmacokinetically, HCQ, Lys05, and DC661 behave similarly under in vitro 
conditions.  Their concentrations appear to increase rapidly within the cell, then steadily 
over time which is likely with induction of some degree of lysosomal biogenesis.  This 
allows them to increase the sequestering capacity of the cell, as the lysosomal 
compartment becomes larger.  Using developed in vitro PK models for HCQ one would 
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expect these drugs to have a higher affinity for the lysosome based on pH-partition 
theory.  Contrary to that assumption, Lys05 whole cell uptake was less perturbed by 
alkalinizing lysosomal pH with monensin, and DC661 even more so, compared to HCQ.  
Based on observations from other studies (McAfee et al., 2012; Rebecca et al., 2019), 
the drugs do appear to alkalinize lysosomal pH like HCQ, but from data within this 
chapter it would appear that this may not be directly related to their overall cell uptake.  
It is possible that binding to cell macromolecules, like PPT1, may play a role in this 
observation as the effect of blunting cell uptake by lysosomal pH alkalinization with 
monensin is proportional to reported PPT1 inhibiting ability of the drugs (Rebecca et al., 
2019).  PPT1 chemical binding affinity for the drugs has not been characterized.  
Another possible explanation is general protein and acid phospholipid binding.  HCQ is 
only about 50% bound to plasma protein, whereas the other two drugs have been 
observed at >99% bound (personal communication with Ravi Amaravadi).  While not 
directly applicable to in vitro observations discussed here, the underlying cause, which 
is an increase in ionic binding that likely cause the drugs to be more heavily protein 
bound, may play a role in cells as well.  This is also relevant in the context of acid-
phospholipids, where the drugs may be shielded from the effects of luminal pH.   
 A major advantage of Lys05 and DC661, relative to HCQ, is in the context of the 
acidic microenvironment.  Solid tumors generally have non-homogenous extracellular 
regions with varying pH from 6.3 to 7.0 (Lee and Griffiths, 2020).  This physiologically-
acidic extracellular pH has been shown to inhibit HCQ, Lys05, and DC661 suggest that 
the physicochemical properties of HCQ are what allow the acidic microenvironment to 
inhibit its activity, and that is primarily caused through PK means – i.e. by reduced 
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overall uptake of the drug into cells.  HCQ growth inhibiting capability is completely lost 
under acidic conditions, but Lys05 and DC661 still maintain some activity.  This is 
connected with a mean reduction in cell uptake of HCQ by 6-fold, versus <2-fold for 
Lys05 and DC661.  
 As HCQ is currently the only clinically-approved autophagy inhibitor, this is a 
major shortcoming in its use.  Ironically, autophagy has been suggested as a protective 
mechanism under acidic extracellular conditions (Marino et al., 2012; Xie et al., 2015), 
and is suggested to be elevated under acidic extracellular conditions (Tan et al., 2016).  
This suggests that cells that are more prone to autophagy inhibition are those that HCQ 
would be unable to target due to acidic extracellular inhibition of its activity, further 
promoting the advantages of Lys05 and DC661.   
 In addition, autophagic flux is also suggested to be increased in 3-D in vitro 
cultures relative to 2-D (Follo et al., 2016; Wang et al., 2016; Bingel et al., 2017).  In 
addition, 3-D cultures more closely mimic pH gradients observed in vivo, as they have 
acidic core regions relative to the peripheral regions, and is associated with reduced 
weakly basic lipophilic drug uptake overall within core regions (Swietach et al., 2012). 
One would assume Lys05 and DC661 would more effectively permeabilize through the 
bulk of a 3-D system with an acidifying pH gradient.  
   From an in vivo PK standpoint, Lys05 and DC661 have specific advantages and 
disadvantages relative to HCQ.  The dimeric drugs have much longer half-lives than 
HCQ, which would allow them to be administered less frequently in a clinical setting 
assuming that property extrapolates from mice to humans.  However, the downside is 
obvious toxicity concerns as the drugs will maintain concentrations for a longer period of 
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time.  Lys05 and DC661 also were not observed in the brains of mice.  This is a 
potential benefit, as it completely avoids neurotoxic side effects induced by inhibition of 
PPT1 (personal communication with Ravi Amaravadi).  On the other hand, metastatic 
colonies in the brain cannot be targeted, which is a major area of concern as autophagy 
inhibition is generally desired in late stage cancers where metastasis is already 
abundant.  Further characterization of the specific mechanism by which Lys05 and 
DC661 are excluded from the brain are needed, whether it be through impermeability of 
the blood-brain barrier, or strong affinity for ABCB1 efflux transporters.   
 From a pharmacokinetics perspective, overall Lys05 and DC661 appear to 
overcome a major shortcoming of HCQ, which is susceptibility to the acidic 
microenvironment present in solid tumors.  While this is a major benefit, to develop a 
lead compound, certain aspects of the drugs need to be characterized to understand 
more specifically how they interact with the cell.  Ideally, it would be important to 
investigate why they do not completely follow the same physicochemically-driven 
intracellular pharmacokinetics as HCQ.  Understanding what drives their distribution on 
a cellular level would allow development of an ideal lead dimeric CQ analogue, while 
simultaneously optimizing for properties that give the drug a more optimal clinical PK 
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HCQ, the touted miracle cure gone flop of the COVID-19 age, may still be the 
magic bullet for some late stage cancers.  Just kidding, magic bullets are what 
naturopaths sell to you in the form of homeopathic aspirin solutions and concentrated 
fruit extracts.  Hype aside, HCQ does have potential to be a viable combination therapy 
option for patients with certain late stage cancers.  As outlined in this dissertation the 
shortcomings of HCQ are far and few between, as is often the case with first generation 
agents.  The focus of this dissertation work was motivated by one of the first phase I 
clinical trials using HCQ to treat solid tumors, led by Rebecca Barnard, a former 
graduate student in the Gustafson Lab, which highlighted a major roadblock of clinical 
treatment with HCQ (Barnard et al., 2014).  This roadblock was the observation that 
there was no correlation between HCQ blood concentration and excised tumor 
concentration in canine patients, referred to multiple times throughout this work as the 
“HCQ PK/PK disconnect”.  In a clinical setting, a mathematical relationship is generally 
assumed between tumor (or peripheral compartment) concentration and that of 
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blood/plasma.  The relationship may be linear or non-linear, or characterized by certain 
macrophysiological covariates. Generally, there is some way to draw correlation and 
modify drug dosing if adequate concentrations at the target are not achieved.   
The first step I took to approach this problem was to develop a first generation 
HCQ PBPK model that could characterize PK of HCQ in mice and humans based on 
physiologic factors.  This model also incorporated a lysosomal compartment into the 
tissue, allowing us insight into the PK of lysosomes, the presumed mechanistic site of 
action of HCQ, as well as whole tissue. The model was developed by breaking up key 
tissues in HCQ ADMET into compartments interconnected by blood flow.  Within 
compartments HCQ was trapped within lysosomes, bound to melanin, metabolized, or 
excreted depending on the tissue being characterized.  This complex systems model 
was characterized largely by physiological and biochemical parameters, with little in the 
way of unknown parameter optimization, giving it physiologic relevance as an approach 
to characterizing drug pharmacokinetics.  With this model, HCQ PK in mice and humans 
was described and variabilities assigned to specific, measurable physiological or 
biochemical factors.  The power of this approach is to characterize patient 
subpopulations directly, based on key parameters within the model.  For example, 
patients with metabolic disorders or renal disease could be simulated directly by 
modifying relevant parameters.  This was a first generation model, and is unproven in 
the clinic, but with access to more clinical data could be further refined as a valuable 
tool for individual patient prediction of HCQ PK.   
To lay the groundwork for further refinement of this model, particularly attempts 
to characterize long-term HCQ PK due to trends observed when simulating multiple-
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month administration of HCQ, the next step was to define cell-level factors that 
influenced HCQ PK.  The intracellular look at HCQ pharmacokinetics highlighted a few 
key findings that will drive the way we think about administering this drug going forward.  
The first is that the sequestering capability of lysosomes is dramatic – in MB231 cells is 
roughly 92% of total cell uptake.  This has implications for other drugs related to HCQ in 
terms of structure and physicochemical properties. It also highlights that internal or 
external factors that influence the lysosome will likely also influence HCQ PK.  The 
second is that this lysosomal compartment is dynamic in terms of physical volume 
fraction of the cell, as well as pH.  For the hBC lines examined, the cytosolic/lysosomal 
pH gradient appeared to be consistent across cell lines; however, the lysosomal volume 
fraction was different and was correlated with the total uptake of HCQ in the cell.  In 
other cell lines, the pH gradient may be altered in addition to the lysosomal volume 
fraction.  This may have strong implications in vivo as well.  As of now, there is minor 
evidence that lysosomal biogenesis may occur in vivo (McChesney, 1983).  This needs 
to be investigated further, but has implications for the way we administer these drugs, 
especially for long term use or in patients that have been receiving TFEB-activating 
drugs prior, or in addition to, other drugs that may be candidates for lysosomal 
sequestration.   
It is fairly clear with HCQ that it has some particularly important shortcomings, in 
terms of distribution.  Not only is its uptake and subsequent efficacy blocked by an 
acidic extracellular space, which is the norm in solid tumors rather than the exception, 
but it is capable of modulating its own distribution.  While yet to be proven in vivo, it is 
an important consideration as the result of this work in considering the HCQ PK/PK 
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disconnect.  Clinical dosing with monoclonal antibodies, such as nivolumab, have been 
recently observed to have time-varying clearance in human patients, dependent on the 
state of cachexia (Bajaj et al., 2017; Wang et al., 2017; Wang et al., 2020).  In the case 
of nivolumab, and other monoclonal antibodies like ipilimumab (Sanghavi et al., 2020), 
clearance is decreased when the patient’s health improves, as cachexia and 
subsequent clearance of the drug is reduced.  Lessons from this work, discovered 
through clinical population pharmacokinetic modeling, can be hypothetically 
extrapolated to HCQ PK as extended dosing with HCQ may increase the lysosomal 
volume fraction of tissue and tumor, which would decrease blood clearance of the drug 
over time.  Until a more defined relationship is drawn between HCQ PK in blood and 
peripheral tumor compartments, the lack of correlation remains cause for concern in 
clinical dosing as the drug moves into Phase II and III clinical trials.   
More importantly, other compounds that behave like HCQ may presumably 
modify their own volume of distribution and will be subject to these same discrepancies.  
This is important in developing future drugs, for example in the case of CDK4/6 
inhibitors where lysosomal sequestration blunted their efficacy in lysosomally-rich cell 
lines, and mechanistically-similar compounds were synthesized to side-step this source 
of resistance (Fassl et al., 2020).  Due to the extensive amount of data necessary to 
characterize HCQ kinetics and dynamic feedback within the non-homogenous tumor 
microenvironment, it is necessary to consider mechanistically-similar drugs that may 
minimize or avoid completely the shortcomings of HCQ.  Prior to recent findings through 
target inhibition of PPT1 (Nicastri et al., 2018; Rebecca et al., 2019), the mechanistic 
action of HCQ was generally assumed to be indirect – through lysosomal deacidification 
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and/or lysosomal membrane permeabilization.  Characterization of mechanistically-
similar drugs, then, should be focused on approaches to maximize indirect activity 
(LMP, deacidification), as well as substrate affinity to PPT1.  The focus of Chapter 4 
was characterizing mechanistically similar next generation analogues of HCQ in the 
context of what made them more potent, primarily through characterizing the indirect 
activity.   
Dimeric chloroquine analogues, Lys05 and DC661, showed enhanced potency 
compared to HCQ.  They were also shown, experimentally, to be better suited to 
maintain potency under acidic extracellular conditions – connected to cellular uptake.  
Both drugs seem to cause lysosomal biogenesis and have similar in vitro PK profiles to 
HCQ, suggesting they may also modify their own distribution; however, this potential 
problem with HCQ may not be as significant of an issue with Lys05 and DC661 if it 
occurs in vivo.  This is due to the extremely long half-life in mice, which would allow the 
drugs to be dosed less frequently and likely make their PK more predictable.  In 
addition, PK of these drugs would be less influenced by acidic extracellular pH, so if the 
lack of correlation between tumor PK and blood PK for HCQ observed in canine 
lymphoma patients is truly due to this factor then it would likely be resolved with Lys05 
and DC661.  The next step in investigating this mechanism would be to test these drugs 
in tumor-bearing mice at different dosing levels to directly modify blood concentrations 
and observe the trend in tumors side-by-side with HCQ.  The major downside to these 
drugs is potential for toxicity.  Having such a long half-life would require dose:exposure 
predictions to be very accurate, working within the narrow therapeutic range of cancer 
treatment, as side effects from overdoses would be long-lived.   
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Another potential note to clinical treatment with these drugs is activity within the 
CNS.  HCQ has been linked with psychosis in some patients (Mascolo et al., 2018), and 
so the observation that Lys05 and DC661 do not accumulate in the brain could be 
considered a positive attribute of these drugs.  The downside of lack of accumulation in 
the brain is that autophagy-dependency and autophagy-inhibition with HCQ in clinical 
trials is currently aimed at patients with late stage cancer, where the brain is either the 
site of a solid tumor or the site of metastatic spread.  This poses an obvious potential 
problem when treating patients with these drugs alone or in combination with other 
therapies. Whether the drugs are unable to cross the blood-brain barrier, or are strong 
constituents for CNS efflux transporters is currently unknown.  Regardless, this factor is 
one that is necessary to characterize for clinical administration of these agents, as 
structural modifications may be appropriate if CNS activity is desired. 
 
Future Directions and Studies 
The exciting, and simultaneously frustrating nature of this work is that in 
answering a few questions we have created many more.  The path this work will take 
going forward can follow multiple different routes, depending on what is deemed most 
pertinent to characterize.  Intrinsic and extrinsic factors relating to HCQ and CQ 
analogue drug uptake may benefit from further characterization in vitro as well as in 
vivo.  In addition, other questions formulated as a result of this work may also create 
interesting projects, specifically around further characterization of TFEB effects on other 
drugs, further characterization of the lysosomal dye, ETP, and investigation into the 
interplay between lysosomal pH and HCQ modulation. 
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From the work described within this dissertation, it is clear that HCQ activates a 
lysosomal biogenesis feedback loop that increases its own volume of distribution within 
the cell.  The extent to which that feedback loop operates; however, is subject to further 
characterization.  In this work we identified that concentrations as low as 10uM, which 
are relative maximal concentrations achievable in vivo, can induce lysosomal 
biogenesis significant enough to alter HCQ distribution.  From an in vitro standpoint, 
timepoint-based characterization within the 1-24 hour range, as well as out past 24 
hours of exposure are necessary to determine the mathematical relationship between 
HCQ drug uptake and modulation of the lysosomal compartment.  In addition, a dose-
response study is also warranted.  Concentrations between 1-10µM of HCQ are 
clinically-relevant, and so the in vitro PK curve of HCQ at 3-4 concentrations within this 
range and potentially higher should be evaluated to determine the therapeutic range in 
which this lysosomal biogenesis effect should be considered. Additionally, this HCQ-
altered lysosomal compartment has only been investigated in vitro, but the real 
applicability of this effect would be if it occurs in vivo.  There is limited data available 
that observes HCQ tissue PK over long term dosing at multiple timepoints (McChesney, 
1983), but this data does suggest that steady-state levels of HCQ in tissue are not 
achieved at the same time as blood (Wei et al., 1995), if at all.  A comprehensive PK 
study linking steadily increasing tissue PK, steady-state blood PK, and 
immunohistological characterization of lysosomal biogenesis in tissue/tumor is 
necessary to truly investigate the role of lysosomal biogenesis in in vivo altered 
distribution of HCQ.  Only then can this phenomenon be truly extrapolated to other 
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lysosomotropic agents and linked with the lysosomal in vitro MDR that has been 
observed in many studies.     
On the subject of TFEB-induced lysosomal biogenesis altering volume of 
distribution of lysosomotropic agents, it would be a rather quick and interesting study to 
investigate the applicability relative to a panel of such drugs.  Experiments would 
consist of in vitro conditions used for HCQ in Chapter 3, wherein the ability of TFEB, 
through Torin1, to increase the sequestration of other weakly basic drugs (panel of 8 or 
so) would be investigated.  To strengthen this study, it would be necessary to also test 
drugs with anionic and zwitterionic structures – drugs not associated with lysosomal 
uptake.   
Further characterization of Lys05 and DC661 is also warranted, both in 
comparison to HCQ and alone.  These drugs appear to activate the same lysosomal 
feedback loop that alters cellular volume of distribution of HCQ, and so similar 
experiments as those for further characterization of HCQ should be pursued.  Further 
studies with organoids would have better implications for in vivo activity than 2-D 
studies as well.  Specifically, the larger organoids become the more pronounced their 
internal pH gradient.  Investigating organoid size relative to drug uptake of HCQ, Lys05, 
and DC661 might better explain how they operate in vivo.  In addition, 
immunohistological studies investigating drug uptake, lysosomal biogenesis, and 
autophagy inhibition relative to distance from the organoid periphery might advance our 
understanding of how these drugs affect localized acidic niches in the in vivo tumor 
microenvironment.  To investigate intrinsic factors related to uptake even further it is 
clear that chemical affinity to PPT1 and the role in which it plays in cellular uptake of 
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these drugs is warranted.  Regarding in vivo PK, multiple dose studies, and different 
dosages are required to determine steady-state levels of these drugs as well as if they 
follow linear PK with dose.   
A rather interesting observation described in recent literature, and observed in 
some of my experiments (data not included), is around the proposed mechanism of 
HCQ to alkalinize lysosomal pH.  Recent observations suggest the possibility of pH-
recovery in lysosomes.  Studies with LysoTracker Red, a lysosomotropic fluorescent 
compound that accumulates in the lysosome due to acidic lysosomal pH, is shown to be 
quenched upon addition of HCQ to cells preloaded with LysoTracker Red.  This 
observation is consistent with HCQ’s proposed mechanism to alkalinize lysosomal pH, 
and consistent with LysoTracker Red displacement from the lysosome as the pH 
increases.  However, it is observed that treatment with HCQ for 24 hours prior to 
LysoTracker Red addition still allow for some LysoTracker Red fluorescence within the 
lysosomal compartment, which is inconsistent with HCQ quenching of lysosome pH 
over long term continuous exposure.  This has been observed in recent studies with CQ 
as well (Lu et al., 2017; Mauthe et al., 2018).  Investigation into the time-based aspect 
of this phenomena, as well as an underlying mechanistic cause would be extremely 
valuable data as it contests the proposed mechanism of HCQ autophagy-inhibition as 
well as the long-accepted mechanism of lysosomotropic drugs to alkalinize lysosomal 
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Supplementary Figure 2.1.  Simulated lysosomal concentrations in mouse tissue. 




Supplementary Figure 2.2.  Simulated concentrations of HCQ in tissue. Simulated 
HCQ in human liver, kidney, and gut following a single oral dose of 200mg (A), 400mg 
(B), or IV infusion of 200mg (C), and 400mg (D).  
 
 
Supplementary Figure 2.3.  Simulated lysosomal concentrations. Concentrations of 
HCQ in human liver, kidney, and gut lysosomes following a single oral dose of 200mg 







Supplementary Figure 2.4.  Simulated concentrations of HCQ in human eyes. 
Eyes after a single oral dose (A), 30 days of once daily oral dosing (B), and 60 days of 
once daily oral dosing (C) with 200, 600, and 1200mg HCQ.  Grey dotted lines indicate 
















Supplementary Figure 3.1. Calculation of cell volumes.  Volume for each cell line was 
determined by staining with live cell marker Trypan Blue, and then imaging suspended cells on 
a Countess Cell Counter System (A).  Live cell diameter was determined by the mean cell 
diameter from 4 replicates (B).  Cell volume was then calculated from the diameter for each cell 
line by assuming suspended cells were spherical (C).  The geometric mean of the cell volume 




Supplementary Figure 3.2. Calculation of lysosomal volume fractions.  Lysosome volume 
fraction of each cell line was determined by in-house macro methods.  Live cells were treated 
with 1µM ETP for 30 minutes, followed by 10µM Hoechst 33342 for 10 minutes, and then 
imaging at 60x oil immersion confocal microscopy.  5-10 image stacks were taken per replicate 
at a step-size of 0.24µm, and 43 slices were taken per image stack on DAPI and Cy3 channels 
(A). Raw confocal image stacks were converted to .tif files and imported into Python version 
3.7.6.  Each slice of each image stack was analyzed to determine the peak signal to noise ratio 
(PSNR) using the sewar module (https://pypi.org/project/sewar/), and the top 10 slices were 
used for analysis (B). A FIJI macro that calculated the Cy3 (lysosome) area for each raw .vsi 
image slice based on an algebraic threshold of mean intensity was applied to raw images (C) to 
generate a lysosome area per slice, which is visualized in (D).  Volume fraction for cells was 
calculated using the following equation:  Volume fraction = ∑(AreaLys∙ step distance) / Vcell 
 
 
Supplementary Figure 3.3. Static PK Model Accounts for Variability Introduced by 
Modifying pH Parameters.  To further investigate the capability of the model to simulate HCQ 
PK, we experimentally tested pH parameters within the model to compare to simulation data.  
We first investigated HCQ whole cell uptake at 1hr in MDA-MB-231 cells at pHe of 7.6 (N) and 
7.0 (A) at 1µM and 10µM for 1 hour and compared to simulation prediction in this cell line (A).  
194 
 
The kinetic uptake curve was not visibly altered between pHe or concentrations of HCQ µM (B).  
MDA-MB-231 growth inhibition was almost completely blunted in the presence of the acidic vs. 
neutral pH after 96hr of exposure (C). The role of the lysosome/cytosol pH gradient in MDA-MB-
231 cells by pretreating cells with 25µM monensin (MN) for 30 minutes prior to adding 10µM 
HCQ for 1 hr (D). 
 
 
Supplementary Figure 3.4. HCQ and Torin1 treatment causes an increase in lysosomes 
within the cell.  Representative images of T47D (top), MDA-MB-468 (center), and MDA-MB-
231 (bottom) imaged with ETP after treatment with HCQ (center) or Torin 1 (right).  An increase 
in lysosomes was visually apparent in all 3 cell lines (in addition to MCF7 – Figure 3) after both 
treatments.  All cell lines appeared to have visibly larger lysosomes in HCQ treated vs. Torin 1 
treated images.  To prepare figures for publication the raw images threshold was adjusted to the 





Supplementary Figure 3.5. HCQ treatment causes lysosomal swelling.  MDA-MB-468 (left), 
T47D (center), and MCF7 (right) cells were transfected with GFP-LAMP-1 BacMam and treated 
with 10µM HCQ for 24 hours.  Control cell lines (top) were observed to have LAMP-1 positive 
(lysosomes) vesicles appearing as small puncta located in the perinuclear region.  HCQ treated 
cells (bottom) were all observed to have lysosomes that were much larger with much more 
defined membrane edges, though some smaller puncta were still present.  To prepare images 
for publication, the 43-slice image stack was consolidated into a single image using EFI 
processing on Olympus CellSens software.  All images were put through a sharpen filter, and 
then the GFP threshold was adjusted to the same upper and lower bounds across the entire 
























Supplementary Figure 4.1.  CQ analogues simulation versus observed data under 
neutral and acidic conditions.  MDA-MB-231, MDA-MB-468, and MCF7 cell lines 
were treated with 1 or 10 µM of HCQ, Lys05, or DC661 in neutral (N) or acidic (A) 
media culture conditions for 1 hour.  MDA-MB-231, MDA-MB-468, and MCF7 cell line 
data is displayed in columns left, middle, and right, respectively, with HCQ, Lys05, and 
DC661 in rows top, middle, and bottom, respectively.  The cell PK model was used to 
simulate neutral and acidic conditions at 1 hour for each cell line using the cell line 
profile and media pH.  HCQ was simulated using the base model presented in chapter 
3.  Lys05 was simulated using conditions 5 and 6 presented in table 4.1, and DC661 
was simulated using conditions 1 and 3 presented in table 4.1. 
 
 
